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ABSTRACT  
   
Cellular redox phenomena are essential for the life of organisms. Described 
here is a summary of the synthesis of a number of redox-cycling therapeutic 
agents. The work centers on the synthesis of antitumor antibiotic bleomycin 
congeners. In addition, the synthesis of pyridinol analogues of α-tocopherol is 
also described.  
The bleomycins (BLMs) are a group of glycopeptide antibiotics that have 
been used clinically to treat several types of cancers. The antitumor activity of 
BLM is thought to be related to its degradation of DNA, and possibly RNA. 
Previous studies have indicated that the methylvalerate subunit of bleomycin 
plays an important role in facilitating DNA cleavage by bleomycin and 
deglycobleomycin. A series of methylvalerate analogues have been synthesized 
and incorporated into deglycobleomycin congeners by the use of solid-phase 
synthesis. All of the deglycobleomycin analogues were found to effect the 
relaxation of plasmid DNA. Those analogues having aromatic C4-substituents 
exhibited cleavage efficiency comparable to that of deglycoBLM A5. Some, but 
not all, of the deglycoBLM analogues were also capable of mediating sequence-
selective DNA cleavage.  
The second project focused on the synthesis of bicyclic pyridinol 
analogues of α-tocopherol. Bicyclic pyridinol antioxidants have recently been 
reported to suppress the autoxidation of methyl linoleate more effectively than α-
  ii 
tocopherol. However, the complexity of the synthetic routes has hampered their 
further development as therapeutic agents. Described herein is a concise synthesis 
of two bicyclic pridinol antioxidants and a facile approach to their derivatives with 
simple alkyl chains attached to the antioxidant core. These analogues were shown 
to retain biological activity and exhibit tocopherol-like behaviour. 
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CHAPTER 1 
INTRODUCTION 
1.1 General introduction 
1.1.1 Radicals and reactive oxygen species (ROS) 
        A radical is a species that possesses one or more unpaired electrons [1]. A 
molecule may lose or gain electrons singly or in pairs. One-electron transfer 
processes involve radicals. Two-electron transfers may involve either a 
simultaneous transfer of two electrons or two sequential one-electron transfers 
[2]. Both one-electron oxidations and one-electron reductions produce radicals [3]. 
Numerous oxydoreductases generate radicals as intermediates through their 
catalytic cycles, even though most biochemical oxidoreductions imply the 
exchange of two electrons [4]. 
        Reactive oxygen species (ROS) include radicals, as well as other reactive 
singlet oxygen compounds [5]. The most important ROS are superoxide (O2·-), 
hydroxyl radical (HO·), nitric oxide (NO·), and hydrogen peroxide (H2O2) [5,6]. 
The primary ROS formed in vivo are superoxide and hydrogen peroxide. 
Hydrogen peroxide is generated through nonenzymatic or enzymatic dismutation 
of superoxide [5]. However, the most reactive and harmful ROS is the hydroxyl 
radical, which can be formed from H2O2, but also via the reaction of superoxide 
with NO to produce peroxynitrite (OONO-), the latter of which decomposes to 
form NO2 and HO· (Figure 1.1) [7]. ROS play both harmful and beneficial roles 
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[9]. At low or moderate levels, ROS exert beneficial effects on cellular responses 
and immune functions; at high concentrations, they generate oxidative stress, a 
harmful process that can damage cell structures [10-20]. Oxidative stress plays a 
major part in the development of chronic and degenerative aliments such as cancer, 
arthritis, aging, autoimmune disorders, cardiovascular and neurodegenerative 
diseases [21-25]. 
 
O2 O2 H2O2 HO H2O
ONOO
+ NO
NO2 HO
+ e- + e- + e- + e-
+e-
+
+ H+ + H+
H+ H2O
_
 
Figure 1.1. The formation of reactive oxygen species. (Modified from ref. 8) 
 
1.1.2 Redox reactions in biological systems 
        Cellular redox phenomena are essential for the life of organisms. In biological 
systems, all processes that provide energy result from redox reactions [26,27]. 
Redox reactions are also important for intracellular radical production [28]. The 
major intracellular radical products are generated from the electron transport chain 
in mitochondria, endoplasmic reticulum and nuclear membrane(Figure 1.2) [29]. 
For instance, when cells use oxygen to generate energy, radicals are created as a 
by-product of ATP production by the mitochondria. Moreover, radicals are also 
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formed in endogenous and normal cell components, such as quinones (or 
precursors), flavins, organic thiols, orthocatechols, tetrahydrobiopterins and 
various other species [30]. The formed radicals can diffuse from the site of their 
production before their further oxidation or reduction  
CoQ10
Cyt C
e- e-
H
+ H+ H+
H+
Inner
mitochondrial
membrane
Complex I Complex III Complex IV Complex V
Complex II
NADH NAD+
Succinate Fumarate
1/2 O2 H2O
ADP  + Pi ATP  + H2O
 
Figure 1.2. Mitochondrial electron transport chain. 
 
to even-electron species. In addition, the metabolism of miscellaneous xenobiotics 
(drugs, phytochemicals, pollutants) also generates C, N, S, or O-centered radicals 
as a result of a one-electron exchange [30]. These organic radicals are likely to be 
rapidly reoxidized, and the ultimate product of such a one-electron chain reaction 
is superoxide anion (O2·-). Finally, the redox reactions involving a metal complex 
(mainly iron, but also including copper, chromium, and vanadium) can also be 
important for radical production. Extensive evidence supports the idea that an iron 
ion can react with a peroxide, which can either be hydrogen peroxide or an organic 
hydroperoxide, to produce a HO· or RO· radical (Figure 1.3) [31-35].    
  4 
H2O2 HOFe
2++ Fe3++
ROOH ROFe2++ Fe3++
+ OH-
+ OH-  
Figure 1.3. Metal-ion catalyzed redox decomposition of peroxides to produce 
radicals. 
 
1.1.2 Redox cycling antitumor drugs 
        Extensive evidence supports the involvement of redox reactions and reactive 
oxygen species in the mechanism of many anticancer drugs. There are a number of 
antitumor drugs that are capable of redox cycling and can also interact directly 
with DNA. These interactions can involve noncovalent binding to the DNA minor 
groove, intercalation, alkylation, and DNA strand cleavage [36]. DNA is a 
polynucleotide that carries the genetic information, and thus is vital to the 
function of cells. Although DNA interactive agents are generally very toxic to 
normal cells as well as abnormal cells, some of them have been found to be 
effective against life-threatening diseases such as cancers.  
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Figure 1.4. Structures of some redox cycling antitumor agents. (a) 
diaziridinylquinones, (b) adriamycin (doxorubicin), (c) mitomycin C, (d) 
etoposide, (e) tirapazamine. 
         
        Figure 1.4 shows several well known redox-cycling anticancer agents. There 
are many anticancer agents of this type containing quinones in their structures 
such as diaziridinylquinones (Figure 1.4a) and adriamycin (doxorubicin, Figure 
1.4b). Figure 1.5 depicts the mechanism of action for quinone-containing 
antitumor agents. By virtue of their quinone structure, the antitumor agents can 
undergo a biochemical reduction by one or two electrons that is catalyzed by a 
flavoenzyme in the organism using NAD(P)H as the electron source [37]. 
Electrons are transferred from the NAD(P)H to the quinone of the antitumor 
agents leading to the formation of the semiquinone. The subsequent electron 
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transfer from the semiquinone to oxygen results in the production of superoxide. 
This redox cycle continues until the system becomes anaerobic. The formation of 
superoxide is the beginning of a cascade that generates H2O2, and subsequently 
hydroxyl radicals (HO·), which is the most reactive and harmful ROS (Figure 1.1). 
The reactive radicals generated can cause the oxidative cleavage of DNA backbone 
[38]. Doxorubicin (Figure 1.4a) belongs to the anthracyclines, a well-known class 
of DNA damaging agents. It is well established that this class of compounds 
possesses the capacity to undergo redox cycling with the generation of ROS [39]. 
The process is similar to that of diaziridinylquinones (Figure 1.5). However, other 
possibilities have also been proposed to account for the activity of doxorubicin 
and the mechanisms are still uncertain [40-43]. But it has been asserted that the 
redox-cycling process “is responsible for most if not all biological activity” [44]. 
        Mitomycin C (Figure 1.4c) is the best known of all the aziridinylquinones 
and is a very potent DNA alkylating agent. Extensive research has been focused 
on its inter- and intra-strand cross-linking interaction with DNA [45-47]. 
Although redox cycling can participate and lead to ROS, it is generally claimed 
that this aspect exerts a minor influence on cancer cell lethality [48]. Etoposide 
(Figure 1.4d) is a semisynthetic analogue of the antitumor antibiotic 
podophyllotoxin. Etoposide can be metabolically activated by oxidation and 
demethylation to an o-quinone derivative [49]. Evidence supports the involvement  
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Figure 1.5. Redox cycling of quinone-containing antitumor agents initiated by a 
one-electron reduction and the subsequent pathways. (Adapted from ref. 37) 
 
of ROS in the mechanism [50]. Tirapazamine (Figure 1.4e) is a bioreductively 
activated antitumor agent that selectively kills hypoxic cells in solid tumors [51]. 
One-electron reduction, possibly by enzymes such as NADPH-cytochrome p450 
reductase or xanthine oxidase, produces its radical intermediate, which undergoes 
homolytic cleavage and generates hydroxyl radicals (Figure 1.6) [52].  
 
N
N
N
NH2
O
O
enzyme
1 e-, H+
O2O2
N
N
N
NH2
O
OH
N
N
N
NH2
O
+ HO
 
Figure 1.6. Mechanism for formation of hydroxyl radicals by tirapazamine. 
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1.1.3 Redox cycling antioxidants 
        Antioxidants are substances that can neutralize excess radicals and counteract 
oxidative stress in cells [53]. Therefore, antioxidants are widely used as ingredients 
in dietary supplements, and have also gained enormous attention as potential 
therapeutic agents to prevent radical damage in living systems [54]. Antioxidants 
are generally classified as enzymatic antioxidants (e.g., superoxide dismutase, 
catalase and glutathione peroxidase) and non-enzymatic antioxidants. This section 
deals with natural and synthetic non-enzymatic antioxidants [9]. Figure 1.7 shows 
several well-known small molecule antioxidants. α-Tocopherol (vitamin E, Figure 
1.7a) is a lipophilic vitamin, and is perhaps the best-known natural antioxidant 
(discussed later in Section 1.3) [55]. The antixoidant activity of L-ascorbic acid 
(vitamin C, Figure 1.7b) results from its ability to donate electrons sequentially 
(Figure 1.8) [56]. Vitamin C is a cofactor in a variety of enzymatic  
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Figure 1.7. Structures of some redox cycling antioxidants. (a) α-tocopherol 
(vitamin E), (b) L-ascorbic acid (vitamin C), (c) β-carotene, (d) quercetin 
(flavonoid), (e) ubiquinone (coenzyme Q), (f) idebenone. 
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Figure 1.8. Two-electron oxidation of vitamin C. 
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reactions and also works synergistically with vitamin E to protect against radical 
damage [57]. β-Carotene (Figure 1.7c), which can be oxidatively cleaved  in the 
human body, is a potent antioxidant and well known for its singlet oxygen 
quenching ability [58]. Quercetin (Figure 1.7d), the most abundant dietary 
flavonoid, is a strong antioxidant as a consequence of its structural features that 
enable radical scavenging. The catechol group in the B-ring is important for 
stabilizing the aroxyl radical [59]. Ubiquinone (coenzyme Q, Figure 1.7e) is a 
family of benzoqunones, which differ in the length of the lipophilic side chain. 
The antioxidative effect of ubiquinone resides in its electron-transport ability 
because ubiquinone can undergo a two-electron reduction to produce 
hydroquinone (Figure 1.9) [60]. Idebenone (Figure 1.7f), a synthetic analogue of 
coenzyme Q10, is an experimental drug for the treatment of Alzheimer’s disease 
and other neurological defects [61].  
+ e- + e-
O
O
O
O
CH3
R
O
O
O
O
CH3
R
O
O
O
O
CH3
R
 
Figure 1.9. Two-electron reduction of ubiquinone. 
 
1.2 Bleomycins: DNA damaging agents 
1.2.1 Bleomycins 
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        The bleomycins (BLMs) are a class of glycopeptide antibiotics that show 
antitumor properties and are used clinically for the treatment of several types of 
cancers [62]. Bleomycins were first isolated from a culture broth of the 
actinomycete Streptomyces vericillus in the early 1960’s by Umerzawa et al. [63]. 
The structure of bleomycin with the assignment of the relative and absolute 
stereochemistry was determined through a series of chemical hydrolyses of the 
parent compound followed by X-ray crystallographic characterization by 
Umezawa et al. in 1977 [64]. This early structural identification contained a β-
lactam, which was revised to its correct structure in 1978 [65]. The structures of 
BLM family members differ only by the nature of their C-termini (Figure 1.10). 
The clinically used anticancer drug Blenoxane, which is composed ~60% of 
bleomycin A2 and ~30% of bleomycin B2, with trace amounts of other bleomycin 
congeners, is used for the treatment of Hodgkin’s lymphoma, carcinomas of the 
skin, head and neck, and testicular cancers [62,66].  
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Figure 1.10. Bleomycin family members. 
 
         Bleomycin can selectively cleave DNA at 5'-GC-3' or 5'-GT-3' sites in the 
presence of a metal ion and oxygen [67]. More recently, it was found that 
bleomycin can also degrade some RNA, in both the presence and absence of Fe 
ion, and RNA may represent another therapeutic target [68-70]. Evidence has 
supported a mechanism in which Fe(II) forms a complex with bleomycin, which 
can interact with O2 in vivo [71]. Other metals, such as copper, cobalt and 
manganese, have also demonstrated an ability to support BLM-mediated DNA 
cleavage [72-74]. 
        Deglycobleomycin (Figure 1.11), lacking the carbohydrate moiety, cleaves 
DNA in a sequence selective manner similar to the natural bleomycin [75]. 
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Despite a lower efficiency and a decreased double- to single-stranded cleavage 
ratio, deglycobleomycin is more readily accessible synthetically and therefore has 
been used successfully for understanding the essential structural elements 
necessary to perform sequence-selective oxidative DNA degradation [76], 
potentially leading to the development of improved antitumor BLMs. 
 
H
N NH2
H
NH2
NH2O
N N
H2N
CH3HN
O
N
H
H
O
CH3
H
N
NH
HO
CH3
O
HO CH3
H
H
O
N
S
S
N
O
N
H
N
O
R
NH HN
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Figure 1.11. Structures of deglycobleomycin A5 and A6. 
 
1.2.2 Structural domains in bleomycins 
        Bleomycin, exemplified by bleomycin A5 and bleomycin A6 in Figure 1.12, 
has four structural domains. The C-terminus domain consists of a bithiazole 
moiety and a positively charged polyamine C-substituent as in bleomycin A5 and 
A6. This domain plays an important role in DNA binding [77,78]. The linker 
region, which consists of L-threonine and methylvalerate organizes the metal 
binding domain and the DNA binding domain to facilitate productive DNA 
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binding and thereby enable cleavage [66,79,92(b),99,106(b)(c)]. The metal binding 
domain is composed of β-hydroxyhistidine and pyrimidoblamic acid moieties. 
This domain is responsible for the chelation of a metal ion cofactor and oxygen 
activation [80,81] and is likely also involved in the sequence selectivity of DNA 
cleavage [79,82]. The carbohydrate moiety participates in the metal ion binding 
[83,84], and also in cell surface recognition [85] and the cellular effects of the drug 
[86,87]. These four domains are discussed in detail below.  
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Figure 1.12. Functional domains of bleomycin A5 and A6. 
 
1.2.2.1 DNA binding domain 
        The DNA binding domain consists of the bithiazole moiety and an alkyl 
substituent bearing a positively charged functional group. Several studies utilized 
fluorescence spectroscopy and proton magnetic resonance spectroscopy to 
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examine bleomycin binding to calf thymus DNA have demonstrated the 
interaction of bithiazole and the terminal amine moiety with various 
deoxyribodinucleotides [88], suggesting that this portion of the molecule was 
involved in the binding of bleomycin to DNA.  
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Figure 1.13. Deglycobleomycin congeners containing thiazole-modified analogues. 
 
        To better understand the role of the DNA binding domain in the sequence 
selectivity of DNA cleavage, bithiazole analogues have been synthesized and 
incorporated into bleomycin. Monothiazole bleomycin analogues (Figure 1.13), in 
which either of the two thiazole rings was replaced with S-methyl-L-cysteine, was 
found to lose DNA sequence selectivity. Presumably, it was resulted from 
inefficient DNA binding [89]. This result suggested that the DNA binding domain 
could provide a source of DNA affinity to support sequence-selective DNA 
cleavage. In addition, bleomycins containing chloro-substituted bithiazole 
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analogues (Figure 1.13), demonstrated DNA sequence selectivity in the presence 
of UV light. Additional studies confirmed that the metal binding domain could be 
responsible for the observed pattern of DNA cleavage [90(a)]. It has been found 
that EDTA-conjugated bithiazole analogues afforded strand scission in DNA with 
no sequence selectivity in the presence of Fe2+ [90(b)]. This argued that the 
bithiazole moiety and the metal binding domain could act in a cooperative manner 
to display selective DNA cleavage. Another line of evidence to support this 
conclusion is that modified bithiazoles were shown to yield different sequence 
selectivity (Figure 1.14). Hecht and coworkers showed that bleomycin containing 
a trithiazole moiety exhibited altered sequence selectivity from 5'-GC-3' to 5'-GT-
3' [91]. Ohno and co-workers have also developed two deglycobleomycin 
analogues containing a distamycin moiety in the place of the bithiazole moiety 
that can shift the sequence selectivity to 5'-AT-3' rich regions [92]. 
 
  17 
H
N NH2
NH2
N
H3CO
CH3HN
O
N
H
H
O
CH3
H
NHO
R
O
HO CH3
H
H
O
N
H
N
O
O
H
NH
N
O
NH
N
3
R = H
R = CH3
H
N NH2
H
NH2
NH2O
N N
H2N
CH3HN
O
N
H
H
O
CH3
H
N
NH
HO
CH3
O
HO CH3
H
H
O
N
S
S
N
N
H
N
O
N
S
NH HN
NH2
O
 
Figure 1.14. Deglycobleomycins that demonstrated alternative DNA cleavage 
patterns. 
 
1.2.2.2 Linker region 
        The linker region consists of L-threonine and methylvalerate moieties. This 
domain of bleomycins was initially thought of as a tether that links the DNA 
binding domain and metal binding domain together. The role of this domain was 
not truly understood and investigated until almost ten years after the isolation of 
this natural product [62,93].  
        The early study of the linker region carried out by Umezawa et al. 
demonstrated that the specific stereochemistry of the substituents on the linker 
backbone was required to promote efficient DNA cleavage [62,92(b)]. Another 
early study of this region carried out by Boger et al. involved incorporating a 
linking peptide chain that lacked the peripheral substituents. This BLM congener 
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was found to exhibit 100 times less effective DNA cleavage than deglycoBLM, 
although sequence selectivity was still retained [94]. Hecht et al. also simplified 
the linker by removing or replacing the threonine with mono-, di-, or tetraglycine 
[95], as well as with tyrosine and methionine (Figure 1.15) [96]. They found that 
the cleavage efficiency decreased significantly and that sequence selectivity was 
affected as well. In addition, Boger et al. reported a systematic study of the role of 
the threonine moiety by replacing it with alanine, serine, valine and 2-(R)-
aminobutyric acid (Figure 1.15) [97]. The efficiency of DNA cleavage was 
dramatically affected after the removal of the hydroxy group on the threonine. 
Increasing the steric bulk of the functionalities on threonine moiety also decreased 
DNA cleavage efficiency. These results suggested that the threonine subunit, 
especially the presence of hydroxyl group, is necessary to support the DNA 
cleavage activity of bleomycin.  
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        The role of the methylvalerate moiety has also been the subject of many 
studies. The initial experiments modifying the methylvalerate moiety showed that 
the absolute stereochemistry and the presence of the 3’-hydroxyl group on the 
methylvalerate moiety were both important to support the function of 
bleomycins [92]. It was suggested that the conformation of the methylvalerate 
moiety played a role in “making the flexible BLM molecule rather inflexible in the 
twisted minor groove of DNA” [92(a)]. By inverting the configuration of the C4 
center, Ohno et al. demonstrated that the corresponding BLM analogues exhibited 
significantly decreased ability to degrade DNA [98].  It was concluded that the 4R 
configuration of the three consecutive asymmetric centers (2S, 3S, 4R) was of 
particular importance [99].  
        A more systematic study of the methylvalerate subunit was reported by the 
Boger laboratory regarding the effects of the C2- and C4-methyl groups and the 
C3-hydroxy group, as well as the length of the linker [99]. By synthesis and 
characterization of a series of BLM analogues containing modifications in the 
methylvalerate moiety of deglycobleomycin A2 (Figure 1.16a), it was revealed that 
each of the substituents played a significant role in the DNA cleavage efficiency 
but had minimal impact on DNA sequence selectivity. The presence of a C3-
hydroxy group had only a modest effect on the bleomycin activity, possibly 
through H-bonding with DNA. The more significant effect of the C4-methyl 
group is linked to the presence of the C2-methyl group. In contrast, the C2-
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methyl group exhibited only a modest effect and its impact is not coupled to the 
presence of the C4-methyl group. These effects were explained by the 
conformation of the resulting BLM analogues after modification. This unique β-
hydroxy-γ-amino acid is believed to orient BLM into a rigid and compact 
conformation essential for DNA interaction [76(a)]. Methyl substitutions at the 
C2- and C4-positions were suggested to stabilize the compact conformation to 
allow for efficient DNA interaction while alteration of that conformation could 
greatly diminish DNA cleavage [99]. Furthermore, it was suggested that the length 
of the linker is also important (C4 > C5 > C3 > C2). However this effect was 
examined in the absence of linker substituents.  
        Since the methylvalerate moiety may be responsible for a conformational 
bend in bleomycin required for efficient DNA cleavage, the Hecht laboratory has 
synthesized a number of conformationally constrained methylvalerate analogues 
and incorporated them into deglycoBLM A5 congeners in order to probe the 
effects of conformational constraint on the native valerate moiety [100]. However, 
none of these analogues mimicked the conformation proposed for the natural 
valerate linker, they all exhibited diminished DNA cleavage activity and lacked 
sequence selectivity (Figure 1.16b). More recently, two deglycoBLM analogues 
modified in the methylvalerate moiety were selected from a 108-member 
deglycoBLM A6 library, both of which contained phenylmethylvalerate moieties 
(Figure 1.16c). These two BLM congeners displayed potencies of supercoiled 
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DNA relaxation greater than that of the parent deglycobleomycin [96,101]. This 
suggested that increased steric bulk at the methylvalerate C4-position could alter 
the efficiency and pattern of DNA cleavage.  
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Figure 1.16. Deglycobleomycin congeners modified in the methylvalerate moiety. 
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1.2.2.3 Metal binding domain 
        The metal binding domain consists of the β-hydroxyhistidine and 
pyrimidoblamic acid moieties. This region is believed to be responsible for metal 
binding, oxygen activation and DNA cleavage selectivity. Based on the X-ray 
crystal structure of Cu(II)•P-3A, a putative biosynthetic precursor of bleomycin, 
the initial metal coordination model of bleomycin was proposed by Umezawa 
[102]. In this model, the P-3A copper complex adopts a square pyramidal 
geometry, in which the N1 of the 4-aminopyrimidine, N3 of imidazole, the 
deprotonated amide of histidine, and the secondary amine of the β-aminoalanine 
form the base of the pyramid with the primary amine of β-aminoalanine as the 
apex (Figure 1.17). Although lacking the carbohydrate moiety and the C5 methyl 
group in the pyrimidine ring, this model provided the first coordination geometry 
of the metal-binding domain. Based on this Cu(II)•P-3A model, a model for the 
Cu(II)•bleomycin structure was proposed, in which the carbamoyl oxygen from 
the carbohydrate formed the remaining coordination site (Figure 1.18) [103]. A 
number of biochemical and spectroscopic studies of the metal-bound complexes 
have since been described and support the proposed coordination geometry of 
bleomycin.  
        The metal binding domain is also important for the sequence selectivity of 
DNA cleavage [76(b),79,104]. The effect of the metal binding domain on DNA 
sequence selectivity is coupled with the DNA binding domain. It has been 
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demonstrated that analogues of the metal binding domain that lacked the bithiazole 
and C-terminus did not display DNA cleavage pattern [76]. However, when 
combined with the bithizole moiety, these analogues demonstrated sequence 
selective DNA cleavage [105(c)].  The sequence selectivity may result from 
hydrogen bonding between guanine in the DNA backbone and the 4-amino group 
as well as the N3 of the pyrimidine ring based on the structure of HOO-
Co(III)•BLM A2 [106]. This was further confirmed by the analogues lacking the 
4-amino group or the analogues with the 4-amino group methylated [107]. The 
analogues were shown to have diminished selectivity for 5'-GC-3' and 5'-GT-3' 
sequences.  
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Figure 1.17. X-ray crystallographically determined structure of Cu(II)•P-3A. 
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Figure 1.18. Proposed structure for Cu(II)•BLM complex. 
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        Another part of the metal binding domain, the β-hydroxyhistidine moiety, 
has also been well studied. Removal of the imidazole ring resulted in decreased 
efficiency and loss of sequence-selective DNA cleavage [96]. The nitrogen atom of 
the amide (Na) and the imidazole nitrogen atom (Nπ) were both essential for metal 
coordination (Figure 1.19) [108]. The Boger laboratory prepared a number of 
analogues modified in the β-hydroxyhistidine moiety that provided some useful 
insights about this subunit [109]. It was found that removal of the β-hydroxy 
group from β-hydroxyhistidine did not significantly affect either the cleavage 
efficiency or the sequence selectivity. Additionally, the replacement of Na with N-
methylamide or ester resulted in sequence neutral DNA cleavage as well as 
diminished DNA cleavage efficiency [109]. This is presumably because this 
moiety was unable to coordinate the metal properly with the amide nitrogen atom. 
Modification of the imidazole ring nitrogen or replacement of the imidazole ring 
with a totally different ring system, such as oxazole, thiophene or 
pyrrolobenzene, resulted in less cleavage efficiency [96,101]. These results 
suggested that both the position and electronic nature of the Nπ and Nσ are 
important for metal binding and sequence selectivity of DNA cleavage (Figure 
1.19). 
  25 
H
N NH2
H
NH2
NH2O
N N
H2N
CH3HN
O
N
H
H
O
CH3
H
N
NH
HO
CH3
O
HO CH3
H
H
O
N
S
S
N
O
N
H
N
O
N
H
S
N!
N"
H
N NH2
H
NH2
NH2O
N N
H2N
CH3HN
O
N
H
H
O
CH3
H
N
NH
HO
CH3
O
HO CH3
H
H
O
N
S
S
N
O
R
O
N
H
S
H
HO
R =
H
N
O
N
H
Na
 
Figure 1.19. Deglycobleomycins congeners modified in the β-hydroxyhistidine 
moiety. 
 
1.2.2.4 Carbohydrate moiety 
        The carbohydrate moiety is comprised of L-gulose and carbamoyl-D-
mannose. Of all the functional domains of bleomycin, the carbohydrate moiety is 
the least well understood [76a]. The carbohydrate moiety may participate in metal 
ion binding [83,84], as well as in cell surface recognition [85], and the cellular 
effects of the drug [83,111]. The C3 carbamoyl group on the mannose moiety has 
been postulated to provide an additional axial ligand for metal coordination [111]. 
It is also suggested that the disaccharide moiety together with C2-acetamido side 
chain of pyrimidoblamic acid act as a “shield” to protect the activated meal-oxo 
species [112]. Removal of the carbohydrate moiety from bleomycin provided 
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deglycobleomycin, which has a lower DNA cleavage potency and a decreased ratio 
of double-strand cleavage to single-strand cleavage [45,76(b),104(b)]. 
Interestingly, removal of the mannose moiety has a minimal effect on DNA 
cleavage efficiency, whereas removal of the gulose resulted in a significant 
diminished DNA cleavage [113]. Recently, Hecht et al. applied a microbubble 
technique to demonstrate that the carbohydrate moiety could assist BLM in 
binding selectively to cancer cells [85]. The experiments showed the BLM A5–
microbubble conjugate adhered to cultured MCF-7 human breast carcinoma cells 
whereas no adhesion of the deglycoBLM A5–microbubble conjugate was observed 
in cancer cells. In addition, the BLM A5-microbubble was found to bind 
selectively to MCF-7 cells while there was no adhesion of the BLM A5-
microbubble conjugate to the “normal” breast cell line MCF-10A. These results 
support the concept that the carbohydrate moiety of BLM A5 is required for 
tumor cell targeting.  
 
1.2.3 Mechanism of action of bleomycins 
        The primary mechanism of action of BLM is generally believed to be the 
generation of single- and double-strand breaks in chromosomal DNA with a metal 
ion cofactor [114]. Ferrous ion is believed to form a complex with bleomycin, 
which can interact with O2 in vivo (Figure 1.20). The pyrimidoblamic acid and β-
hydroxyhistidine make up the Fe(II) binding domain that binds oxygen through a 
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single electron reduction [115,116]. The formed reactive species is termed 
“activated bleomycin” [71(d), 114(a)]. This ternary complex is believed to be 
responsible for DNA cleavage. 
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Figure 1.20. The proposed structure of Fe(II)•BLM complex interacting with O2. 
 
        The formation of “activated bleomycin” has been studied theoretically for 
many years, and has resulted in a number of proposals. However, the actual 
structure of the “activated bleomycin” has not yet been observed experimentally 
and the detailed mechanism of the antitumor activity of bleomycin is still 
unknown. A possible catalytic cycle by which bleomycin degrades DNA is 
suggested in Figure 1.21 [114(c)]. In the first step, iron metal coordinates with 
bleomycin and binds one molecule of dioxygen [117]. The next step is activation 
of the ternary complex of bleomycin. In this step, a one-electron reduction is 
believed to occur either chemically or by a microsomal NAD(P)H-cytochrome 
p450 reductase-catalyzed reduction [116]. As mentioned above, the reactive 
species formed is termed “activated bleomycin”; it is believed to be the species 
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involved in DNA degradation. This species can degrade DNA while being oxidized 
to Fe(III)•BLM. In the final step, further reduction occurs to regenerate 
Fe(II)•BLM.  
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BLM Fe(III) O2
Activated 
Fe   BLM
BLM Fe(III)
degradation
products
DNA
e-
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Figure 1.21. The catalytic cycle of the Fe•BLM complex. 
 
        There are two mechanisms proposed involving the activated bleomycin 
mediating DNA single-strand and double-strand degradation. Figure 1.22 shows 
the first proposed mechanism for oxidative DNA strand-scission by “activated 
bleomycin” [118]. This pathway starts from the homolytic abstraction of the C4'-
hydrogen of deoxyribose generating a C4' radical species, which reacts with an 
oxygen molecule to form a hydroperoxyl radical. Following reduction of the 
hydroperoxide, this intermediate then undergoes a Criegee-type rearrangement that 
leads to the cleavage of the C3'-C4' bond of deoxyribose. The “cleaved” sugar is 
further decomposed by an anti-elimination, generating the base propenal, a 5'-
phosphoronucleotide and a 3'-oligonucleotide.  
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        At low oxygen concentration, bleomycin is believed to produce alkali-labile 
DNA lesions (Figure 1.23) [119]. After C4'-hydrogen abstraction to form a radical 
species on ribose, the resulting intermediate undergoes a one-electron oxidation to 
form a carbocation, which can immediately react with water to produce a C4'-
hydroxyl nucleoside. Further collapse of this species results in a DNA strand 
scission product containing a terminal 3'-phosphate, and a 5'-phosphate [119]. 
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Figure 1.22. Proposed mechanism for oxidative DNA strand-scission by 
“activated bleomycin”. 
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Figure 1.23. Proposed mechanism for the formation of alkali-labile lesions in 
DNA. 
 
        In addition to DNA, bleomycins have also been shown to degrade some RNA 
substrates [114(c),69(c)], including DNA-RNA heteroduplex [120], and different 
types of RNAs such as transfer RNA [69(a)], messenger RNA [121], and 
ribosomal RNA [69(b)]. The significance of RNA as a potential therapeutic target 
for bleomycin can be envisioned for several reasons. First, RNA is located in the 
cytoplasm, and therefore, should be much more easily accessible, whereas the 
majority of cellular DNA is located in the cell nucleus [122]. Moreover, there are 
several repair mechanisms by which certain bleomycin-induced DNA lesions can 
be repaired. However there is currently no evidence to support analogous robust 
mechanisms by which damaged RNA can be repaired.  
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         Studies have suggested that the degradation of RNA oligonucleotides is 
substantially more complex than the degradation of DNA [69(c)]. The oxidative 
damage of RNA is believed to occur at both the C4' and C1' positions of the ribose 
sugar (Figure 1.24). However, C1'-hydrogen abstraction did not lead directly to 
strand scission. Furthermore, treatment of the rearranged aldehyde with 1,2-
diaminobenzene resulted in the formation of a dinucleotide quinoxaline with 
release of the nucleobase, carbon dioxide, and the 5'-phosphate [123].  
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Figure 1.24. Degradation of chimeric octanucleotide by Fe(II)•BLM in the 
presence of 1,2-diaminobenzene. 
 
1.3 α-Tocopherol and bicyclic pyridinol antioxidants 
1.3.1 Vitamin E and α-Tocopherol  
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        Vitamin E is a lipophilic vitamin having excellent antioxidant potency. The 
vitamin E family includes eight members: α-, β-, γ-, δ-tocopherol and α-, β-, γ-, δ-
tocotrienol. The vitamin E family members have methylated hydroquinone 
moieties and an isoprenoid chain (Figure 1.25). Since the discovery of vitamin E 
several decades ago its roles in human health and its biological functions have been 
studied extensively [124].  
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Figure 1.25. Structures of vitamin E family members. 
 
        α-Tocopherol (α-TOH) is not only the major component of vitamin E but 
also the most active form in human body (Figure 1.26). α-Tocopherol is known to 
react readily with a variety of radicals and thus can prevent membrane 
peroxidation in the cell [125]. In addition, α-tocopherol can prevent the radical 
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oxidation of low density lipoproteins (LDLs), which act as the major carrier of 
cholesterol in human body. Oxidation of LDLs is strongly implicated in the 
development of atherosclerosis diseases [126].  Because of its antioxidant 
capacity, α-TOH has been studied for the treatment of several diseases, such as 
cardiovascular disease [127], diabetes mellitus [128], dementia [129] and cancer 
[130]. α-Tocopherol is best known as a chain-breaking antioxidant that prevents 
lipid peroxidation by scavenging the lipid peroxyl radicals in the peroxidation 
chain [125(a)]. 
O
HO
!-tocopherol 
(!-TOH)  
Figure 1.26. Structure of α-tocopherol (α-TOH) 
 
        Lipid peroxidation is a radical chain reaction, and has been studied 
extensively since the 1960s. The chain reactions of lipid peroxidation before 
quenching by any antioxidants is summarized as shown in Figure 1.27. Steps other 
than those shown in Figure 1.27 are possible, including the coupling of various 
radicals in the chain termination step to form several stable species, such as L–L, 
L–O–O–L, and L–O–L; but it is more common to show that the initiating radical 
(i.e., L•) undergoes dimerization in the chain termination step [131(a)].  
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L + [4]
LOO + L-H
kp LOOH + L [3]
Chain initiation:
H
L LOO [2]
Chain propagation:
O2
+
+
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L L  
Figure 1.27. Chain reactions in lipid peroxidation before quenching by any 
antioxidants. 
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Figure 1.28. Inhibition of lipid peroxidation. 
 
        Inhibition of lipid peroxidation can, in principle, be accomplished in several 
ways (Figure 1.28). One involves suppressing the initiation step that produces the 
radical L• [131(a)(b)]. The chain reactions can also be interrupted when an 
antioxidant functions as a hydrogen atom donor to react with the peroxyl radical 
(LOO•) [131(b)]. A third way involves accelerating the chain termination sequence 
by introducing a new termination mechanism. For example, nitric oxide (NO) 
inhibits lipid peroxidation; the available data suggest its antioxidant activity results 
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from the chain termination [131(c)]. The last two quenching mechanisms are 
substantially similar, since in both case antioxidants react with the peroxyl 
radicals.  
        As mentioned above, α-tocopherol is generally believed to quench lipid 
peroxidation by transferring its phenolic hydrogen to the propagating peroxyl 
radical (Figure 1.29), since α-TOH reacts with LOO• at a rate (kq ~ 106 M-1s-1) 
much faster than that of chain propagation (kp ~ 10–100 M-1s-1; Figure 1.27, 
Equation 3) [132]. The addition of oxygen to L• to form LOO• (Figure 1.27, 
Equation 2) is extrememly fast with rate constants on the order of 109 M-1s-1 
[131(d),(e)]. Thus, the reaction of phenolic antioxidants with L• is normally 
neglected at low concentration of phenols and normal concentration of oxygen 
[139(b)]. However, it is probably overly simplistic to assert that any given 
antioxidant should act in only one fashion.  
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Figure 1.29. Quenching of lipid peroxidation by α-tocopherol. 
 
        After transferring a phenolic hydrogen atom to the peroxy radical (Figure 
1.29) to quench the lipid peroxidation, the generated α-TOH radicals from the 
quenching step are stable because the unpaired electron on the oxygen atom can be 
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delocalized into the aromatic ring structure. Thus, they are insufficiently reactive 
to abstract H• from the methylene groups of the unsaturated fatty acyl moieties of 
membrane phospholipids [30]. Furthermore, due to the stability of the α-TOH 
radicals, α-TOH can be regenerated by cooperating with vitamin C and NADH 
(Figure 1.30) [133].  
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Figure 1.30. Regeneration of α-TOH by vitamin C and NADH [30]. 
 
1.3.2 Tocopherol-like analogues  
        Recently, considerable effort has been devoted to identifying synthetic 
antioxidants with activity superior to α-TOH [132(a),134]. Current research has 
been met with limited success due to the decomposition of compounds upon 
extended exposure to the atmosphere [135]. The ongoing goal includes compound 
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stability towards air oxidation as well as high reactivity with peroxyl radical. The 
bond dissociation enthalpy (BDE) of the phenolic O–H bond plays an important 
role in the antioxidant activity. Phenols that have lower O–H BDEs are generally 
better antioxidants. An increase in electron density of the aromatic ring leads to a 
lower BDE by stabilizing the electron deficient ArO• radical [136]. Another 
important parameter used in the design of new phenolic antioxidants is the 
ionization potential (IP), which indicates the electron transferring ability of 
phenols. With a lower IP value, it is easier for a phenol to lose electrons and be 
oxidized. An increase in IP suggests higher air-stability of the compounds 
[132(a),134(d),137]. Substitution with electron-donating groups (e.g., –NH2) at 
positions ortho and para to the phenolic OH group can lower BDEs, and increase 
rates of H-atom transfer to peroxyl radicals. However, good electron-donating 
substituents also lead to a decrease in the IP of the phenol, making the substance 
less stable to air oxidation. 
        Porter, Pratt and coworkers first reported that incorporation of two nitrogen 
atoms at the 3- and 5-positions or one nitrogen atom at the 3-position of the 
phenolic ring significantly raises the IP, which improves the air stability of the 
compounds, and also lowers the O–H BDE to some extent [134(b),134(c),138]. 3-
Pyridinols (e.g., 2 in Figure 1.31) exhibited a higher radical inhibition rate than 5-
pyrimidinols (e.g., 1 in Figure 1.31). In addition, the same laboratory reported the 
fusion of an aliphatic ring to the free 5-position in the 3-pyridinol structures to 
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provide compounds 3 and 4 (Figure 1.31). Interestingly, compounds 3 and 4 were 
shown to be highly effective antioxidants, exhibiting 88-fold and 28-fold greater 
potency, respectively, than α-TOH in suppressing the autoxidation of methyl 
linoleate. It is suggested that improved stereo-electronic behavior increases the 
radical quenching rate [139].  
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Figure 1.31. Structures of 5-pyrimidinol, 3-pyrimidinol and tocopherol-like 
analogues. 
        The bicyclic 6-amino-3-pyridinols (compounds 3 and 4) have since been 
elaborated by the Porter laboratory and our laboratory by conjugating the 
pyridinol cores with the phytyl side chain of α-TOH (e.g., compounds 5, 6 and 7) 
[140]. The lipophilic phytyl group in α-TOH is believed to assist in the 
accumulation of the antioxidant in membranes, including mitochondrial 
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membranes, thereby protecting the cells and mitochondria from oxidative stress 
[141]. Although these analogues displayed promising biological profiles, the 
syntheses have not proven simple—all requiring 15 or more steps. The arduous 
approaches have therefore hindered the further development of these analogues. 
Thus, the development of simpler and more readily available analogues retaining 
biological activity has become an ongoing and important goal. 
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CHAPTER 2 
SYNTHESIS OF DEGLYCOBLEOMYCIN A6 ANALOGUES MODIFIED IN 
THE METHYLVALERATE MOIETY 
2.1 Introduction 
2.1.1 Solid-phase synthesis of deglycobleomycin A6 
        In 1982, the Umezawa and Hecht laboratories independently reported the 
syntheses of bleomycins by solution-phase methods [142,143]. Their work gave 
an impetus to the study of the mechanism of action of bleomycins [76(a)], and 
initiated a wave of synthetic studies of bleomycins and their analogues within the 
synthesis community. These approaches have depended on the synthesis of the 
constituent amino acids, followed by the coupling of these amino acids to 
assemble the BLM scaffold. Despite the initial synthesis and the subsequent 
improvements, the synthesis of bleomycins remained an arduous process for 
synthetic chemists. 
        The pioneering work of Bruce Merrifield, which introduced solid phase 
peptide synthesis (SPPS), dramatically changed the strategy for peptide synthesis 
[144]. Merrifield’s SPPS simplified the tedious and demanding steps of traditional 
solution-phase peptide synthesis. Nowadays, advances in solid phase synthesis 
have expanded from peptides to O-, N-, and S-linked glycopeptides [145], 
oligosaccharides [146], and even natural product-like small molecules [147]. 
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Scheme 2.1. Principles of solid phase peptide synthesis [148].  
 
        The principles of solid phase synthesis are illustrated in Scheme 2.1 [148]. 
Construction of a peptide chain on an insoluble solid support has obvious 
benefits. The coupling of amino acids is driven by employing excess reagents and 
the physical losses can be minimized since the peptide is bound to the solid 
support. Separation of the intermediate peptides from the reaction mixture can be 
achieved simply by filtration and washing the solid phase with solvents. The N-
protected C-terminal amino acid residue of the target peptide is first attached to 
the solid support via its carboxylic acid group. The reactive functional groups at 
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the side chain of the amino acid should be masked with side chain protecting 
groups, which are not affected during the peptide coupling reactions. The terminal 
amino group of the attached amino acid is masked with N-protecting groups, 
which can be removed before the coupling of the next amino acid. The subsequent 
N-protected amino acid is added by activation of its α-carboxylic acid. After the 
coupling reaction is complete, the resin-bound product is removed from the 
reaction mixture by filtration and washing with excess solvent. This process 
(deprotection/coupling) is repeated until the desired peptide sequence is formed. 
In the final step, the peptide is released from the solid support and the side chain 
protecting group is removed simultaneously. Generally, the side chain protecting 
groups are chosen so that they can be removed under the same conditions used for 
cleavage of the target peptide from the solid support.  
        Two main strategies are used in solid phase peptide synthesis: the Boc/Bzl 
and the Fmoc/Boc approaches [148]. The Boc/Bzl method is based on the strategy 
of graduated acidolysis to achieve selectivity in the removal of N-protecting 
groups and side chain protecting groups [149]. The Fmoc/Boc method is based on 
an orthogonal protection strategy, which uses the base-labile N-Fmoc group for 
protection of the α-amino group and the acid-labile side chain protecting group 
and resin linkers [150]. Since this orthogonal strategy employs a different 
mechanism to remove the N-protecting groups and side chain protecting groups, it 
requires considerately milder conditions than those utilized in Boc/Bzl method. 
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The cleavage condition is more convenient and the operation is simplified, thus 
Fmoc-based SPPS is now generally the method of choice for the routine synthesis 
of peptides. 
        After two decades of effort in the synthesis of bleomycins (BLMs), 
deglycobleomycins and their analogues, a significant breakthrough occurred in 
2000 when the Hecht laboratory first reported the solid phase synthesis of 
deglycobleomycin A5 (Scheme 2.2) [151]. This methodology was improved and 
applied to the synthesis of bleomycin A5 [69(e)] and deglycobleomycin A5 
analogue with a conformationally constrained methylvalerate [100]. This has 
permitted the facile synthesis of various (deglyco)BLM analogues [91,152]. In 
2003, the successful construction of a 108-member deglycobleomycin A6 library 
further confirmed the robustness of this methodology [96].  
 
2.1.2 Synthesis of methylvalerate and its analogues 
        (2S, 3S, 4R)-4-Amino-3-hydroxy-2-methylpentanoic acid (methylvalerate) 
2.1 is one of subunits of the linker region of bleomycin (Figure 2.1). This unique 
β-hydroxy-γ-amino acid has attracted the interest of several research laboratories 
due to the challenging preparation of three contiguous stereocenters at the 
backbone of this compound. In the first attempt of the synthesis of 2.1, which 
was reported by Yoshioka et al., the corresponding ketone derivative 2.2 was 
reduced nonselectively with sodium borohydride to produce a mixture of four 
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stereoisomers [153]. The desired isomer (2S, 3S, 4R) was isolated as the minor 
isomer from the mixture in 12% yield (Scheme 2.3). The protocol 
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was improved by Hecht et al., in which the major isomer (2R, 3S, 4R) obtained 
was epimerized to the desired product via a cyclic lactam intermediate (Scheme 
2.4) [154]. 
 
H2N
OH
OOH
CH3CH3  
Figure 2.1. Structure of the methylvalerate moiety of BLM. 
 
        In order to improve the synthetic route, Ohgi described the first 
stereospecific approach to the methylvalerate moiety starting from 5-deoxy-L-
arabino-γ-lactone, which could be obtained from L-rhamnose in four steps (Scheme 
2.5) [155]. The 3’-hydroxyl group of compound 2.3 was mesylated selectively, 
followed by the formation of epoxide 2.4 under basic condition. Regioselective 
epoxide opening with lithium dimethylcuprate, followed by reductive 
debenzylation, and hydrolysis of lactam under acidic condition provided 2.1 as the 
HCl salt.  
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Scheme 2.3. Yoshioka’s original synthesis of methylvalerate [153]. 
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Scheme 2.4. Hecht’s improvement on Yoshioka’s synthesis [154]. 
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Scheme 2.5. Ohgi’s stereospecific route to methylvalerate [155]. 
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        Seeking a more facile method, Ohno first employed a selective aldol reaction 
to generate the three consecutive stereocenters, giving isomers 2.5 and 2.6, which 
were converted to methylvalerate 2.1 under acidic conditions (Scheme 2.6) [156].  
A more stereocontrolled synthesis was reported by Dipardo and Bock using chiral 
enolates to mediate a highly stereo-controlled aldol reaction (Scheme 2.7) [157]. 
The aldol reaction provided the corresponding ketone 2.7, which was reduced 
stereoselectively to 2.8 with zinc borohydride. 
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Scheme 2.7. Bock’s synthesis of methylvalerate [157]. 
 
        Ohno [158(a)], and later Boger [158(b)] further modified this method, in 
which the synthesis was simplied to three steps (Scheme 2.8) and in 61% total 
yield. In this method, Evans’ chiral enolate was applied and proved highly 
efficient in mediating stereocontrolled aldol reaction [159]. This method works by 
temporarily creating a chiral enolate by appending a chiral auxiliary (Scheme 2.9). 
The pre-existing chirality from the auxiliary is then transferred to the aldol adduct 
by performing a diastereoselective aldol reaction. Upon subsequent removal of the 
auxiliary, the desired aldol stereoisomer is revealed. The synthesis of the proposed 
methylvalerate analogues (2.9–2.20) (Figure 2.2) was accomplished using Ohno 
and Boger’s method. 
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Scheme 2.8. Ohno’s [158], and later Boger’s [159] synthesis of methylvalerate. 
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2.1.3 Design of methylvalerate analogues 
        Methyl substitutions at the C2 and C4-positions were suggested to stabilize 
the compact conformation to allow for efficient DNA interaction [99] while 
alteration of that conformation can greatly diminish DNA cleavage [100]. 
Additionally, it has been found that increased steric bulk at the methylvalerate C4-
position can alter the efficiency and pattern of DNA cleavage [96,101]. Recently, 
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we have constructed a 108-member deglycoBLM A6 library on a solid support. 
Two members of this library, both of which contained phenylmethylvalerate 
moieties, displayed potencies of supercoiled DNA relaxation greater than that of 
the parent deglycobleomycin [96,101]. To further investigate the effect of steric 
hindrance within the valerate moiety on the DNA cleavage efficiency of (deglyco) 
BLM, we designed a series of valerate analogues (Figure 2.2) to probe the effects 
of steric bulk at the C2- as well as C4-position, possibly allowing deglycoBLM to 
have better DNA cleavage efficiency.  
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Figure 2.2. Fmoc-methylvalerate analogues prepared for incorporation into 
deglycobleomycin A6 analogues. 
 
2.2 Results 
2.2.1 Analogues of methylvalerate to be incorporated into deglycobleomycin 
A6  
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        The designed analogues (Figure 2.2) involve modifications that introduce 
steric bulk at either the C2- or C4-position, or both of these two positions. Based 
on the native valerate moiety (2.9) of bleomycin, the methyl group was replaced 
with isobutyl, sec-butyl, and tert-butyl groups, to afford analogues 2.10–2.12. 
The incorporation of 2.10 has been already reported, and exhibited a potency of 
relaxation of supercoiled plasmid DNA comparable to that of deglycobleomycin 
A6 itself [96]. Analogues 2.11 and 2.12 were prepared; the steric alterations to the 
butyl group were hoped to affect the cleavage properties of BLM. Analogues 
2.13–2.16 involve replacement of the methyl group at the C4-position with 
various cyclic substituents. Analogue 2.14 has already been prepared and 
incorporated into deglycoBLM A6 previously; the resulting deglycoBLM 
analogue was shown to improve the DNA cleavage potency of deglycobleomycin 
[96]. The phenyl group of 2.14 was replaced with a cyclohexyl group affording 
2.13.  With additional bromo and methyl groups, respectively, at the ortho-
position of the phenyl ring of 2.14, analogues 2.15 and 2.16 were designed to 
enhance the steric effects of the phenyl group in 2.14. These modifications 
focused on probing the limit of effects of steric bulk at the C4-position of the 
methylvalerate moiety. Additionally, another three analogues containing n-butyl, 
isobutyl and phenyl groups at the C2-position (2.17–2.19) were prepared to 
probe the effect of steric bulk at this position, which has been less studied. 
Finally, analogue 2.10 with isobutyl groups at both the C2- and C4-positions was 
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prepared. This particular analogue was envisioned to provide a deglycoBLM 
analogue with additional steric bulk for biochemical evaluation.  
 
2.2.2 Synthesis of Fmoc-methylvalerate moiety  
        The synthesis of Fmoc-methylvalerate analogues is shown in Scheme 2.10. 
The Weinreb amides were prepared from their corresponding Boc-protected amino 
acids [160,161]. Compounds 2.9a–2.16a were treated with lithium aluminum 
hydride to afford their Boc protected aldehydes 2.9b–2.16b; the resulting crude 
products were used for the next step without further purification. The 
aminoaldehydes were treated with the appropriate Z-boron enolate [92b,159] of 
chiral acyloxazolidinones 2.21–2.24, giving products 2.9c–2.20c in yields that 
varied from 66% to 95%. For the chiral acyloxazolidinones 2.21 [96], 2.22 [162] 
and 2.23 (Scheme 2.11) [163], the preparation was achieved in a single step from 
the corresponding acyl chlorides and lithiated oxazolidinone. Compound 2.24 was 
prepared by using 4-methylvaleric acid activated with pivaloyl chloride [164]. The 
chiral auxiliary was removed with lithium peroxide in 3:1 THF–H2O at 0 oC. The 
Boc group was then removed with TFA and treated with N-(9-
fluorenylmethoxycarbonyloxy)succinimide, which yielded the desired amino acid 
derivatives 2.9–2.20 in yields ranging from 14% to 95%.  
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Scheme 2.10. Synthesis of analogues of methylvalerate. 
 
2.2.3. Solid-phase synthesis of deglycoBLM analogues 2.26–2.36  
         The synthesis of deglycoBLM analogues 2.26–2.36, is outlined in Scheme 
2.12. The TentaGel amino functionalized resin (preloading of 0.48 mmol/g) was 
first attached with a hydrazine-labile Dde linker developed by Bycroft et al 
[165,166], followed by the treatment of di-Boc spermine in the presence of 
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Hünig’s base in DMF [167]. The amino group was coupled immediately with the 
Fmoc-protected bithiazole in the presence of HBTU and Hünig’s base in DMF. 
After the resin was washed successively with DMF, CH2Cl2 and MeOH, we 
assayed an aliquot of the resin using the Kaiser test to confirm the absence of free 
amino groups [168]. The coupling was quantified by Fmoc-cleavage with a 
solution of 20% piperidine in DMF and gave a loading of 0.12 mmol/g, 
corresponding to a 25% coupling efficiency. Fmoc cleavage was based on the 
dibenzylfulvene–piperidine adduct formed upon treatment of the resin with 
piperidine. The optical densities of 5540 M-1 at 290 nm and 7300 M-1 at 300 nm 
were used to calculate the loading from a known weight of dry resin. After the 
Fmoc group was removed from the dipeptide using a solution containing 20% 
piperidine in DMF, commercially available Fmoc-threonine was coupled to the 
free amine using HBTU, HOBt and Hünig’s base in DMF. Fmoc analysis of the 
tripeptide indicated that the coupling had proceeded in 83% yield. Following by 
the removal of the Fmoc group from the resin-bound tripeptide, the synthesis of 
the tetrapeptide was accomplished by coupling with valerate analogues 2.10–2.20 
(Figure 2.2), respectively, in the presence of HBTU, HOBt and Hünig’s base in 
DMF. Fmoc analysis indicated the couplings had proceeded in yields varying 
from 80% to 98%. Following an additional treatment with piperidine solution, the 
commercial Nα-Fmoc-Nim-tritylhistidine was coupled to the resin using HATU, 
HOAt and Hünig’s base [169,170], which provided the resin-bound pentapeptide 
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in 78% yield. Before the final coupling of the Boc-pyrimidoblamic acid moiety, 
the structure of the pentapeptide was verified by cleavage of a small sample from 
the resin with 2% hydrazine in DMF. The resulting solution was concentrated, 
and analyzed by MALDI-MS. After the molecular weight of the pentapeptide 
was confirmed, final Fmoc removal with 20% piperidine in DMF was followed by 
coupling with Boc-pyrimidoblamic acid by employing BOP and Hünig’s base at 0 
oC. This coupling was allowed to proceed over night in the absence of light to 
afford the fully protected deglycoBLM. Deprotection of the trityl and Boc groups 
was accomplished using a 90:5:5 TFA–Me2S–triisopropylsilane solution [171]. 
The cleavage of the final products from the resin was achieved using a solution of 
2% hydrazine in DMF. The crude deglycobleomycin analogues were purified by 
C18 reversed phase HPLC. The overall yields of the final coupling, deprotection 
and cleavage steps varied from 27% to 59%. The purified deglycobleomycin 
analogues were characterized by 1H NMR spectroscopy and high resolution mass 
spectrometry.  
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Scheme 2.11. Synthesis of chiral acyloxazolidinones. 
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Scheme 2.12. Synthesis of deglycobleomycin analogues 2.26–2.36. 
 
2.2.4. Relaxation of supercoiled plasmid DNA by deglycoBLM analogues 
modified in the valerate moiety  
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        All the deglycoBLM A6 analogues were evaluated for their potency in 
relaxing supercoiled plasmid DNA. Figure 2.3 shows the image of agarose gel 
electrophoresis of plasmid DNA. A single nick at any site on the supercoiled 
circular (Form I) DNA results in a relaxed circular DNA, which is termed Form II 
DNA. The introduction of nicks on both strands of the plasmid DNA with 
relatively close proximity in DNA sequence produces linear duplex (Form III) 
DNA. This situation is illustrated schematically in Figure 2.3, which also shows 
where the bands will appear on the gel. Figures 2.4–2.6 shows the results of all 
deglycoBLM A6 analogues in relaxing supercoiled DNA plasmid in the presence 
of equimolar Fe2+. All of the deglycoBLM analogues containing modified valerate 
moieties were shown to exhibit the ability to nick supercoiled DNA. Among 
these, the potencies of deglycoBLMs 2.27 and 2.32 in DNA relaxation were 
comparable to those of deglycoBLM, itself (Figures 2.4 and 2.5). DeglycoBLMs 
2.29, 2.30, 2.31, 2.33, 2.34, 2.35 and 2.36 also displayed quite strong relaxation of 
supercoiled plasmid DNA, all of them were found to convert completely the 
supercoiled DNA substrate to nicked and linear forms when employed at 4 µM 
concentration in the presence of equimolar Fe2+. DeglycoBLM analogues 2.26 and 
2.28 exhibited moderate activity in effecting relaxation of supercoiled DNA. It is 
interesting that some of the analogues (notably 2.30, 2.31, 2.32 and 2.35) 
displayed quite efficient plasmid DNA relaxation when employed at 1 µM 
concentration in the presence of equimolar Fe2+. Also, it is notable that 
  58 
introduction of ortho substituents into the aromatic ring (cf 2.30 vs 2.31 and 2.32 
in Figure 2.5) was found to affect greater DNA relaxation. 
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                                                   Anode + 
 
Figure 2.3. Image of an agarose gel electrophoresis separation of plasmid DNA 
molecules showing the bands for three forms of plasmid DNA. 
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Figure 2.4. Relaxation of supercoiled pBR322 plasmid DNA by 
Fe(II)•deglycoBLM A6 analogues 2.26–2.28. Lane 1, DNA alone; lane 2, 4 µM 
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deglycoBLM A5 (2.25); lane 3, 2 µM Fe(II)•deglycoBLM A5 (2.25); lane 4, 4 µM 
Fe(II)•deglycoBLM A5 (2.25); lane 5, 4 µM deglycoBLM 2.26; lane 6, 1 µM 
Fe(II)•deglycoBLM 2.26; lane 7, 2 µM Fe(II)•deglycoBLM 2.26; lane 8, 4 µM 
Fe(II)•deglycoBLM 2.26; lane 9, 4 µM deglycoBLM 2.27; lane 10, 1 µM 
Fe(II)•deglycoBLM 2.27; lane 11, 2 µM Fe(II)•deglycoBLM 2.27; lane 12, 4 µM 
Fe(II)•deglycoBLM 2.27; lane 13, 4 µM deglycoBLM 2.28; lane 14, 1 µM 
Fe(II)•deglycoBLM 2.28; lane 15, 2 µM Fe(II)•deglycoBLM 2.28; lane 16, 4 µM 
Fe(II)•deglycoBLM 2.28. This experiment was performed by Paul Zaleski.  
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Figure 2.5. Relaxation of supercoiled pBR322 plasmid DNA by 
Fe(II)•deglycoBLM A6 analogues 2.29–2.32. Lane 1, DNA alone; lane 2, 4 µM 
deglycoBLM A5 (2.25); lane 3, 2 µM Fe(II)•deglycoBLM A5 (2.25); lane 4, 4 µM 
Fe(II)•deglycoBLM A5 (2.25); lane 5, 4 µM deglycoBLM 2.29; lane 6, 1 µM 
II 
III 
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Fe(II)•deglycoBLM 2.29; lane 7, 2 µM Fe(II)•deglycoBLM 2.29; lane 8, 4 µM 
Fe(II)•deglycoBLM 2.29; lane 9, 4 µM deglycoBLM 2.30; lane 10, 1 µM 
Fe(II)•deglycoBLM 2.30; lane 11, 2 µM Fe(II)•deglycoBLM 2.30; lane 12, 4 µM 
Fe(II)•deglycoBLM 2.30; lane 13, 4 µM deglycoBLM 2.31; lane 14, 1 µM 
Fe(II)•deglycoBLM 2.31; lane 15, 2 µM Fe(II)•deglycoBLM 2.31; lane 16, 4 µM 
Fe(II)•deglycoBLM 2.31; lane 17, 4 µM deglycoBLM 2.32; lane 18, 1 µM 
Fe(II)•deglycoBLM 2.32; lane 19, 2 µM Fe(II)•deglycoBLM 2.32; lane 20, 4 µM 
Fe(II)•deglycoBLM 2.32. This experiment was performed by Paul Zaleski.  
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Figure 2.6. Relaxation of supercoiled pBR322 plasmid DNA by 
Fe(II)•deglycoBLM A6 analogues 2.33–2.36. Lane 1, DNA alone; lane 2, 4 µM 
deglycoBLM A5 (2.25); lane 3, 2 µM Fe(II)•deglycoBLM A5 (2.25); lane 4, 4 µM 
Fe(II)•deglycoBLM A5 (2.25); lane 5, 4 µM deglycoBLM 2.33; lane 6, 1 µM 
Fe(II)•deglycoBLM 2.33; lane 7, 2 µM Fe(II)•deglycoBLM 2.33; lane 8, 4 µM 
Fe(II)•deglycoBLM 2.33; lane 9, 4 µM deglycoBLM 2.34; lane 10, 1 µM 
II 
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Fe(II)•deglycoBLM 2.34; lane 11, 2 µM Fe(II)•deglycoBLM 2.34; lane 12, 4 µM 
Fe(II)•deglycoBLM 2.34; lane 13, 4 µM deglycoBLM 2.35; lane 14, 1 µM 
Fe(II)•deglycoBLM 2.35; lane 15, 2 µM Fe(II)•deglycoBLM 2.35; lane 16, 4 µM 
Fe(II)•deglycoBLM 2.35; lane 17, 4 µM deglycoBLM 2.26; lane 18, 1 µM 
Fe(II)•deglycoBLM 2.36; lane 19, 2 µM Fe(II)•deglycoBLM 2.36; lane 20, 4 µM 
Fe(II)•deglycoBLM 2.36. This experiment was performed by Paul Zaleski.  
 
 
2.2.5. Sequence-selective DNA cleavage  
        We also tested the ability of each deglycoBLM analogues to affect the 
sequence-selective cleavage of a linear duplex DNA. This assay was performed on 
a 5′-32P-end labeled 158-base pair DNA restriction fragment (Figure 2.7). As 
shown in Figure 2.8, Fe(II)•deglycoBLM A5 itself showed several sites of 
cleavage. The strongest cleavage sites at the 5′-end of the labeled strand were two 
5′-GC-3′ sites (5′-GC11-3′ and 5′-GC35-3′) and three 5′-GT-3′ sites (5′-GT14-3′, 
5′-GT17-3′ and 5′-GT27-3′). Treatment of deglycoBLM analogues 2.26–2.28 to 
some extent effected cleavage at the same sites. Analogue 2.27, which displayed 
the highest potency in the relaxation of supercoiled plasmid DNA, also exhibited 
the strongest cleavage of the linear duplex DNA. In addition, Fe(II)•deglycoBLM 
analogue 2.27 was shown to effect cleavage at two new sites, which were not 
apparent with Fe(II)•deglycoBLM A5 or with any of the other analogues in the 
present study (cf Figure 2.8, lanes 11–13). Specifically, deglycoBLM 2.27 
induced unique cleavage at G12 and A15 of the duplex DNA. Compared to 
deglycoBLM 2.27, Fe(II)•DeglycoBLM analogues 2.29–2.36 produced some but 
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weaker cleavage of the linear duplex DNA. Also, none of these analogues effected 
cleavage at G12 or A15. 
        The deglycooBLM analogues were also tested for their cleavage of a 5′-32P-
end labeled hairpin DNA, which had been identified on the basis of its strong 
binding to BLM A5 [101,172,173]. As shown in Figure 2.11, deglycoBLM 
analogue 2.27 produced similar but weaker cleavage on the hairpin DNA compared 
to deglycoBLM A5, while cleavage by analogues 2.26 and 2.28 was even weaker 
than analogue 2.27. The remaining analogues also cleaved this hairpin DNA rather 
weakly (data not shown). 
 
 
    1 
5'-AGCTTTAATG  CGGTAGTTTA  TCACAGTTAA  ATTGCTAACG  CAGTCAGGCA 
 
    51 
    CCGTGTATGA  AATCTAACAA  TGCGCTCATC  GTCATCCTCG  GCACCGTCAC 
 
   101 
    CCTGGATGCT  GTAGGCATAG  GCTTGGTTAT  GCCGGTACTG  CCGGGCCTCT 
 
   151 
    TGCGGGAT-3' 
 
Figure 2.7. Sequence of the 158-base pair DNA duplex used as a substrate for 
cleavage by deglycoBLM analogues.  
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Figure 2.8. Cleavage of a [5′-32P]-end labeled 158-base pair DNA duplex by 
deglycoBLM A5 and deglycoBLM analogues 2.26–2.28. Lane 1, DNA alone; lane 
2, 10 µM deglycoBLM A5 (2.25); lane 3, 1 µM Fe(II)•deglycoBLM A5 (2.25); 
lane 4, 5 µM Fe(II)•deglycoBLM A5 (2.25); lane 5, 10 µM Fe(II)•deglycoBLM 
A5 (2.25); lane 6, 10 µM deglycoBLM 2.26; lane 7, 1 µM Fe(II)•deglycoBLM 
2.26; lane 8, 5 µM Fe(II)•deglycoBLM 2.26; lane 9, 10 µM Fe(II)•deglycoBLM 
2.26; lane 10, 10 µM deglycoBLM 2.27; lane 11, 1 µM Fe(II)•deglycoBLM 2.27; 
lane 12, 5 µM Fe(II)•deglycoBLM 2.27; lane 13, 10 µM Fe(II)•deglycoBLM 
2.27; lane 14, 10 µM deglycoBLM 2.28; lane 15, 1 µM Fe(II)•deglycoBLM 2.28; 
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lane 16, 5 µM Fe(II)•deglycoBLM 2.28; lane 17, 10 µM Fe(II)•deglycoBLM 
2.28; lane 18, G + A lane. This experiment was performed by Paul Zaleski.  
    
    1      3     5     7     9   11   13   15   17   19   21 
 
 
Figure 2.9. Cleavage of a [5′-32P]-end labeled 158-base pair DNA duplex by 
deglycoBLM A5 and deglycoBLM analogues 2.29–2.32. Lane 1, DNA alone; lane 
2, 10 µM deglycoBLM A5 (2.25); lane 3, 1 µM Fe(II)•deglycoBLM A5 (2.25); 
lane 4, 5 µM Fe(II)•deglycoBLM A5 (2.25); lane 5, 10 µM Fe(II)•deglycoBLM 
A5 (2.25); lane 6, 10 µM deglycoBLM 2.29; lane 7, 1 µM Fe(II)•deglycoBLM 
2.29; lane 8, 5 µM Fe(II)•deglycoBLM 2.29; lane 9, 10 µM Fe(II)•deglycoBLM 
2.29; lane 10, 10 µM deglycoBLM 2.30; lane 11, 1 µM Fe(II)•deglycoBLM 2.30; 
lane 12, 5 µM Fe(II)•deglycoBLM 2.30; lane 13, 10 µM Fe(II)•deglycoBLM 
2.30; lane 14, 10 µM deglycoBLM 2.31; lane 15, 1 µM Fe(II)•deglycoBLM 2.31; 
lane 16, 5 µM Fe(II)•deglycoBLM 2.31; lane 17, 10 µM Fe(II)•deglycoBLM 
2.31; lane 18, 10 µM deglycoBLM 2.32; lane 19, 1 µM Fe(II)•deglycoBLM 2.32; 
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lane 20, 5 µM Fe(II)•deglycoBLM 2.32; lane 21, 10 µM Fe(II)•deglycoBLM 
2.32; lane 22, G + A lane. This experiment was performed by Paul Zaleski.  
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Figure 2.10. Cleavage of a [5′-32P]-end labeled 158-base pair DNA duplex by 
deglycoBLM A5 and deglycoBLM analogues 2.33–2.36. Lane 1, DNA alone; lane 
2, 10 µM deglycoBLM A5 (2.25); lane 3, 1 µM Fe(II)•deglycoBLM A5 (2.25); 
lane 4, 5 µM Fe(II)•deglycoBLM A5 (2.25); lane 5, 10 µM Fe(II)•deglycoBLM 
A5 (2.25); lane 6, 10 µM deglycoBLM 2.33; lane 7, 1 µM Fe(II)•deglycoBLM 
2.33; lane 8, 5 µM Fe(II)•deglycoBLM 2.33; lane 9, 10 µM Fe(II)•deglycoBLM 
2.33; lane 10, 10 µM deglycoBLM 2.34; lane 11, 1 µM Fe(II)•deglycoBLM 2.34; 
lane 12, 5 µM Fe(II)•deglycoBLM 2.34; lane 13, 10 µM Fe(II)•deglycoBLM 
2.34; lane 14, 10 µM deglycoBLM 2.35; lane 15, 1 µM Fe(II)•deglycoBLM 2.35; 
lane 16, 5 µM Fe(II)•deglycoBLM 2.35; lane 17, 10 µM Fe(II)•deglycoBLM 
2.35; lane 18, 10 µM deglycoBLM 2.36; lane 19, 1 µM Fe(II)•deglycoBLM 2.36; 
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lane 20, 5 µM Fe(II)•deglycoBLM 2.36; lane 21, 10 µM Fe(II)•deglycoBLM 
2.36; lane 22, G + A lane. This experiment was performed by Paul Zaleski.  
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Figure 2.11. Cleavage of a [5′-32P]-end labeled 64-nucleotide hairpin DNA by 
deglycoBLM A5 and deglycoBLM analogues 2.26–2.28. Lane 1, DNA alone; lane 
2, 20 µM deglycoBLM A5 (2.25); lane 3, 5 µM Fe(II)•deglycoBLM A5 (2.25); 
lane 4, 20 µM Fe(II)•deglycoBLM A5 (2.25); lane 5, 20 µM deglycoBLM 2.26; 
lane 6, 5 µM Fe(II)•deglycoBLM 2.26; lane 7, 20 µM Fe(II)•deglycoBLM 2.26; 
lane 8, 20 µM deglycoBLM 2.27; lane 9, 5 µM Fe(II)•deglycoBLM 2.27; lane 10, 
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20 µM Fe(II)•deglycoBLM 2.27; lane 11, 20 µM deglycoBLM 2.28; lane 12, 5 
µM Fe(II)•deglycoBLM 2.28; lane 13, 20 µM Fe(II)•deglycoBLM 2.28. This 
experiment performed by Paul Zaleski.  
 
2.3 Discussion 
        The development of solid-phase methodology has greatly facilitated the 
preparation of a significant number of (deglyco) BLMs with structure alteration of 
the “amino acid” constitutes. The elaboration of a combinatorial library of 
deglycoBLMs having 108 analogues involved both single and multiple 
substitutions within the deglycoBLM molecule [96]. The biochemical evaluation 
of the 108-membered deglycoBLM library afforded some deglycoBLM analogues 
with unique properties, such as improved DNA relaxation potencies or different 
DNA cleavage patterns. The interesting properties of deglycoBLM analogues 
resulting from struture alteration of multiple constituents suggest that a larger 
combinatorial library might provide analogues having improved biochemical 
properties. Another important finding of this 108-membered library is that when 
modification of a single amino acid building block rendered the resulting (deglyco) 
BLM dysfunctional in DNA cleavage, incorporation of other substitutions 
simultaneously would not restore function [96,101]. This finding argues for the 
need to assure that every modified amino acid building block employed in the 
combinatorial library can in principle support BLM analogue function. In this 
study, 11 methylvalerate analogues (2.10–2.20) (Figure 2.2) were prepared as 
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Fmoc derivatives (Scheme 2.10) and incoporated as single modifications in each of 
11 deglycoBLM analogues (Scheme 2.12). Each of the newly prepared 
deglycoBLM analogues was then compared with deglycoBLM A5 in each of three 
types of DNA cleavage assays. 
        Shown in Figures 2.4–2.6 are the results of nicking of supercoiled pBR322 
plasmid DNA. This assay permitted the assessment of single-strand (Form II) and 
double-strand (From III) DNA cleavage activity for each analogue and enabled the 
identification of those analogues exhibiting the greatest potency. All of the 
deglycoBLM analogues were found to retain their ability to nick the supercoiled 
plasmid DNA. As noted in Figures 2.4–2.6, deglycoBLM analogues 2.27 and 2.32 
were the most potent in effecting the nicking of supercoiled plasmid DNA with a 
potency at least as great as deglycoBLM A5. In comparison, deglycoBLMs 2.26 
and 2.28 were the least potent analogues in mediating DNA relaxation, and the 
remaining seven analogues (2.29, 2.30, 2.31, 2.33, 2.34, 2.35 and 2.36) displayed 
intermediate efficiencies. Interestingly, four of the deglycoBLM analogues (2.30, 
2.31, 2.32 and 2.35) were more efficient at nicking the plasmid DNA to afford 
Form II DNA at a concentration of 1 µM, and analogues 2.30 and 2.35 also 
produced a significant amount of linear duplex (Form III) DNA when used at 1 
µM concentration (Figure 2.5), suggesting a greater propensity to produce double-
strand DNA nicks. Interestingly, deglycoBLM analogues 2.26–2.28, which are 
isomers, differing only in the nature of the butyl substituent at C4-position of the 
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methylvalerate moiety, exhibited different DNA nicking efficiency. DeglycoBLM 
2.27 was one of the two most potent analogues studied while 2.26 and 2.28 were 
the least potent. The deglycoBLMs having an aromatic substituent at C2- or C4-
position of the methylvalerate moiety (2.30, 2.31, 2.32 and 2.35) all produced a 
significant amount of Form II DNA. DeglycoBLMs 2.30 and 2.35, both of which 
had benzyl substituents within the methylvalerate moiety, produced the greatest 
amount of Form III DNA. These structural observations can help to guide the 
choice of additional methylvalerate analogues for preparation and evaluation. 
        Each of the deglycoBLM analogues was tested for sequence selectivity of 
DNA cleavage utilizing a 158 base pair 5′-32P end-labeled DNA duplex [174]. As 
shown in Figure 2.8, Fe(II)•deglycoBLM A5 produced cleavage at a number of 
sites, including the expected 5′-GT-3′ and 5′-GC-3′ sites, as well as 5′-AT9-3′ and 
5′-AT21-3′. All 11 deglycoBLMs effected DNA strand scission, producing 
cleavage bands at the same positions as deglycoBLM A5. DeglycoBLM 2.27, 
which exhibited the greatest efficiency at 158-bp DNA duplex cleavage as well as 
plasmid DNA relaxaton, produced additional new cleavage bands at 5′-CG12-3′ 
and 5′-TA15-3′ sequences.  
        Recently, we have described a strategy for selecting 64-nucleotide hairpin 
DNAs that are bound strongly by BLM. Hairpin DNAs selected for their ability 
to bind strongly to BLM were used to determine the relationship between high-
affinity DNA binding sites and the cleavage efficiency and selectivity of BLM on 
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these DNAs. While the characterization of the cleavage of such DNAs by 
Fe•BLM is ongoing, the first two reports [101,173] make it clear that such 
strongly bound DNAs are cleaved at sites quite different from those of randomly 
chosen DNAs, that alkali labile lesions are more prominent, and that BLM 
analogues (such as deglycoBLM) exhibit cleavage patterns that are significantly 
different from those displayed by BLM itself [101,173]. 
        Accordingly, one of the strongly bound hairpin DNAs has been employed as 
a substrate for cleavage by deglycoBLMs 2.26–2.36. As shown in Figure 2.11, 
deglycoBLM analogue 2.27, which provide strong cleavage of the 158-base pair 
DNA duplex, was also the most efficient at mediating cleavage of the 64-
nucleotide hairpin DNA substrate. Unlike the linear DNA duplex, which was 
cleaved by 2.27 at two new sites, the cleavage pattern of the hairpin DNA was the 
same for 2.27 and for deglycoBLM A5. 
 
2.4 Experimental 
General methods:  Chemicals and solvents were of reagent grade and were used 
without further purification. All reactions involving air or moisture-sensitive 
reagents or intermediates were performed under an argon atmosphere. Flash 
chromatography was carried out using Silicycle 200-400 mesh silica gel. Analytical 
TLC was carried out using 0.25 mm EM silica gel 60 F250 plates that were 
visualized by irradiation (254 nm) or by staining with p-anisaldehyde stain. HPLC 
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separations were performed on a Waters 600 series HPLC multi-solvent delivery 
system using a Kratos 747 UV detector. The crude products were purified on an 
Alltech Alltima C18 reversed phase semi-preparative (250 x 10 mm, 5 µm) HPLC 
column using aq 0.1% TFA and CH3CN mobile phases. A linear gradient was 
employed (100:0 0.1% aq TFA/CH3CN → 40:60 0.1% aq TFA/CH3CN) over a 
period of 30 min at a flow rate of 4 mL/min. 1H and 13C NMR spectra were 
obtained using Inova 400, Inova 500 or VNMRS 800 MHz Varian instruments. 
Chemical shifts were reported in parts per million (ppm, δ) referenced to the 
residual 1H resonance of the solvent (CDCl3, 7.26 ppm). 13C spectra were 
referenced to the residual 13C resonance of the solvent (CDCl3, 77.0 ppm). 
Splitting patterns were designated as follows: s, singlet; br, broad; d, doublet; dd, 
doublet of doublets; t, triplet; q, quartet; m, multiplet. High resolution mass 
spectra were obtained in the Arizona State University CLAS High Resolution 
Mass Spectrometry Laboratory.  
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CH3
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N-(t-Butoxycarbonyl)-D-alanine N-methyoxyl-N-methylamine (2.9a) [96]. 
To a solution of 5.00 g (26.4 mmol) of N-D-Boc-alanine in 150 mL of CH2Cl2 was 
added 3.70 mL (26.4 mmol) of NEt3 and 11.7 g (26.4 mmol) of benzotriazol-1-
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yloxytris(dimethylamino)-phosphonium hexafluorophosphate (BOP). The 
mixture was stirred at room temperature for 5 min, and 2.80 g (29.1 mmol) of 
O,N-dimethylhydroxylamine hydrochloride was added, followed by 4.10 mL 
(29.1 mmol) of NEt3. The pH of the reaction was kept at a value higher than 8.0 
and the progress of the reaction was monitored by silica gel TLC. The 
transformation was complete within 2 h. The reaction mixture was then diluted 
with 300 mL of EtOAc and washed with three 50-mL portions of 1 N HCl and 
three 50-mL portions of sat aq NaHCO3. The combined organic layer was washed 
with brine, dried (MgSO4) and concentrated under diminished pressure. The crude 
product was then purified by chromatography on a silica gel column (15 x 5 cm). 
Elution with 2:1 hexanes–EtOAc gave 2.9a as a white solid: yield 5.4 g (88%); 
silica gel TLC Rf 0.55 (1:1 hexanes–EtOAc); 1H NMR (CDCl3) δ 1.29 (d, 3H, J = 
6.8 Hz), 1.42 (s, 9H), 3.19 (s, 3H), 3.75 (s, 3H), 4.66 (d, 1H, J = 6.4 Hz) and 5.25 
(d, 1H, J = 7.2 Hz); 13C NMR (CDCl3) δ 18.7, 28.3, 32.1, 46.5, 61.5, 79.5, 155.2 
and 173.7; mass spectrum (MALDI-TOF), m/z 255.1 (M+Na)+ (theoretical 
255.1). 
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N-(t-Butoxycarbonyl)-D-alaninal (2.9b) [96]. To a stirred solution of 4.42 g 
(19.0 mmol) of N-(t-butoxycarbonyl)-D-alanine N-methyoxyl-N-methylamine 2.9a 
in 120 mL of anhydrous THF was added 903 mg (23.8 mmol) of LiAlH4 at 0 oC. 
The reaction was slowly warmed to room temperature and its progress was 
monitored by TLC. Reduction was complete within 2–3 h, and the reaction was 
quenched by slow addition of 3.70 g (1.40 mmol) of KHSO4 in 20 mL of water at 
0 oC. The resulting mixture was extracted with three 50-mL portions of EtOAc, 
and the organic layer was washed with three 30-mL portions of 1 N HCl and three 
30-mL portions of sat aq NaHCO3. The combined organic layer was then washed 
with brine, dried over Na2SO4 and concentrated under diminished pressure to give 
2.9b as a white solid: yield 2.8 g (86%); silica gel TLC Rf 0.60 (1:1 hexanes–
EtOAc); 1H NMR (CDCl3) δ 1.31 (d, 3H, J = 7.2), 1.45 (s, 9H), 4.21 (dq, 1H, J = 
6), 5.09 (br, 1H) and 9.54 (s, 1H). 
BocHN
N
CH3
OH
CH3
O
O
O
 
(1R,2S,3S,4’S)-[2-Hydroxy-4-(4’-isopropyl-2’-oxo-oxazolidine-3’-yl)-1,3-
dimethyl-4-oxobutyl]carbamic acid tert-butyl ester (2.9c) [96]. To a stirred 
solution of 1.10 g (6.49 mmol) of (S)-(+)-4-isopropyl-3-propionyl-2-
oxazolidinone 2.21 in 1 mL of anhydrous CH2Cl2 at 0 oC was added 6.91 mL (6.91 
mmol) of a 1.0 M solution of Bu2BOTf in CH2Cl2 followed by 1.20 mL (9.10 
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mmol) of (iPr)2NEt. After 45 min, the solution was cooled to –78 oC for 15 min. 
A solution of 1.10 g (6.51 mmol) of N-(tert-butoxycarbonyl)-D-alaninal 2.9b in 4 
mL of CH2Cl2 was added and the solution was allowed to warm to room 
temperature overnight. The reaction was quenched by the addition of 10 mL of 
potassium phosphate buffer, pH 7, and was then extracted with three 50-mL 
portions of Et2O. The combined organic layer was washed with brine and 
concentrated under diminished pressure. The crude oil was dissolved in 21 mL of 
MeOH and cooled to 0 oC, then 7mL of 30% H2O2 was added slowly. The 
mixture was stirred at 0 oC for 4 h, then 20 mL of water was added and the 
reaction mixture was concentrated under diminished pressure. The residue was 
extracted with three 30-mL portions of ethyl ether and the combined organic layer 
was washed with three 30-mL portions of 5% NaHCO3. The resulting organic 
solution was washed with brine, dried over Na2SO4 and concentrated under 
diminished pressure. The residue was purified by flash chromatography on a silica 
gel column (25 x 3.2 cm). Elution with 1:4 hexanes/EtOAc gave 2.9c as a colorless 
solid: yield 1.90 g (82%); silica gel TLC Rf 0.56 (1:1 hexanes–EtOAc); 1H NMR 
(CDCl3) δ 0.84 (d, 3H, J = 7.2), 0.88 (d, 3H, J = 7.2), 1.16 (d, 3H, J = 6.4), 1.27 
(d, 3H, J = 6.8), 1.41 (s, 9H), 2.31 (m, 1H), 3.05 (br, 1H), 3.72 (br, 2H), 3.95 (br, 
1H), 4.16-4.27 (m, 2H), 4.41-4.45 (m, 1H) and 4.60 (br, 1H); mass spectrum 
(MALDI-TOF), m/z 381.2 (M+Na)+ (theoretical 381.2). 
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(2S,3S,4R)-4-tert-Butoxycarbonylamino-3-hydroxy-2-methylpentanoic acid 
(2.9d) [96]. To a cooled (0 oC) solution containing 2.96 g (8.27 mmol) of 2.9c in 
64 mL of 3:1 THF–H2O was added 0.76 mL (49.6 mmol) of 30% H2O2 followed 
by 396 mg (16.5 mmol) of LiOH. After stirring at 0 oC for 3 h, the excess peroxide 
was quenched at 0 oC by the addition of 33 mL of 1.5 N aq Na2SO3 and the pH 
was adjusted to 9–10 with sat aq NaHCO3. The oxazolidinone was recovered by 
extraction with three 20-mL portions of CH2Cl2. The aqueous layer was then 
acidified to pH~2 with 1 N HCl, and extracted with three 40-mL portions of 
EtOAc. The combined organic layer was dried over Na2SO4 and concentrated 
under diminished pressure to give the crude product as a colorless solid: yield 1.94 
g (95%); silica gel TLC Rf 0.10 (8:2:0.2:0.1 CH2Cl2–hexanes–MeOH–AcOH); [α] 
D
23 +1.61 (c 0.50, MeOH); 1H NMR (CDCl3) δ 1.17 (d, 3H, J = 6.4 Hz), 1.26 (d, 
3H, J = 6.8 Hz), 1.41 (s, 9H), 2.64 (m, 1H), 4.09-4.11 (m, 2H), 4.79 (d, 1H, J = 
6.8 Hz) and 5.98 (br, 1H). 
FmocHN
OH
CH3
OH
CH3
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(2S,3S,4R)-4-(H-Fluoren-9-ylmethoxycarbonylamino)-3-hydroxy-2-
methylpentanoic acid (2.9e) [96]: To a solution of 985 mg (3.98 mmol) of 1d in 
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7 mL of Me2S was added 21 mL of TFA. The reaction mixture was stirred at room 
temperature for 2 h. The solution was concentrated under a stream of argon and 
concentrated further under diminished pressure. The resulting oil was dissolved in 
21 mL of 5% aq K2CO3 solution followed by the addition of 1.50 g (4.38 mmol) 
of N-(9-fluorenyl methoxycarbonyloxy) succinimide (FmocOSu) in 14 mL of 
dioxane. The reaction was stirred at room temperature overnight, and the solution 
was extracted successively with three 20-mL portions of ethyl ether and three 20-
mL portions of EtOAc. The combined organic layer was dried over Na2SO4, 
filtered and concentrated under diminished pressure. The crude product was 
purified by flash chromatography on a silica gel column (25 x 3.2 cm). Elution 
with 93:5:2 CH2Cl2–MeOH–AcOH gave 2.9e as a yellow solid: yield 1.38 g 
(94%); mp 92-94 oC; silica gel TLC Rf 0.14 (8:2:0.2:0.1 CH2Cl2–hexanes–MeOH–
AcOH); [α] D23 +1.6 (c 0.50, MeOH); 1H NMR (CDCl3) δ 1.17 (d, 3H, J = 5.2), 
1.25 (d, 3H, J = 6.4), 2.59 (m, 1H), 3.76-3,79 (m, 2H), 4.17-4.18 (m, 1H), 4.39-
4.46 (m, 2H), 4.89 (d, 1H, J = 7.6), 7.27-7.31 (m, 2H), 7.35-7.39 (m, 2H), 7.55 (d, 
2H, J = 7.2) and 7.74 (d, 2H, J = 7.6); 13C NMR (CDCl3) δ 11.9, 16.2, 41.8, 47.3, 
48.9, 66.6, 74.9, 120.0, 124.9, 127.1, 127.8, 141.3, 143.8, 156.1 and 178.0; mass 
spectrum (MALDI-TOF), m/z 392.1 (M+Na)+ (theoretical 392.1). 
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N-(t-Butoxycarbonyl)-D-leucine N-methyoxyl-N-methylamine (2.10a) [96]. 
To a solution of 2.00 g (8.62 mmol) of N-D-Boc-leucine in 30 mL of CH2Cl2 was 
added 1.20 mL (8.62 mmol) of NEt3 and 3.80 g (8.62 mmol) of BOP. The mixture 
was stirred at room temperature for 5 min, and 0.93 g (9.53 mmol) of O,N-
dimethylhydroxylamine hydrochloride was added, followed by 1.30 mL (9.53 
mmol) of NEt3. The pH of the reaction was kept at a value higher than 8.0 and the 
progress was monitored by silica gel TLC. The transformation was complete 
within 2 h. The reaction mixture was then diluted with 100 mL of EtOAc and 
washed three 20-mL portions of 1 N HCl and three 20-mL portions of sat aq 
NaHCO3. The combined organic layer was washed with brine, dried (MgSO4) and 
the solvent was concentrated under diminished pressure. The crude product was 
then purified by chromatography on a silica gel column (15 x 5 cm). Elution with 
2:1 hexanes–EtOAc gave 2.10a as a colorless oil: yield 1.90 g (80%); silica gel 
TLC Rf 0.50 (1:1 hexanes–EtOAc); 1H NMR (CDCl3) δ 0.91 (d, 6H, J = 6.4 Hz), 
1.39 (s, 9H), 1.36-1.44 (m, 2H), 1.64-1.71 (m, 1H), 3.19 (s, 3H), 3.75 (s, 3H), 
4.68 (d, 1H, J = 3.6 Hz) and 5.03 (d, 1H, J = 9.2 Hz); mass spectrum (MALDI-
TOF), m/z 297.2 (M+Na)+ (theoretical 297.2). 
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N-(t-Butoxycarbonyl)-D-leucinal (2.10b) [96]. To a stirred solution of 1.17 g 
(4.31 mmol) of N-(t-butoxycarbonyl)-D-leucine N-methyoxyl-N-methylamine 
2.10a in 50 mL of anhydrous THF was added 203 mg (5.31 mmol) of LiAlH4 at 0 
oC. The reaction was slowly warmed to room temperature and its progress was 
monitored by TLC. Reduction was usually completed with 2–3 h, and then was 
quenched by slow addition of 0.8 g (1.44 mmol) of KHSO4 in 10 mL of water at 0 
oC. The resulting mixture was extracted with three portions of 30 mL of EtOAc, 
and the organic layer was washed three times with 20 mL of 1N HCl and three 
times with 20 mL of sat aq NaHCO3. The combined organic layer was then 
washed with brine, dried over Na2SO4 and concentrated under diminished pressure 
to give 2.10b as a colorless oil: yield 805 mg (88%); silica gel TLC Rf 0.56 (1:1 
hexanes–EtOAc); 1H NMR (CDCl3) δ 0.92-0.94 (m, 6H), 1.45 (s, 9H), 1.38-1.91 
(m, 3H), 4.23 (m, 1H), 4.94 (s, 1H) and 9.55 (s, 1H). 
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(1R,2S,3S,4’S)-[2-Hydroxy-1-isobutyl-4-(4’-isopropyl-2’-oxo-oxazolidine-3’-
yl)-3-methyl-4-oxo-butyl]carbamic acid tert-butyl ester (2.10c) [96]. To a 
stirred solution of 650 mg (3.45 mmol) of (S)-(+)-4-isopropyl-3-propionyl-2-
oxazolidinone 2.21 in 1 mL of anhydrous CH2Cl2 at 0 oC was added 4.00 mL (4.00 
mmol) of a 1.0 M solution of Bu2BOTf in CH2Cl2 followed by 0.90 mL (5.33 
mmol) of (iPr)2NEt. After 45 min, the solution was cooled to –78 oC for 15 min. 
A solution of 816 mg (3.81 mmol) of N-(tert-butoxycarbonyl)-D-leucinal 2.10b in 
4 mL of CH2Cl2 was added and the solution was allowed to warm to room 
temperature overnight. The reaction was quenched by the addition of 10 mL of 
pH 7 potassium phosphate buffer, and was then extracted with three portions of 
30 mL of Et2O. The combined organic layer was washed with brine and 
concentrated under diminished pressure. The crude oil was dissolved in 15 mL of 
MeOH and cooled to 0 oC, then 5 mL of 30% H2O2 was added slowly. The 
mixture was stirred at 0 oC for 4 h when 10 mL of water was added and the 
reaction mixture was concentrated under diminished pressure. The residue was 
extracted with three 20-mL portions of ethyl ether and the combined organic layer 
was washed with three 30-mL portions of 5% NaHCO3. The resulting organic 
solution was washed with brine, dried over Na2SO4 and concentrated under 
diminished pressure. The residue was purified by flash chromatography on a silica 
gel column. Elution with 1:4 hexanes–EtOAc gave 2.10c as a colorless solid: yield 
1.10 g (80%); mp 133-134 oC; silica gel TLC Rf 0.51 (1:1 hexanes–EtOAc); 1H 
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NMR (CDCl3) δ 0.83-0.90 (m, 12H), 1.29 (d, 3H, J = 7.2), 1.40 (s, 9H), 1.70 (m, 
2H), 2.30 (m, 1H), 3.12 (d, 1H, J = 3.6), 3.62-3.70 (m, 2H), 3.94-4.00 (m, 1H), 
4.16-4.26 (m, 3H) and 4.35-4.44 (m, 2H); 13C NMR (CDCl3) δ 11.7, 14.6, 17.9, 
21.5, 23.8, 24.7, 28.3, 28.3, 39.4, 40.8, 50.6, 58.2, 63.2, 74.7, 79.4, 153.3, 155.7 
and 177.6; mass spectrum (MALDI-TOF), m/z 423.2 (M+Na)+(theoretical 
423.2). 
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(2S,3S,4R)-4-tert-Butoxycarbonylamino-3-hydroxy-2,6-dimethylheptanoic 
acid (2.10d) [96]. To a cooled (0 oC) solution containing 826 mg (2.06 mmol) of 
2.10c in 36 mL of 3:1 THF–H2O was added 1.90 mL (13.4 mmol) of 30% H2O2 
followed by 99.0 mg (4.10 mmol) of LiOH. After stirring at 0 oC for 3 h, the 
excess peroxide was quenched at 0 oC by the addition of 8.2 mL of 1.5N aq 
Na2SO3 and the pH was adjusted to 9–10 with sat aq NaHCO3, and the 
oxazolidinone was removed by extraction with three 10-mL portions of CH2Cl2. 
The aqueous layer was then acidified to pH~2 with 1N HCl, and extracted with 
three 10-mL portions of EtOAc. The combined organic layer was dried over 
Na2SO4 and concentrated under diminished pressure to give the crude product as a 
colorless solid: yield 512 mg (87%); silica gel TLC Rf 0.15 (8:2:0.2:0.1 CH2Cl2–
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hexanes–MeOH–AcOH); [α] D23 +31.8 (c 1.0, MeOH); 1H NMR (CDCl3) δ 0.88-
0.92 (m, 6H), 1.25 (d, 3H, J = 6.8), 1.39 (m, 1H), 1.44 (s, 9H), 1.55 (m, 1H), 1.63 
(m, 1H), 2.61-2.65 (m, 1H), 3.67-3.78 (m, 2H), 5.55 (d, 1H, J = 9.2) and 5.79 (d, 
1H, J = 9.6); 13C NMR (CDCl3) δ 11.9, 21.4, 23.8, 24.7, 28.3, 39.8, 42.0, 52.5, 
74.8, 77.3, 156.1 and 180.4; mass spectrum (MALDI-TOF), m/z 312.2 (M+Na)+ 
(theoretical 312.2). 
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(2S,3S,4R)-4-(H-Fluoren-9-ylmethoxycarbonylamino)-3-hydroxy-2,6-
dimethylheptanoic acid (2.10e) [96]: To a solution of 624 mg (1.52 mmol) of 
2.10d in 7 mL of Me2S was added 12 mL of TFA. The reaction mixture was 
stirred at room temperature for 2 h. The solution was concentrated under a stream 
of argon and concentrated further under diminished pressure. The resulting oil was 
dissolved in 12 mL of 5% K2CO3 solution followed by the addition of 0.80 g (2.37 
mmol) of FmocOSu in 20 mL of dioxane. After the reaction was stirred at room 
temperature overnight, the solution was extracted with three 20-mL portions of 
ethyl ether and three 20-mL portions of EtOAc. The combined organic layer was 
dried over Na2SO4, filtered and concentrated under diminished pressure. The crude 
product was then purified by flash chromatography on a silica gel column. Elution 
  82 
with 93:5:2 CH2Cl2–MeOH–AcOH gave 2.10e as a yellow solid: yield 825 mg 
(93%); silica gel TLC Rf 0.20 (8:2:0.2:0.1 CH2Cl2–hexanes–MeOH–AcOH);); [α] 
D
24 +18.0 (c 0.4, MeOH); 1H NMR (CDCl3) δ 0.90-0.93 (m, 6H), 1.28 (d, 3H, J = 
6.5), 1.29-1.30 (m, 1H), 1.55-1.62 (m, 2H), 2.60-2.64 (m, 1H), 3.71-3.77 (m, 2H), 
4.21 (dd, 1H, J = 6.0, J = 6.5), 4.48-4.51 (m, 2H), 7.32-7.34 (m, 2H), 7.40-7.43 
(m, 2H), 7.60 (d, 2H, J = 7.5) and 7.78 (d, 2H, J = 7.5); 13C NMR (CDCl3) δ 11.5, 
20.8, 21.4, 23.9, 24.6, 39.8, 47.4, 51.6, 66.3, 75.0, 120.0, 124.9, 127.0, 127.7, 
141.4, 143.8, 156.4 and 177.2; mass spectrum (MALDI-TOF), m/z 434.2 
(M+Na)+ (theoretical 434.2). 
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N-(t-Butoxycarbonyl)-D-phenylalanine N-methyoxyl-N-methylamine 
(2.14a) [96]. To a solution of 2.00 g (7.50 mmol) of N-D-Boc-phenylalanine in 30 
mL of CH2Cl2 was added 1.10 mL (7.50 mmol) of NEt3 and 3.30 g (7.50 mmol) of 
BOP. The mixture was stirred at room temperature for 5 min, and 0.81 g (8.32 
mmol) of O,N-dimethylhydroxylamine hydrochloride was added followed by 1.20 
mL (8.35 mmol) of NEt3. The pH of the reaction was kept at a value higher than 
8.0 and the reaction progress was monitored by TLC. The transformation was 
completed within 2 h. The reaction mixture was then diluted with 100 mL of 
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EtOAc and washed three times with 20 mL of 1N HCl and three times with 20 
mL of sat aq NaHCO3. The combined organic layer was washed with brine, dried 
(MgSO4) and the solvent was removed under diminished pressure. The crude 
product was then purified by chromatography on a silica gel column. Elution with 
2:1 hexanes–EtOAc gave 2.14a as a colorless oil: yield 2.30 g (98%); silica gel 
TLC Rf 0.46 (1:1 hexanes–EtOAc); 1H NMR (CDCl3) δ 1.37 (s, 9H), 2.85 (dd, 
1H, J = 6.8 Hz, 7.2 Hz), 3.01 (dd, 1H, J = 13.2 Hz, 6.2 Hz), 3.14 (s, 3H), 3.63 (s, 
3H), 4.91 (m, 1H), 5.17 (d, 1H, J = 7.6 Hz) and 7.14-7.27 (m, 5H). 
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N-(t-Butoxycarbonyl)-D-phenylalaninal (2.14b) [96]. To a stirred solution of 
1.17 g (4.32 mmol) of 2.14a in 50 mL of anhydrous ethyl ether was added 80.7 mg 
(2.12 mmol) of LiAlH4 at 0 oC. The reaction was slowly warmed to room 
temperature and its progress was monitored by TLC. Reduction was usually 
completed with 2–3 h, and then was quenched by slow addition of 368 mg (2.71 
mmol) of KHSO4 in 10 mL of water at 0 oC. The resulting mixture was extracted 
with three portions of 20 mL of EtOAc, and the organic layer was washed three 
times with 20 mL of 1N HCl and three times with 20 mL of sat aq NaHCO3. The 
combined organic layer was then washed with brine, dried over Na2SO4 and 
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concentrated under diminished pressure to give 2.14b as a white solid: yield 361 
mg (80%); silica gel TLC Rf 0.60 (1:1 hexanes–EtOAc); 1H NMR (CDCl3) δ 1.45 
(s, 9H), 3.10 (d, 2H, J = 6.4), 4.41 (m, 1H), 5.03 (br, 1H), 7.15-7.32 (m, 5H) and 
9.62 (s, 1H). 
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(1R,2S,3S,4’S)-[1-Benzyl-2-hydroxy-4-(4’-isopropyl-2’-oxo-oxazolidine-3’-
yl)-3-methyl-4-oxo-butyl]carbamic acid tert-butyl ester (2.14c) [96]. To a 
stirred solution of 1.19 g (4.76 mmol) of (S)-(+)-4-isopropyl-3-propionyl-2-
oxazolidinone 2.21 in 2 mL of anhydrous CH2Cl2 at 0 oC was added 5 mL (5.00 
mmol) of a 1.0 M solution of Bu2BOTf in CH2Cl2 followed by 1.16 mL (6.67 
mmol) of (iPr)2NEt. After 45 min, the solution was cooled to –78 oC for 15 min. 
A solution of 816 mg (4.33 mmol) of N-(tert-butoxycarbonyl)-D-phenylalaninal 
2.14b in 4 mL of CH2Cl2 was added and the solution was allowed to warm to 
room temperature overnight. The reaction was quenched by the addition of 10 mL 
of pH 7 potassium phosphate buffer, and was then extracted with three portions 
of 30 mL of Et2O. The combined organic layer was washed with brine and 
concentrated under diminished pressure. The crude oil was dissolved in 30 mL of 
MeOH and cooled to 0 oC, then 10 mL of 30% H2O2 was added slowly. The 
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mixture was stirred at 0 oC for 4 h when 10 mL of water was added and the 
reaction mixture was concentrated under diminished pressure. The residue was 
extracted with three 20-mL portions of ethyl ether and the combined organic layer 
was washed with three 30-mL portions of 5% NaHCO3. The resulting organic 
solution was washed with brine, dried over Na2SO4 and concentrated under 
diminished pressure. The residue was purified by flash chromatography on a silica 
gel column. Elution with 1:4 hexanes–EtOAc gave 2.14c as a colorless solid: yield 
1.66 g (88%); silica gel TLC Rf 0.51 (1:1 hexanes–EtOAc); [α] D23 +59.4 (c 1.4, 
MeOH); 1H NMR (CDCl3) δ 0.87-0.95 (m, 6H), 1.32 (d, 3H, J = 7.2 Hz), 1.40 (s, 
9H), 2.29 (m, 1H), 2.93 (m, 1H), 3.02 (m, 1H), 3.40 (br, 1H), 3.75-3.78 (m, 1H), 
3.91-3.93 (m, 2H), 4.13-4.21 (m, 2H), 4.34-4.38 (m, 1H), 4.44 (d, 1H, J = 9.6) 
and 7.15-7.27 (m, 5H); 13C NMR (CDCl3) δ 11.4, 14.7, 17.9, 27.9, 36.6, 39.1, 
52.3, 58.1, 63.3, 72.4, 79.5, 126.3, 128.3, 129.9, 137.7, 153.2, 155.4 and 177.8; 
mass spectrum (MALDI-TOF), m/z 457.2 (M+Na)+ (theoretical 457.2). 
 
BocHN
OH
OH
CH3
O
 
(2S,3S,4R)-4-tert-Butoxycarbonylamino-3-hydroxy-2-methyl-5-
phenylpentanoic acid (2.14d) [96]. To a cooled (0 oC) solution containing 1.58 g 
(3.64 mmol) of 2.11c in 36 mL of 3:1 THF–H2O was added 3.60 mL (22.8 mmol) 
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of 30% H2O2 followed by 179.6 mg (7.63 mmol) of LiOH. After stirring at 0 oC 
for 3 h, the excess peroxide was quenched at 0 oC by the addition of 15.2 mL of 
1.5N aq Na2SO3 and the pH was adjusted to 9–10 with sat aq NaHCO3, and the 
oxazolidinone was removed by extraction with three 10-mL portions of CH2Cl2. 
The aqueous layer was then acidified to pH~2 with 1N HCl, and extracted with 
three 10-mL portions of EtOAc. The combined organic layer was dried over 
Na2SO4 and concentrated under diminished pressure to give the crude product as a 
colorless solid: yield 996 mg (85%); silica gel TLC Rf 0.13 (8:2:0.2:0.1 CH2Cl2–
hexanes–MeOH–AcOH); [α] D23 +33 (c 0.47, MeOH); 1H NMR (MeOH-d4) δ 
1.13 (d, 3H, J = 7.2 Hz), 1.21 (s, 9H), 2.48 (m, 1H), 2.60 (m, 1H), 3.12 (dd, 1H, J 
= 3.1 Hz, J = 13.5 Hz), 3.66 (m, 1H), 3.83 (br, 1H) and 7.15 (m, 5H); mass 
spectrum (MALDI-TOF), m/z 346.2 (M+Na)+ (theoretical 346.2). 
 
FmocHN
OH
OH
CH3
O
 
(2S,3S,4R)-4-(H-Fluoren-9-ylmethoxycarbonylamino)-3-hydroxy-2-methyl-
5-phenylpentanoic acid (2.14e) [96]: To a solution of 996 mg (3.08 mmol) of 
2.9d in 9 mL of Me2S was added 15 mL of TFA. The reaction mixture was stirred 
at room temperature for 2 h. The solution was concentrated under a stream of 
argon and concentrated further under diminished pressure. The resulting oil was 
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dissolved in 15 mL of 5% K2CO3 solution followed by the addition of 1.14 g (3.39 
mmol) of FmocOSu in 20 mL of dioxane. After the reaction was stirred at room 
temperature overnight, the solution was extracted with three 20-mL portions of 
ethyl ether and three 20-mL portions of EtOAc. The combined organic layer was 
dried over Na2SO4, filtered and concentrated under diminished pressure. The crude 
product was then purified by flash chromatography on a silica gel column. Elution 
with 93:5:2 CH2Cl2– MeOH–AcOH gave 2.14e as a yellow solid: yield 1.16 g 
(85%); mp 149-151 oC; silica gel TLC Rf 0.16 (8:2:0.2:0.1 CH2Cl2–hexanes–
MeOH–AcOH); [α] D23 +34.6 (c 0.5, MeOH); 1H NMR (CDCl3) δ 1.28 (d, 3H, J 
= 7.2 Hz), 2.64-2.66 (m, 1H), 2.78-2.83 (m, 1H), 3.04 (dd, 1H, J = 7.2, 13.6 Hz), 
3.84-3.94 (m, 1H), 4.07-4.11 (m, 1H), 4.26-4.30 (m, 1H), 4.40-4.44 (m, 1H), 4.72 
(d, 1H, J = 8.8 Hz), 6.06 (d, 1H, J = 10.0), 7.12-7.30 (m, 7H), 7.36-7.40 (m, 1H), 
7.44-7.47 (m, 2H) and 7.74 (d, 2H, J = 7.6 Hz); 13C NMR (CDCl3) δ 10.7, 36.2, 
41.1, 47.3, 53.3, 66.5, 72.4, 120.0, 124.9, 120.6, 127.0, 127.7, 128.5, 129.7, 137.1, 
141.3, 143.7, 156.1 and 181.6;  mass spectrum (MALDI-TOF), m/z 446.2 
(M+Na)+ (theoretical 446.2). 
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N-(t-Butoxycarbonyl)-D-2-bromophenylalanine N-methyl-N-methoxyamide 
(2.15a). To a solution of 1.00 g (2.90 mmol) of N-Boc-D-2-bromophenylalanine in 
20 mL of CH2Cl2 was added 405 µL (2.90 mmol) of NEt3 and 1.30 g (2.90 mmol) 
of benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate 
(BOP). The reaction mixture was stirred at room temperature for 5 min, and 312 
mg (3.21 mmol) of N-methyl-N-methoxylamine hydrochloride was added, 
followed by 446 µL (3.21 mmol) of NEt3. The pH of the reaction was kept at a 
value higher than 8.0 and the progress of the reaction was monitored by silica gel 
TLC. The reaction was complete within 2 h. The reaction mixture was then 
diluted with 100 mL of EtOAc and washed with three 20-mL portions of 1N HCl 
and three 20-mL portions of sat aq NaHCO3. The combined organic layer was 
washed with brine, dried (MgSO4) and the solvent was concentrated under 
diminished pressure. The crude product was purified by chromatography on a 
silica gel column (25 x 3.2 cm). Elution with 2:1 hexanes–EtOAc gave 2.15a as a 
white solid: yield 931 mg (83%); silica gel TLC Rf 0.46 (1:1 hexanes–EtOAc); 1H 
NMR (CDCl3) δ 1.33 (s, 9H), 3.00-3.03 (m, 1H), 3.13 (s, 1H), 3.16-3.17 (m, 1H), 
3.69 (s, 3H), 5.07-5.08 (m, 1H), 5.20-5.22 (m, 1H), 7.05-7.08 (m, 1H), 7.17-7.22 
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(m, 2H) and 7.51 (d, 2H, J = 8.0 Hz); 13C NMR (CDCl3) δ 19.2, 28.3, 32.1, 39.0, 
49.9, 61.7, 79.5, 127.1, 128.4, 131.7, 132.7, 136.2, 154.9 and 172.0; mass 
spectrum (MALDI-TOF), m/z 410.8 and 409.2 (M+Na)+ (theoretical 411.1 and 
409.1); mass spectrum (APCI), m/z 389.0861 and 387.0916 (M+H)+ 
(C16H24N2O4Br requires 389.0899 and 387.0919).  
 
N
H
O
Boc
H
Br
                 
N-(t-Butoxycarbonyl)-D -2-bromophenyalaninal (2.15b). To a stirred solution 
of 902 mg (2.32 mmol) of 2.11b in 50 mL of anhydrous THF was added 111 mg 
(2.91 mmol) of LiAlH4 at 0 oC. The reaction was warmed slowly to room 
temperature and its progress was monitored by silica gel TLC. Reduction was 
complete within 2–3 h, and the reaction was quenched by slow addition of 444 mg 
(3.33 mmol) of KHSO4 in 10 mL of water at 0 oC. The resulting mixture was 
extracted with three 20-mL portions of EtOAc, and the organic layer was washed 
with three 20-mL portions of 1N HCl and three 20-mL portions of sat aq 
NaHCO3. The combined organic layer was then washed with brine, dried over 
Na2SO4 and concentrated under diminished pressure to give 2.15b as a white solid: 
yield 629 mg (82%); silica gel TLC Rf 0.51 (1:1 hexanes–EtOAc); 1H NMR 
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(CDCl3) δ 1.41 (s, 9H), 2.75-2.94 (m, 2H), 4.13 (m, 1H), 5.12 (br, 1H), 7.02-7.35 
(m, 1H), 7.51-7.61 (m, 3H) and 9.69 (s, 1H). The product was used promptly for 
the next preparation of 2.15c. 
 
BocHN
N
OH
CH3
O
O
O
Br
 
(1R,2S,3S,4′S)-[1-(2′-Bromobenzyl)-2-hydroxy-4-(4′-isopropyl-2′-oxo-
oxazolidin-3′-yl)-3-methyl-4-oxobutyl]carbamic acid tert-butyl ester (2.15c). 
To a stirred solution of 220 mg (1.2 mmol) of (S)-(+)-4-isopropyl-3-propionyl-2-
oxazolidinone (2.21) in 1 mL of anhydrous CH2Cl2 at 0 oC was added 1.39 mL 
(1.39 mmol) of a 1.0 M solution of Bu2BOTf in CH2Cl2 followed by 319 µL (1.8 
mmol) of (iPr)2NEt. After 45 min, the solution was cooled to –78 oC for 15 min. 
A solution of 430 mg (1.31 mmol) of 2.15b in 1 mL of CH2Cl2 was added and the 
solution was allowed to warm to room temperature overnight. The reaction was 
quenched by the addition of 10 mL of potassium phosphate buffer, pH 7.0, and 
was then extracted with three 30-mL portions of Et2O. The combined organic 
layer was washed with brine and concentrated under diminished pressure. The 
crude oil was dissolved in 15 mL of MeOH and cooled to 0 oC, then 5 mL of 30% 
H2O2 was added slowly. The mixture was stirred at 0 oC for 4 h, then 10 mL of 
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water was added and the reaction mixture was concentrated under diminished 
pressure. The residue was extracted with three 20-mL portions of ethyl ether and 
the combined organic layer was washed with three 30-mL portions of 5% 
NaHCO3. The resulting organic solution was washed with brine, dried over 
Na2SO4 and concentrated under diminished pressure. The residue was purified by 
flash chromatography on a silica gel column (25 x 3.2 cm). Elution with 1:4 
hexanes–EtOAc gave 2.15c as a colorless solid: yield 507 mg (84%); silica gel TLC 
Rf 0.45 (1:1 hexanes–EtOAc); [α]24D +84.9 (c 1.5, MeOH); 1H NMR (CDCl3) δ 
0.87 (dd, 6H, J = 7.6 and 7.2 Hz), 1.11 (s, 3H), 1.28 (s, 9H), 2.28-2.35 (m, 1H), 
2.81-2.87 (m, 1H), 3.28-3.39 (m, 2H), 3.91-4.04 (m, 3H), 4.18-4.26 (m, 2H), 
4.42-4.44 (m, 1H), 4.58 (d, 1H, J = 9.2 Hz), 7.01-7.05 (m, 1H), 7.17-7.25 (m, 2H) 
and 7.48 (d, 1H, J = 8.0 Hz); 13C NMR (CDCl3) δ 12.2, 14.7, 17.9, 19.1, 28.2, 
36.8, 39.8, 53.0, 58.2, 63.4, 74.1, 79.4, 125.1, 127.3, 131.7, 132.7, 138.0, 153.3, 
155.5 and 177.2; mass spectrum (MALDI-TOF), m/z 537.4 and 535.1 
(M+Na)+(theoretical 537.1 and 535.1); mass spectrum (APCI), m/z 513.1604 and 
515.1586 (M+H)+ (C23H34N2O6Br requires 513.1600 and 515.1580). 
 
BocHN
OH
OH O
Br
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(2S,3S,4R)-4-tert-Butoxycarbonylamino-5-(2′-bromophenyl)-3-hydroxy-2-
methylpentanoic acid (2.15d). To a cooled (0 oC) solution containing 599 mg 
(1.17 mmol) of 2.15c in 24 mL of 3:1 THF/H2O was added 1.1 mL (7.01 mmol) of 
30% H2O2 followed by 56 mg (2.32 mmol) of LiOH. After stirring at 0 oC for 3 h, 
the excess peroxide was quenched at 0 oC by the addition of 4.7 mL of 1.5 N aq 
Na2SO3 and the pH was adjusted to 9–10 with sat aq NaHCO3. The oxazolidinone 
was recovered by extraction with three 10-mL portions of CH2Cl2. The aqueous 
layer was then acidified to pH ~2 with 1 N HCl, and extracted with three 10-mL 
portions of EtOAc. The combined organic layer was dried over Na2SO4 and 
concentrated under diminished pressure to give the crude product as a colorless 
solid: yield 440 mg (94%); silica gel TLC Rf 0.20 (8:2:0.2:0.1 CH2Cl2–hexanes–
MeOH–AcOH); [α]23D +55.1 (c 0.8, MeOH); 1H NMR (CDCl3) δ 1.15 (d, 3H, J 
= 7.2 Hz), 1.30 (s, 9H), 2.56-2.61 (m, 1H), 2.75 2.85 (m, 1H), 2.91-2.96 (m, 1H), 
3.95-4.05 (m, 2H), 7.07-7.10 (m, 1H), 7.24-7.30 (m, 2H) and 7.54 (d, 1H, J = 
8.0 Hz); mass spectrum (MALDI-TOF), m/z 426.1 and 424.0 (M+Na)+ 
(theoretical 426.1 and 424.1); mass spectrum (APCI), m/z 402.0907 and 404.0896 
(M+H)+ (C17H25NO5Br requires 402.0916 and 404.0896). 
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(2S,3S,4R)-5-(2′-Bromophenyl-4-(9H-fluoren-9-ylmethoxycarbonylamino)-
3-hydroxy-2-methylpentanoic acid (2.15e). To a solution of 409 mg (1.02 
mmol) of 2.15d in 5 mL of Me2S was added 8 mL of TFA. The reaction mixture 
was stirred at room temperature for 2 h. The solution was concentrated under a 
stream of argon and concentrated further under diminished pressure. The resulting 
oil was dissolved in 8 mL of 5% aq K2CO3 solution followed by the addition of 
338 mg (1.12 mmol) of FmocOSu in 10 mL of dioxane. The reaction was stirred at 
room temperature overnight, and the solution was then extracted successively 
with three 20-mL portions of ethyl ether and three 20-mL portions of EtOAc. 
The combined organic layer was dried over Na2SO4, filtered and concentrated 
under diminished pressure. The crude product was purified by flash 
chromatography on a silica gel column (25 x 3.2 cm). Elution with 93:5:2 CH2Cl2–
MeOH–AcOH gave 2.15e as a yellow solid: yield 448 mg (84%); mp 104-105 oC; 
silica gel TLC Rf 0.18 (8:2:0.2:0.1 CH2Cl2–hexanes–MeOH–AcOH); [α]23D +13.0 
(c 0.54, MeOH); 1H NMR (CDCl3) δ 1.25 (d, 3H, J = 7.0 Hz), 2.51-2.59 (m, 1H), 
2.62-2.69 (m, 1H), 2.82-2.87 (m, 1H), 3.22 (d, 1H, J = 14.0 Hz), 3.40-3.94 (m, 
3H), 4.07-4.11 (m, 1H), 4.20-4.24 (m, 1H), 4.87 (d, 1H, J = 7.5 Hz), 6.91-6.99 
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(m, 1H), 7.06 -7.14 (m, 2H), 7.18-7.22 (m, 2H), 7.30 (d, 2H, J = 3.5 Hz), 7.35-
7.41 (m, 3H) and 7.65 (d, 2H, J = 7.5 Hz); 13C NMR (CDCl3) δ 10.5, 35.1, 40.6, 
46.1, 52.9, 65.8, 73.2, 118.9, 124.0, 126.0, 126.5, 126.7, 127.3, 130.5, 131.8, 
136.5, 140.3, 142.6, 142.9, 155.2 and 179.6; mass spectrum (MALDI-TOF), m/z 
548.4 and 546.7 (M+Na)+ (theoretical 548.1 and 546.1); mass spectrum (APCI), 
m/z 524.1078 and 526.1075 (M+H)+ (C27H27NO5Br requires 524.1072 and 
526.1052). 
 
N
H
N
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N-(t-Butoxycarbonyl)-D-2-methylphenylalanine N-methyl-N-
methoxyamide (2.16a). To a solution of 1.00 g (3.61 mmol) of N-Boc-D-2-
methylphenylalanine in 30 mL of CH2Cl2 was added 499 µL (3.61 mmol) of NEt3 
and 1.60 g (3.61 mmol) of BOP reagent. The reaction mixture was stirred at room 
temperature for 5 min, and 384 mg (3.93 mmol) of N-methyl-N-methoxylamine 
hydrochloride was added, followed by 549 µL (3.93 mmol) of NEt3. The pH of 
the reaction was kept at a value higher than 8.0 and the progress of the reaction 
was monitored by silica gel TLC. The transformation was complete within 2 h. 
The reaction mixture was then diluted with 100 mL of EtOAc and washed 
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successively with three 20-mL portions of 1 N HCl and three 20-mL portions of 
sat aq NaHCO3. The combined organic layer was washed with brine, dried 
(MgSO4) and the solvent was concentrated under diminished pressure. The crude 
product was purified by chromatography on a silica gel column (25 x 3.2 cm). 
Elution with 2:1 hexanes–EtOAc gave 2.16a as a white solid: yield 1.1 g (97%); 
silica gel TLC Rf 0.46 (1:1 hexanes–EtOAc); 1H NMR (CDCl3) δ 1.36 (s, 9H), 
2.37 (s, 3H), 2.84-2.88 (m, 1H), 3.06 (dd, 1H, J = 7.5 and 6.5 Hz), 3.14 (s, 3H), 
3.60 (s, 3H), 4.99-5.00 (m, 1H), 5.27 (d, 1H, J = 8.0 Hz) and 7.10-7.12 (m, 4H); 
13C NMR (CDCl3) δ 19.3, 28.3, 32.0, 36.6, 50.1, 61.4, 79.4, 125.7, 126.8, 130.2, 
134.8, 136.2, 136.8, 155.1 and 172.6; mass spectrum (MALDI-TOF), m/z 345.3 
(M+Na)+ (theoretical 345.2); mass spectrum (APCI), m/z 323.1981 (M+H)+ 
(C17H27N2O4 requires 323.1971). 
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N-(t-Butoxycarbonyl)-D-2-methylphenylalaninal (2.16b). To a stirred solution 
of 947 mg (2.94 mmol) of 2.16a in 50 mL of anhydrous THF was added 139 mg 
(3.71 mmol) of LiAlH4 at 0 oC. The reaction was warmed slowly to room 
temperature and its progress was monitored by silica gel TLC. The reduction was 
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complete within 2–3 h, and the reaction was quenched by the slow addition of 560 
mg (4.13 mmol) of KHSO4 in 10 mL of water at 0 oC. The resulting mixture was 
extracted with three 20-mL portions of EtOAc, and the organic layer was washed 
with three 20-mL portions of 1N HCl and three 20-mL portions of sat aq 
NaHCO3. The combined organic layer was then washed with brine, dried over 
Na2SO4 and concentrated under diminished pressure to give 2.16b as a white solid: 
yield 687 mg (89%); silica gel TLC Rf 0.60 (1:1 hexanes–EtOAc); 1H NMR 
(CDCl3) δ 1.41 (s, 9H), 2.36 (s, 3H), 2.75 (m, 1H), 3.10 (m, 1H), 4.15 (m, 1H), 
5.11 (m, 1H), 7.04-7.12 (m, 4H) and 9.60 (s, 1H). The product was used 
promptly for the preparation of 2.16c. 
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(1R,2S,3S,4′S)-[2-Hydroxy-1-(2′-methylbenzyl)-4-(4′-isopropyl-2′-oxo-
oxazolidin-3′-yl)-3-methyl-4-oxobutyl]carbamic acid tert-butyl ester (2.16c). 
To a stirred solution of 249 mg (1.34 mmol) of (S)-(+)-4-isopropyl-3-propionyl-
2-oxazolidinone (2.21) in 1 mL of anhydrous CH2Cl2 at 0 oC was added 1.57 mL 
(1.57 mmol) of a 1.0 M solution of Bu2BOTf in CH2Cl2 followed by 361 µL (2.07 
mmol) of (iPr)2NEt. After 45 min, the solution was cooled to –78 oC for 15 min. 
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A solution of 390 mg (1.48 mmol) of 2.16b in 2 mL of CH2Cl2 was added and the 
solution was allowed to warm to room temperature overnight. The reaction was 
quenched by the addition of 10 mL of potassium phosphate buffer, pH 7.0, and 
was then extracted with three 30-mL portions of Et2O. The combined organic 
layer was washed with brine and concentrated under diminished pressure. The 
crude oil was dissolved in 15 mL of MeOH and cooled to 0 oC, then 5 mL of 30% 
H2O2 was added slowly. The mixture was stirred at 0 oC for 4 h, then 10 mL of 
water was added and the reaction mixture was concentrated under diminished 
pressure. The residue was extracted with three 20-mL portions of ethyl ether and 
the combined organic layer was washed with three 30-mL portions of 5% 
NaHCO3. The resulting organic solution was washed with brine, dried over 
Na2SO4 and concentrated under diminished pressure. The residue was purified by 
flash chromatography on a silica gel column (25 x 3.2 cm). Elution with 1:4 
hexanes–EtOAc gave 2.16c as a colorless solid: yield 482 mg (80%); silica gel TLC 
Rf 0.48 (1:1 hexanes–EtOAc); [α]24D +83.7 (c 1.0, MeOH); 1H NMR (CDCl3) δ 
0.86 (dd, 6H, J = 8.8 and 7.2 Hz), 1.13 (s, 3H), 1.31 (s, 9H), 2.31 (s, 3H), 2.32-
2.33 (m, 1H), 2.65-2.71 (m, 1H), 3.17-3.22 (m, 2H), 3.31 (d, 1H, J = 13.2 Hz), 
3.77-3.98 (m, 2H), 4.16-4.23 (m, 2H), 4.38-4.41 (m, 1H), 4.46 (d, 1H, J = 9.2 Hz) 
and 7.06-7.11 (m, 4H); 13C NMR (CDCl3) δ 11.8, 14.7, 17.9, 19.5, 28.3, 34.1, 
39.5, 52.4, 58.1, 63.3, 73.4, 79.4, 125.7, 126.3, 130.3, 130.4, 136.4, 136.7, 153.3, 
155.3 and 177.5; ; mass spectrum (MALDI-TOF), m/z 471.5 (M+Na)+ 
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(theoretical 471.2); mass spectrum (APCI), m/z 449.2655 (M+H)+ (C24H37N2O6 
requires 449.2652). 
 
BocHN
OH
OH O
Me
 
(2S,3S,4R)-4-tert-Butoxycarbonylamino-3-hydroxy-2-methyl-5-(2′-
methylphenylpentanoic acid (2.16d). To a cooled (0 oC) solution containing 599 
mg (1.34 mmol) of 2.16c in 24 mL of 3:1 THF/H2O was added 1.20 mL (8.02 
mmol) of 30% H2O2 followed by 63.9 mg (2.70 mmol) of LiOH. After stirring at 0 
oC for 3 h, the excess peroxide was quenched at 0 oC by the addition of 5.3 mL of 
1.5 N aq Na2SO3 and the pH was adjusted to 9–10 with sat aq NaHCO3. The 
oxazolidinone was recovered by extraction with three 10-mL portions of CH2Cl2. 
The aqueous layer was then acidified to pH ~2 with 1 N HCl, and extracted with 
three 10-mL portions of EtOAc. The combined organic layer was dried over 
Na2SO4 and concentrated under diminished pressure to give the crude product as a 
colorless solid: yield 409 mg (90%); silica gel TLC Rf 0.22 (8:2:0.2:0.1 CH2Cl2–
hexanes–MeOH–AcOH); [α]23D +26.4 (c 0.45, MeOH); 1H NMR (CDCl3) δ 1.11 
(d, 3H, J = 7.2 Hz), 1.29 (s, 9H), 2.32 (3H, s), 2.72-2.75 (m, 2H), 3.60 (dd, 2H, J 
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= 7.6 and 7.2 Hz); 3.72-3.96 (m, 2H) and 7.03-7.18 (m, 4H); mass spectrum 
(APCI), m/z 338.1961 (M+H)+ (C18H28NO5 requires 338.1967). 
 
FmocHN
OH
OH O
Me
 
(2S,3S,4R)-4-(9H-Fluoren-9-ylmethoxycarbonylamino)-3-hydroxy-2-methyl-
5-(2′-methylphenylpentanoic acid (2.16e). To a solution of 386 mg (1.14 mmol) 
of 2.16d in 5 mL of Me2S was added 8 mL of TFA. The reaction mixture was 
stirred at room temperature for 2 h. The solution was concentrated under a stream 
of argon and concentrated further under diminished pressure. The resulting oil was 
dissolved in 8 mL of 5% aq K2CO3 solution followed by the addition of 424 mg 
(1.26 mmol) of FmocOSu in 10 mL of dioxane. The reaction was stirred at room 
temperature overnight, and the solution was then extracted successively with three 
20-mL portions of ethyl ether and three 20-mL portions of EtOAc. The combined 
organic layer was dried over Na2SO4, filtered and concentrated under diminished 
pressure. The crude product was purified by flash chromatography on a silica gel 
column (25 x 3.2 cm). Elution with 93:5:2 CH2Cl2–MeOH–AcOH gave 2.16e as a 
yellow solid: yield 499 mg (95%); mp 118-120 oC; silica gel TLC Rf 0.17 
(8:2:0.2:0.1 CH2Cl2–hexanes–MeOH–AcOH); [α]23D +104 (c 0.2, MeOH); 1H 
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NMR (CDCl3) δ 1.23 (d, 3H, J = 9.0 Hz), 2.21 (s, 3H), 2.34-2.41 (m, 1H), 2.60-
2.64 (m, 1H), 3.09-3.12 (m, 1H), 3.71-3.84 (m, 1H), 3.89-3.99 (m, 2H), 4.09-4.19 
(m, 1H), 4.63 (d, 1H, J = 11.5 Hz), 6.98-7.02 (m, 4H), 7.18-7.21 (m, 3H), 7.30 (t, 
2H, J = 9.0 Hz), 7.38 (t, 1H, J = 10.5 Hz) and 7.66 (m, 2H, J = 8.5 Hz); 13C 
NMR (CDCl3) δ 11.3, 19.5, 33.5, 41.5, 47.2, 53.3, 66.6, 73.8, 119.9, 125.0, 125.9, 
126.7, 127.0, 127.7, 130.3, 130.5, 135.9, 136.7, 141.3, 143.6, 156.2 and 181.1; 
mass spectrum (MALDI-TOF), m/z 482.7 (M+Na)+ (theoretical 482.2); mass 
spectrum (APCI), m/z 460.2114 (M+H)+ (C28H30NO5 requires 460.2124). 
 
BocHN
N
OH O
O
O
 
(1R,2S,3S,4′S)-[2-Hydroxy-3-isobutyl-4-(4′-isopropyl-2′-oxo-oxazolidin-3′-
yl)-1-methyl-4-oxobutyl]carbamic acid tert-butyl ester (2.18c). To a stirred 
solution of 2.00 g (8.92 mmol) of 2.24 in 2 mL of anhydrous CH2Cl2 at 0 oC was 
added 10.4 mL (10.4 mmol) of a 1.0 M solution of Bu2BOTf in CH2Cl2 followed 
by 2.40 mL (13.7 mmol) of (iPr)2NEt. After 45 min, the solution was cooled to –
78 oC for 15 min. A solution of 1.70 g (9.81 mmol) of 2.9b in 5 mL of CH2Cl2 was 
added and the solution was allowed to warm to room temperature overnight. The 
reaction was quenched by the addition of 10 mL of potassium phosphate buffer, 
pH 7.0, and was then extracted with three 30-mL portions of Et2O. The combined 
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organic layer was washed with brine and concentrated under diminished pressure. 
The crude oil was dissolved in 24 mL of MeOH and cooled to 0 oC, then 8 mL of 
30% H2O2 was added slowly. The mixture was stirred at 0 oC for 4 h, then 10 mL 
of water was added and the reaction mixture was concentrated under diminished 
pressure. The residue was extracted with three 20-mL portions of ethyl ether and 
the combined organic layer was washed with three 30-mL portions of 5% aq 
NaHCO3. The resulting solution was washed with brine, dried over Na2SO4 and 
concentrated under diminished pressure. The residue was purified by flash 
chromatography on a silica gel column (25 x 3.2 cm). Elution with 1:4 hexanes–
EtOAc gave 2.18c as a colorless solid: yield 2.4 g (67%); silica gel TLC Rf 0.45(1:1 
hexanes–EtOAc); [α]23D +42.5 (c 1.0, MeOH); 1H NMR (CDCl3) δ 0.83-0.90 (m, 
12H), 1.16 (d, 3H, J = 6.5 Hz), 1.40 (s, 9H), 1.42-1.48 (m, 2H), 1.84-1.89 (m, 
1H), 2.34 (d, 1H, J = 3.0 Hz), 2.77 (br, 1H), 3.59-3.61 (m, 1H), 3.69-3.70 (m, 
1H), 4.18-4.20 (m, 1H), 4.23-4.30 (m, 2H), 4.49-4.51 (m, 1H) and 4.86 (d, 1H, J 
= 9.0 Hz); 13C NMR (CDCl3) δ 14.4, 18.0, 21.6, 23.8, 26.4, 28.3, 35.4, 43.2, 48.4, 
58.7, 63.1, 75.8, 79.5, 154.0, 155.9 and 175.8; mass spectrum (MALDI-TOF), 
m/z 423.5 (M+Na)+ (theoretical 423.2); mass spectrum (APCI), m/z 401.2666 
(M+H)+ (C20H37N2O6 requires 401.2652). 
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BocHN
OH
OH O
 
(2S,3S,4R)-4-tert-Butoxycarbonylamino-3-hydroxy-2-isobutylpentanoic acid 
(2.18d). To a cooled (0 oC) solution containing 1.95 g (4.88 mmol) of 2.18c in 64 
mL of 3:1 THF H2O was added 4.60 mL (29.3 mmol) of 30% H2O2 followed by 
234 mg (9.80 mmol) of LiOH. After stirring at 0 oC for 3 h, the excess peroxide 
was quenched at 0 oC by the addition of 19.5 mL of 1.5 N aq Na2SO3 and the pH 
was adjusted to 9–10 with sat aq NaHCO3. The oxazolidinone was recovered by 
extraction with three 10-mL portions of CH2Cl2. The aqueous layer was then 
acidified to pH ~2 with 1 N HCl, and extracted with three 10-mL portions of 
EtOAc. The combined organic layer was dried over Na2SO4 and concentrated 
under diminished pressure to give the crude product as a colorless solid: yield 1.21 
g (84%); silica gel TLC Rf 0.25 (8:2:0.2:0.1 CH2Cl2–hexanes–MeOH–AcOH); 
[α]23D +9.8 (c 0.3, MeOH); 1H NMR (CDCl3) δ 0.86-0.91 (m, 6H), 1.16 (d, 3H, J 
= 6.4 Hz), 1.41 (s, 9H), 1.60 (m, 2H), 2.55-2.59 (m, 2H), 3.60-3.70 (m, 2H), 4.91 
(br, 1H) and 6.14 (br, 1H); mass spectrum (MALDI-TOF), m/z 312.2 (M+Na)+ 
(theoretical 312.2); mass spectrum (APCI), m/z 290.1960 (M+H)+ (C14H28NO5 
requires 290.1967). 
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FmocHN
OH
CH3
OH O
 
(2S,3S,4R)-4-(9H-Fluoren-9-ylmethoxycarbonylamino)-3-hydroxy-2-
isobutylpentanoic acid (2.18e). To a solution of 985 mg (3.98 mmol) of 2.18d in 
12 mL of Me2S was added 20 mL of TFA. The reaction mixture was stirred at 
room temperature for 2 h. The solution was concentrated under a stream of argon 
and concentrated further under diminished pressure. The resulting oil was 
dissolved in 20 mL of 5% aq K2CO3 solution followed by the addition of 1.50 g 
(4.51 mmol) of FmocOSu in 14 mL of dioxane. The reaction was stirred at room 
temperature overnight, and the solution was then extracted successively with three 
20-mL portions of ethyl ether and three 20-mL portions of EtOAc. The combined 
organic layer was dried over Na2SO4, filtered and concentrated under diminished 
pressure. The crude product was then purified by flash chromatography on a 
silica gel column (25 x 3.2 cm). Elution with 93:5:2 CH2Cl2–MeOH–AcOH gave 
2.18e as a yellow solid: yield 1.44 g (85%); mp 70-72 oC; silica gel TLC Rf 0.23 
(8:2:0.2:0.1 CH2Cl2–hexanes–MeOH–AcOH); [α]23D +9.8 (c 0.3, MeOH); 1H 
NMR (CDCl3) δ 0.78-0.82 (m, 6H), 1.09 (d, 3H, J = 7.0 Hz), 1.39-1.43 (m, 1H), 
1.51-1.61 (m, 2H), 2.48-2.51 (m, 2H), 3.62-3.70 (m, 2H), 4.09 (t, 1H, J = 6.5 Hz), 
5.07 (d, 1H, J = 8.5 Hz), 7.20-7.22 (m, 2H), 7.29-7.31 (m, 2H), 7.48 (d, 2H, J = 
8.5 Hz) and 7.66 (d, 2H, J = 7.5 Hz); 13C NMR (CDCl3) δ 14.1, 20.3, 22.6, 25.2, 
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36.2, 45.8, 46.2, 48.3, 65.8, 74.2, 119.0, 124.0, 126.1, 126.7, 140.3, 142.8, 155.1 
and 178.0; mass spectrum (MALDI-TOF), m/z 434.5 (M+Na)+ (theoretical 
434.2); mass spectrum (APCI), m/z 412.2126 (M+H)+ (C24H30NO5 requires 
412.2124). 
 
BocHN
N
OH O
O
O
Ph
 
(1R,2S,3S,4′S)-[3-Benzyl-2-hydroxy-4-(4′-isopropyl-2′-oxo-oxazolidin-3′-yl)-
1-methyl-4-oxobutyl]carbamic acid tert-butyl ester (2.19c). To a stirred 
solution of 1.50 g (5.74 mmol) of 2.23 in 2 mL of anhydrous CH2Cl2 at 0 oC was 
added 6.71 mL (6.71 mmol) of a 1.0 M solution of Bu2BOTf in CH2Cl2 followed 
by 1.54 mL (8.83 mmol) of (iPr)2NEt. After 45 min, the solution was cooled to –
78 oC for 15 min. A solution of 1.10 g (6.33 mmol) of 2.9b in 5 mL of CH2Cl2 was 
added and the solution was allowed to warm to room temperature overnight. The 
reaction was quenched by the addition of 10 mL of potassium phosphate buffer, 
pH 7.0, and was then extracted with three 30-mL portions of Et2O. The combined 
organic layer was washed with brine and concentrated under diminished pressure. 
The crude oil was dissolved in 21 mL of MeOH and cooled to 0 oC, then 7 mL of 
30% H2O2 was added slowly. The mixture was stirred at 0 oC for 4 h, then 10 mL 
of water was added and the reaction mixture was concentrated under diminished 
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pressure. The residue was extracted with three 20-mL portions of ethyl ether and 
the combined organic layer was washed with three 30-mL portions of 5%  aq 
NaHCO3. The resulting solution was washed with brine, dried over Na2SO4 and 
concentrated under diminished pressure. The residue was purified by flash 
chromatography on a silica gel column (25 x 3.2 cm). Elution with 1:4 hexanes–
EtOAc gave 2.19c as a colorless solid: yield 1.84 g (74%); silica gel TLC Rf 0.43 
(1:1 hexanes–EtOAc); [α]24D +13.0 (c 0.46, MeOH); 1H NMR (CDCl3) δ 0.20 (d, 
3H, J = 7.0 Hz), 0.74 (d, 3H, J = 7.0 Hz), 1.25 (d, 3H, J = 6.5 Hz), 1.50 (s, 9H), 
1.90-1.98 (m, 1H), 3.03-3.08 (m, 1H), 3.25-3.28 (m, 1H), 3.72 (br, 1H), 3.87 (m, 
1H), 4.03-4.06 (m, 1H), 4.16 (t, 1H, J = 9.0 Hz), 4.38-4.39 (m, 1H), 4.65-4.69 (m, 
2H), 4.82 (d, 1H, J = 9.0 Hz) and 7.12-7.29 (m, 5H); 13C NMR (CDCl3) δ 13.7, 
17.7, 28.0, 28.3, 33.1, 46.2, 48.2, 58.5, 62.7, 75.6, 79.6, 126.3, 128.3, 129.4, 
138.7, 153.6, 155.6 and 175.2; mass spectrum (MALDI-TOF), m/z 457.5 
(M+Na)+ (theoretical 457.2); mass spectrum (APCI), m/z 435.2494 (M+H)+ 
(C23H35N2O6 requires 435.2495). 
 
BocHN
OH
OH O
Ph
 
(2S,3S,4R)-2-Benzyl-4-tert-butoxycarbonylamino-3-hydroxypentanoic acid 
(2.19d). To a cooled (0 oC) solution containing 1.60 g (3.56 mmol) of 2.19c in 40 
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mL of 3:1 THF/H2O was added 3.34 mL (21.4 mmol) of 30% H2O2 followed by 
171 mg (7.11 mmol) of LiOH. After stirring at 0 oC for 3 h, the excess peroxide 
was quenched at 0 oC by the addition of 14.2 mL of 1.5 N aq Na2SO3 and the pH 
was adjusted to 9–10 with sat aq NaHCO3. The oxazolidinone was recovered by 
extraction with three 10-mL portions of CH2Cl2. The aqueous layer was then 
acidified to pH ~2 with 1N HCl, and extracted with three 10-mL portions of 
EtOAc. The combined organic layer was dried over Na2SO4 and concentrated 
under diminished pressure to give the crude product as a colorless solid: yield 283 
mg (68%); silica gel TLC Rf 0.23 (8:2:0.2:0.1 CH2Cl2–hexanes–MeOH–AcOH); 
1H NMR (CDCl3) δ 1.18 (d, 3H, J = 6.5 Hz), 1.46 (s, 9H), 2.81-2.86 (m, 1H), 
2.95-2.98 (m, 1H), 3.10 (m, 1H), 3.19-3.22 (m, 1H), 3.85 (m, 2H) and 7.21-7.32 
(m, 5H); mass spectrum (MALDI-TOF), m/z 346.4 (M+Na)+ (theoretical 346.2); 
mass spectrum (APCI), m/z 324.1732 (M+H)+ (C17H26NO5 requires 324.1733). 
 
FmocHN
OH
CH3
OH O
 
(2S,3S,4R)-2-Benzyl-4-(9H-fluoren-9-ylmethoxycarbonylamino)-3-
hydroxypentanoic acid (2.19e). To a solution of 783 mg (2.42 mmol) of 2.19d in 
9 mL of Me2S was added 15 mL of TFA. The reaction mixture was stirred at room 
temperature for 2 h. The solution was concentrated under a stream of argon and 
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concentrated further under diminished pressure. The resulting oil was dissolved in 
15 mL of 5% aq K2CO3 solution followed by the addition of 899 mg (2.66 mmol) 
of FmocOSu in 14 mL of dioxane. The reaction was stirred at room temperature 
overnight, and the solution was then extracted successively with three 20-mL 
portions of ethyl ether and three 20-mL portions of EtOAc. The combined organic 
layer was dried over Na2SO4, filtered and concentrated under diminished pressure. 
The crude product was then purified by flash chromatography on a silica gel 
column (25 x 3.2 cm). Elution with 93:5:2 CH2Cl2–MeOH–AcOH gave 2.19e as a 
yellow solid: yield 1.03 g (94%); mp 73-75 oC; silica gel TLC Rf 0.20 (8:2:0.2:0.1 
CH2Cl2–hexanes–MeOH–AcOH); [α]23D -20.8 (c 1.0, MeOH); 1H NMR (CDCl3) 
δ 1.09 (d, 3H, J = 5.5 Hz), 2.70-2.72 (m, 1H), 2.83 (t, 1H, J = 11.5 Hz), 3.03-3.06 
(m, 1H), 3.60-3.75 (m, 2H), 4.08 (t, 1H, J = 6.5 Hz), 4.28-4.32 (m, 2H), 5.02 (d, 
1H, J = 7.5 Hz), 7.07-7.14 (m, 4H), 7.16-7.19 (m, 2H), 7.26-7.31 (m, 2H), 7.45 
(d, 2H, J = 7.0 Hz) and 7.66 (d, 2H, J = 7.5 Hz); 13C NMR (CDCl3) δ 14.1, 33.4, 
46.2, 48.4, 49.9, 65.8, 73.9, 119.1, 123.9, 124.2, 125.5, 126.1, 126.4, 127.5, 137.6, 
140.3, 142.7, 155.3 and 176.8; mass spectrum (MALDI-TOF), m/z 468.6 
(M+Na)+ (theoretical 468.2); mass spectrum (APCI), m/z 446.1972 (M+H)+ 
(C27H28NO5 requires 446.1967). 
 
  108 
BocHN
N
OH O
O
O
 
(1R,2S,3S,4′S)-[1,3-Di-isobutyl-2-hydroxy-4-(4′-isopropyl-2′-oxo-oxazolidin-
3′-yl)-4-oxobutyl]carbamic acid tert-butyl ester (2.20c). To a stirred solution of 
1.47 g (6.50 mmol) of 2.24 in 2 mL of anhydrous CH2Cl2 at 0 oC was added 7.53 
mL (7.53 mmol) of a 1.0 M solution of Bu2BOTf in CH2Cl2 followed by 1.74 mL 
(9.95 mmol) of (iPr)2NEt. After 45 min, the solution was cooled to –78 oC for 15 
min. A solution of 1.53 mg (7.11 mmol) of 2.10b in 5 mL of CH2Cl2 was added 
and the solution was allowed to warm to room temperature overnight. The 
reaction was quenched by the addition of 10 mL of potassium phosphate buffer, 
pH 7.0, and was then extracted with three 30-mL portions of Et2O. The combined 
organic layer was washed with brine and concentrated under diminished pressure. 
The crude oil was dissolved in 24 mL of MeOH and cooled to 0 oC, then 8 mL of 
30% H2O2 was added slowly. The mixture was stirred at 0 oC for 4 h, then 10 mL 
of water was added and the reaction mixture was concentrated under diminished 
pressure. The residue was extracted with three 20-mL portions of ethyl ether and 
the combined organic layer was washed with three 30-mL portions of 5% 
NaHCO3. The resulting organic solution was washed with brine, dried over 
Na2SO4 and concentrated under diminished pressure. The residue was purified by 
flash chromatography on a silica gel column (25 x 3.2 cm). Elution with 1:4 
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hexane/EtOAc gave 2.20c as a colorless solid: yield 2.0 g (71%); silica gel TLC Rf 
0.56 (1:1 hexanes–EtOAc); [α]24D +31.8 (c 1.5, MeOH); 1H NMR (CDCl3) δ 
0.86-0.89 (m, 18H), 1.39-1.42 (m, 15H), 2.32-2.36 (m, 1H), 3.52-3.55 (m, 1H), 
3.66-3.69 (m, 1H), 4.16-4.30 (m, 1H), 4.47-4.50 (m, 1H) and 4.52-4.55 (d, 1H, J 
= 10.0 Hz); 13C NMR (CDCl3) δ 14.3, 18.0, 21.5, 21.6, 23.9, 24.7, 26.4, 28.2, 
28.3, 35.0, 41.4, 42.9, 46.1, 50.8, 58.6, 62.9, 75.7, 79.1, 153.8, 155.6 and 176.1; 
mass spectrum (MALDI-TOF), m/z 465.3 (M+Na)+ (theoretical 465.3); mass 
spectrum (APCI), m/z 443.3117 (M+H)+ (C23H43N2O6 requires 443.3121). 
 
BocHN
OH
OH O
 
(2S,3S,4R)-4-tert-Butoxycarbonylamino-2′,4-di-isobutyl-3-hydroxybutyric 
acid (2.20d). To a cooled (0 oC) solution containing 1.16 g (2.63 mmol) of 2.20c in 
36 mL of 3:1 THF/H2O was added 2.50 mL (15.8 mmol) of 30% H2O2 followed 
by 126 mg (5.26 mmol) of LiOH. After stirring at 0 oC for 3 h, the excess peroxide 
was quenched at 0 oC by the addition of 10.5 mL of 1.5 N aq Na2SO3 and the pH 
was adjusted to 9–10 with sat aq NaHCO3. The oxazolidinone was recovered by 
extraction with three 10-mL portions of CH2Cl2. The aqueous layer was then 
acidified to pH ~2 with 1 N HCl, and extracted with three 10-mL portions of 
EtOAc. The combined organic layer was dried over Na2SO4 and concentrated 
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under diminished pressure to give the crude product as a colorless solid: yield 570 
mg (66%); silica gel TLC Rf 0.18 (8:2:0.2:0.1 CH2Cl2–hexanes–MeOH–AcOH); 
[α]23D +19.8 (c 1.3, MeOH); 1H NMR (CDCl3) δ 0.92-0.99 (m, 12H), 1.45-1.67 
(m, 15H), 2.60-2.70 (m, 1H) and 3.61-3.73 (m, 2H); 13C NMR (CDCl3) δ 18.0, 
21.3, 22.4, 22.9, 23.8, 26.2, 28.3, 32.6, 46.4, 51.6, 58.4, 68.7, 76.0, 158.0 and 
179.6; mass spectrum (MALDI-TOF), m/z 354.4 (M+Na)+ (theoretical 354.2); 
mass spectrum (APCI), m/z 332.2445 (M+H)+ (C17H34NO5 requires 332.2437). 
 
FmocHN
OH
OH O
 
(2S,3S,4R)-2,4-di-isobutyl-4-(9H-fluoren-9-ylmethoxycarbonylamino)-3-
hydroxy-butyric acid (2.20e). To a solution of 561 mg (1.69 mmol) of 2.20d in 6 
mL of Me2S was added 10 mL of TFA. The reaction mixture was stirred at room 
temperature for 2 h. The solution was concentrated under a stream of argon and 
concentrated further under diminished pressure. The resulting oil was dissolved in 
10 mL of 5% aq K2CO3 solution followed by the addition of 628 mg (1.86 mmol) 
of FmocOSu in 14 mL of dioxane. The reaction was stirred at room temperature 
overnight, and the solution was extracted successively with three 20-mL portions 
of ethyl ether and three 20-mL portions of EtOAc. The combined organic layer 
was dried over Na2SO4, filtered and concentrated under diminished pressure. The 
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crude product was then purified by flash chromatography on a silica gel column 
(25 x 3.2 cm). Elution with 93:5:2 CH2Cl2–MeOH–AcOH gave 2.20e as a yellow 
solid: yield 691 mg (90%); mp 78-80 oC; silica gel TLC Rf 0.25 (8:2:0.2:0.1 
CH2Cl2–hexanes–MeOH–AcOH); [α]23D +25.8 (c 1.2, MeOH); 1H NMR 
(CDCl3) δ 0.77-0.83 (m, 12H), 1.24-1.62 (m, 6H), 2.50-2.55 (m, 1H), 3.53-3.64 
(m, 2H), 4.08-4.13 (m, 1H), 4.29-4.38 (m, 1H), 4.85 (d, 1H, J = 9.0 Hz), 7.20-
7.23 (m, 2H), 7.29-7.32 (m, 2H), 7.48 (d, 2H, J = 7.5 Hz) and 7.67 (d, 2H, J = 7.5 
H); 13C NMR (CDCl3) δ 21.2, 21.3, 23.7, 23.9, 24.6, 26.2, 36.9, 38.6, 46.8, 47.3, 
52.1, 66.7, 75.8, 120.0, 125.0, 127.1, 127.7, 141.3, 143.8, 156.5 and 179.5; mass 
spectrum (MALDI-TOF), m/z 476.6 (M+Na)+ (theoretical 476.2); mass spectrum 
(APCI), m/z 454.2589 (M+H)+ (C27H36NO5 requires 454.2593). 
 
N
O
O
O
 
(S)-(+)-4-Isopropyl-3-propionyl-2-oxazolidinone (2.21) [96]. A stirred solution 
of 4.0 g (31.0 mmol) of oxazolidone in 100 mL of anhydrous THF was cooled to 
–78 oC. The 21.3 mL (34.1 mmol) of 1.6 M n-BuLi in hexane was added slowly 
and the mixture was stirred for 10 min. The 3.03 mL (34.1 mmol) of propionly 
chloride was then added slowly and the mixture was stirred for another 30 min. 
Then mixture was then warmed to room temperature over 30 min. Excess 
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propionyl chloride was quenched by the addition of 10 mL of sat aq NH4Cl and 
the THF was removed under diminished pressure. The resulting slurry was then 
extracted with three 40-mL portions of CH2Cl2, and the combined organic layer 
was washed with 25 mL of 1N NaOH solution and then 25 mL of brine, dried 
over Na2SO4 and concentrated under diminished pressure to give the crude 
product as yellow oil. The residue was purified by flash chromatography on a 
silica gel column. Elution with 3:1 hexanes–EtOAc gave 2.21 as a colorless oil: 
yield 5.60 g (95%); silica gel TLC Rf 0.75 (1:1 hexanes–EtOAc); 1H NMR 
(CDCl3) δ 0.85 (d, 3H, J = 6.8 Hz), 0.89 (d, 3H, J = 7.2 Hz), 1.14 (t, 3H, J = 7.4 
Hz), 2.36 (m, 1H), 2.95 (m, 2H), 4.17-4.27 (m, 2H) and 4.39-4.43 (m, 1H); mass 
spectrum (MALDI-TOF), m/z 186.1 (M+H)+ (theoretical 186.1). 
N
O
O
O
 
(S)-(+)-4-Isopropyl-3-(4’-methylvaleryl)-2-oxazolidinone (2.22) [162]. A 
stirred solution of 3.00 g (23.2 mmol) of oxazolidone in 100 mL of anhydrous 
THF was cooled to –78 oC. The 5.50 mL (39.6 mmol) of 2.5 M n-BuLi in hexane 
was added slowly and the mixture was stirred for 30 min. To a separate flask 
containing 3.53 mL (27.9 mmol) 4-methylvaleric acid in 100 mL of THF was 
added 5.51 mL (39.6 mmol) of NEt3 and 3.73 mL (30.3 mmol) of pivaloyl 
chloride at 0 oC. After stirring for 30 min, the lithio-(4S)-4-isopropyl-2-
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oxazolidinone was added. The mixture was warmed to room temperature over 2 h. 
The solution was extracted with EtOAc and the organic layer was washed with sat 
aq NaHCO3, brine, and dried over Na2SO4 and concentrated under diminished 
pressure. The residue was purified by flash chromatography on a silica gel 
column. Elution with 3:1 hexanes–EtOAc gave 2.22 as a colorless oil: yield 5.10 
g (93%); silica gel TLC Rf 0.28 (4:1 hexanes–EtOAc); [a] D23 +75.6 (c 0.92, 
CHCl3); 1H NMR (CDCl3) δ 0.86 (d, 3H, J = 6.8 Hz), 0.89-0.92 (m, 9H), 1.50-
1.62 (m, 3H), 2.35 (m, 1H), 2.81-2.89 (m, 1H), 2.94-3.02 (m, 1H), 4.17-4.27 (m, 
2H) and 4.40-4.44 (m, 1H); 13C NMR (CDCl3) δ 14.6, 18.0, 22.3, 22.3, 27.7, 28.3, 
33.3, 33.6, 58.4, and 63.3; mass spectrum (MALDI-TOF), m/z 228.2 (M+H)+ 
(theoretical 228.2). 
 
N
O
O
Ph
O
 
(S)-(+)-4-Isopropyl-3-phenylpropionyl-2-oxazolidinone (2.24) [164]. A stirred 
solution of 1.12 g (8.65 mmol) of oxazolidone in 25 mL of anhydrous THF was 
cooled to –78 oC. The 6.0 mL (9.95 mmol) of 1.6 M n-BuLi in hexane was added 
slowly and the mixture was stirred for 10 min. The 1.41 mL (9.51 mmol) of 3-
phenylpropionyl chloride was then added slowly and the mixture was stirred for 
another 30 min. Then mixture was then warmed to room temperature over 30 min. 
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Excess 3-phenylpropionyl chloride was quenched by the addition of 6 mL of sat 
aq NH4Cl and the THF was removed under diminished pressure. The resulting 
slurry was then extracted with three 20-mL portions of CH2Cl2, and the combined 
organic layer was washed with 20 mL of 1N NaOH solution and then 20 mL of 
brine, dried over Na2SO4 and concentrated under diminished pressure to give the 
crude product as yellowish solid. The residue was purified by flash 
chromatography on a silica gel column. Elution with 3:1 hexanes–EtOAc gave 
2.24 as a white solid: yield 2.3 g (88%); silica gel TLC Rf 0.70 (1:1 hexanes–
EtOAc); [a] D20 +74.7 (c 0.73, EtOH); 1H NMR (CDCl3) δ 0.82 (d, 3H, J = 7.2 
Hz), 0.88 (d, 3H, J = 6.8 Hz), 2.33 (m, 1H), 2.95-3.00 (m, 2H), 3.16-3.35 (m, 2H), 
4.16-4.24 (m, 2H), 4.38-4.42 (m, 1H) and 7.16-7.29 (m, 5H); mass spectrum 
(MALDI-TOF), m/z 262.1 (M+H)+ (theoretical 262.1). 
 
General procedure for the attachment of bithiazole to the solid support.  To 
a suspension containing 1.0 g (0.48 mmol/g) of NovaSyn TentaGel amino 
functionalized resin was added a solution containing 0.89 g (2.20 mmol) of Boc-
protected spermine and 460 µL (2.64 mmol) of Hünig’s base in 4 mL of DMF. 
After 24 h, the resin was filtered, and washed for 30 sec each with three 5-mL 
portions of DMF, three 5-mL portions of CH2Cl2, and then three 5-mL portions 
of DMF. A solution containing 0.63 g (1.32 mmol) of Fmoc-bithiazole, 0.51 g 
(1.32 mmol) of HBTU, and 460 µL (2.64 mmol) of Hünig’s base in 2 mL of DMF 
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was added. After 30 min, the resin was filtered, and washed for 30 sec each with 
three 5-mL portions of DMF, three 5-mL portions of CH2Cl2, and three 5-mL 
portions of methanol. The resulting resin was dried under diminished pressure 
over KOH pellets. Quantitative Fmoc cleavage analysis indicated a loading of 0.12 
mmol/g (25% over 3 steps). 
 
General procedure for the attachment of threonine to the resin-bound 
dipeptide.  To a suspension containing 200 mg of bithiazole-functionalized resin 
was added, sequentially for 5 min each, three 4-mL solutions containing 20% 
piperidine in DMF. The resulting resin was washed for 30 sec each with three 5-
mL portions of DMF, three 5-mL portions of CH2Cl2, and then three 5-mL 
portions of DMF. A solution containing 27.0 mg (0.079 mmol) of commercially 
available Fmoc-threonine, 29.7 mg (0.079 mmol) of HBTU, 12.1 mg (0.079 mmol) 
of HOBt, and 28 µL (0.16 mmol) of Hünig’s base in 2 mL of DMF was added. 
After 30 min, the resin was filtered and washed for 30 sec each with three 5-mL 
portions of DMF, three 5-mL portions of CH2Cl2, and three 5-mL portions of 
methanol. The resulting resin was dried under diminished pressure over KOH 
pellets. Quantitative Fmoc cleavage analysis indicated a loading of 0.10 mmol/g 
(83%). 
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General procedure for the attachment of methylvalerate (analogues) to the 
resin-bound tripeptide.  To a suspension containing 200 mg of the derivatized 
resin was added sequentially for 5 min each, three 4-mL solutions containing 20% 
piperidine in DMF. The resulting resin was washed for 30 sec each with three 5-
mL portions of DMF, three 5-mL portions of CH2Cl2, and then three 5-mL 
portions of DMF. A solution containing 35 mg (77 µmol) of an Fmoc-
methylvalerate (analogue), 29 mg (77 µmol) of HBTU, 12 mg (77 µmol) of HOBt, 
and 27 µL (0.16 mmol) of Hünig’s base in 2 mL of DMF was added. After 30 
min, the resin was filtered and washed for 30 sec each with three 5-mL portions of 
DMF, three 5-mL portions of CH2Cl2, and three 5-mL portions of methanol. The 
resulting resin was dried under diminished pressure over KOH pellets. 
Quantitative Fmoc cleavage analysis indicated a loading of 0.09 mmol/g (90%). 
 
General procedure for the attachment of histidine to the resin-bound 
tetrapeptide.  To a suspension containing 100 mg of the derivatized resin was 
added sequentially for 5 min each, three 4-mL solutions containing 20% piperidine 
in DMF. The resulting resin was washed for 30 sec each with three 5-mL portions 
of DMF, three 5-mL portions of CH2Cl2, and then three 5-mL portions of DMF. 
A solution containing 30 mg (49 µmol) of commercially available Fmoc-histidine, 
19 mg (49 µmol) of HATU, 7.0 mg (49 µmol) of HOAt, and 17 µL (97 µmol) of 
Hünig’s base in 2 mL of DMF was added. After 30 min, the resin was filtered and 
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washed for 30 sec each with three 5-mL portions of DMF, three 5-mL portions of 
CH2Cl2, and three 5-mL portions of methanol. The resulting resin was dried under 
diminished pressure over KOH pellets. Quantitative Fmoc cleavage analysis 
indicated a loading of 0.07 mmol/g (78%). 
 
General procedure for the synthesis of deglycobleomycin analogues.  To a 
suspension containing 40 mg of the derivatized resin was added sequentially for 
10 min each, three 1-mL solutions containing 20% piperidine in DMF. The 
resulting resin was washed for 30 sec each with three 5-mL portions of DMF, 
three 5-mL portions of CH2Cl2, and three 5-mL portions of DMF. The resin was 
then added to a 10-mL round bottom flask containing 1 mL of DMF and cooled to 
0 oC for 10 min. A mixture containing 5.0 mg (12 µmol) of Boc-pyrimidoblamic 
acid and 16 mg (36 µmol) of BOP reagent was added to the resin with an 
additional 1 mL of DMF. The reaction mixture was cooled for an additional 10 
min, followed by the addition of 13 µL (72 µmol) of Hünig’s base. After 16 h, the 
resin was filtered and washed for 30 sec each with three 5-mL portions of DMF, 
three 5-mL portions of CH2Cl2, and three 5-mL portions of methanol. The 
resulting resin was dried under diminished pressure over KOH pellets.  
 
General procedure for the cleavage of deglycoBLM analogues from the 
resin. To a suspension containing 35–50 mg of resin-bound fully protected 
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deglycobleomycin A6 analogue was added a solution containing 200 µL of 
triisopropylsilane and 200 µL of dimethyl sulfide. After 5 min, 3.6 mL of 
trifluoroacetic acid (TFA) was added to the suspension. After 4 h, the resin was 
filtered and washed for 30 sec each with three 5-mL portions of DMF, three 5-mL 
portions of CH2Cl2, and three 5-mL portions of DMF. The resulting resin was 
treated with 0.5 mL of 2% hydrazine in DMF. The resin was filtered and then 
treated with three 0.5-mL portions of 2% hydrazine in DMF solution for an 
additional 10 min. The eluate was collected and concentrated under diminished 
pressure. The resulting oil was dissolved in 0.1% aq TFA, frozen and lyophilized. 
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Deglycobleomycin analogue 2.26.  HPLC retention time (using the conditions 
described under General Methods): 15.1 min; colorless solid; yield 1.8 mg (55%); 
1H NMR (D2O) δ 0.53 (s, 1H), 0.65 (s, 1H), 0.90 (d, 3H, J = 6.4 Hz), 1.02 (d, 
3H, J = 6.4 Hz), 1.16 (m, 2H), 1.63-1.64 (m, 4H), 1.88-1.95 (m, 7H), 2.45-2.48 
(m, 1H), 2.57-2.64 (m, 2H), 2.94-3.01 (m, 12H), 3.09-3.11 (m, 2H), 3.14-3.19 (m, 
4H), 3.38-3.41 (m, 2H), 3.44-3.47 (m, 2H), 3.53 (t, 1H, J = 5.6 Hz), 3.56-3.60 (m, 
2H), 3.68-3.70 (m, 2H), 3.88-3.90 (m, 2H), 3.97-3.98 (m, 1H), 4.02 (t, 1H, J = 5.6 
Hz), 4.12 (d, 1H, J = 4.2), 7.24 (s, 1H), 7.96 (s, 1H), 8.09 (s, 1H) and 8.58 (s, 
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1H); mass spectrum (MALDI-TOF), m/z 1178.4 (M+Na)+ (theoretical 1178.6); 
mass spectrum (ESI), m/z 1156. 5977 (M + H)+ (C50H82N19O9S2 requires 
1156.5984).  
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Deglycobleomycin analogue 2.27.  HPLC retention time: 14.5 min; colorless 
solid; yield 1.5 mg (47%); 1H NMR (D2O) δ 0.15 (d, 3H, J = 7.2 Hz), 0.30 (d, 
3H, J = 7.2 Hz), 0.57 (d, 3H, J = 7.2 Hz), 0.59 (d, 3H, J = 6.4 Hz), 0.85-0.87 (m, 
2H), 1.08-1.19 (m, 3H), 1.28-1.29 (m, 4H), 1.53-1.61 (m, 7H), 2.22-2.29 (m, 3H), 
2.59-2.66 (m, 9H), 2.71-2.73 (m, 1H), 2.78-2.84 (m, 3H), 3.05 (t, 2H, J = 5.6 Hz), 
3.14-3.33 (m, 3H), 3.31-3.33 (m, 1H), 3.50 (dd, 1H, J = 5.6 and 3.2 Hz), 3.62-
3.68 (m, 3H), 3.75 (d, 1H, J = 4.0 Hz), 4.34 (t, 1H, J = 7.2 Hz), 6.95 (s, 1H), 7.60 
(s, 1H), 7.67 (s, 1H) and 8.25 (s, 1H); mass spectrum (MALDI-TOF), m/z 1156.6 
(M+H)+ (theoretical 1156.6); mass spectrum (ESI), m/z 1156.5991 (M + H)+ 
(C50H82N19O9S2 requires 1156.5984). 
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Deglycobleomycin analogue 2.28.  HPLC retention time (using the conditions 
described under General Methods): 14.3 min; colorless solid; yield 0.98 mg (40%); 
1H NMR (D2O) δ 0.78-1.00 (m, 15H), 1.60 (m, 4H), 1.85-1.91 (m, 7H), 2.08 (m, 
1H), 2.53-2.54 (m, 1H), 2.90-2.98 (m, 14H), 3.03-3.05 (m, 2H), 3.11-3.18 (m, 
3H), 3.34-3.38 (m, 2H), 3.46-3.53 (m, 3H), 3.83-3.85 (m, 2H), 4.18 (d, 1H, J = 
7.2 Hz), 4.29 (t, 1H, J = 7.2 Hz), 7.23 (s, 1H), 7.96 (s, 1H), 8.08 (s, 1H) and 8.50 
(s, 1H); mass spectrum (MALDI-TOF), m/z 1156.4 (M+H)+ (theoretical 1156.6); 
mass spectrum (ESI), m/z 1156.5991 (M + H)+ (C50H82N19O9S2 requires 
1156.5984). 
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Deglycobleomycin analogue 2.29.  HPLC retention time: 15.7 min; colorless 
solid; yield 1.9 mg (59%); 1H NMR (D2O) δ 1.00 (d, 3H, J = 6.4 Hz), 1.11 (d, 
3H, J = 7.2 Hz), 1.19-1.26 (m, 2H), 1.35 (d, 3H, J = 11.2 Hz), 1.71-1.55 (m, 5H), 
1.71-1.73 (m, 4H), 1.96-2.03 (m, 9H), 2.53-2.55 (m, 1H), 2.62-2.65 (m, 2H), 
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2.92-2.97 (m, 2H), 3.02-3.09 (m, 12H), 3.05 (dd, 1H, J = 8.0 and 7.2), 3.24-3.29 
(m, 4H), 3.46-3.48 (m, 1H), 3.52-3.55 (m, 1H), 3.56-3.61 (m, 1H), 3.61-3.68 (m, 
1H), 3.69-3.83 (m, 2H), 3.84-3.98 (m, 1H), 4.23 (d, 1H, J = 5.6 Hz), 4.29 (t, 1H, 
J = 7.2), 7.33 (s, 1H), 8.05 (s, 1H), 8.17 (s, 1H) and 8.66 (s, 1H); mass spectrum 
(MALDI-TOF), m/z 1218.5 (M+Na)+ (theoretical 1218.6); mass spectrum (ESI), 
m/z 1196.6289 (M + H)+ (C53H86N19O9S2 requires 1196.6297). 
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Deglycobleomycin analogue 2.30.  HPLC retention time: 14.7 min; colorless 
solid; yield 1.4 mg (47%); 1H NMR (D2O) δ 0.97 (d, 3H, J = 6.4 Hz), 1.07 (d, 
3H, J = 7.2 Hz), 1.63-1.64 (m, 4H), 1.84-1.95 (m, 7H), 2.35 (t, 1H, J = 12.0 Hz), 
2.56-2.60 (m, 3H), 2.73-2.76 (m, 2H), 2.94-3.01 (m, 14H), 3.15 (t, 2H, J = 5.6 
Hz), 3.32-3.38 (m, 4H), 3.53 (t, 1H, J = 6.4 Hz), 3.66 (t, 1H, J = 5.6 Hz), 3.96-
4.03 (m, 4H), 4.19 (d, 1H, J = 5.6 Hz), 4.55 (t, 1H, J = 6.4 Hz), 6.73 (s, 1H), 6.98 
(d, 1H, J = 8.0 Hz), 7.02 (t, 1H, J = 7.2 Hz), 7.08 (d, 1H, J = 8.0 Hz), 7.91 (s, 
1H), 8.06 (s, 1H) and 8.38 (s, 1H); mass spectrum (MALDI-TOF), m/z 1212.4 
(M+Na)+ (theoretical 1212.6); mass spectrum (ESI), m/z 1190.5833 (M + H)+ 
(C53H80N19O9S2 requires 1190.5828). 
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Deglycobleomycin analogue 2.31.  HPLC retention time: 19.0 min; colorless 
solid; yield 1.2 mg (27%); 1H NMR (D2O) δ 0.99 (d, 3H, J = 7.2 Hz), 1.09 (d, 
3H, J = 7.2 Hz), 1.63-1.64 (m, 4H), 1.83-1.95 (m, 7H), 2.40 (t, 1H, J = 12.0 Hz), 
2.53-2.61 (m, 3H), 2.66-2.69 (m, 1H), 2.94-3.01 (m, 14H), 3.15-3.20 (m, 2H), 
3.31-3.36 (m, 2H), 3.50-3.53 (m, 1H), 3.63-3.67 (m, 2H), 3.84-3.85 (m, 1H), 
3.93-3.94 (m, 1H), 4.01-4.04 (m, 1H), 4.22 (d, 1H, J = 4.8 Hz), 4.23-4.25 (m, 
1H), 4.55 (t, 1H, J = 6.4 Hz), 6.82 (s, 1H), 6.87 (t, 1H, J = 8.0 Hz), 6.96 (d, 1H, J 
= 7.2 Hz), 7.01 (t, 1H, J = 7.2 Hz), 7.05 (d, 1H, J = 8.0 Hz), 7.87 (s, 1H), 8.01 (s, 
1H) and 8.43 (s, 1H); mass spectrum (MALDI-TOF), m/z 1290.7 and 1292.0 
(M+Na)+ (theoretical 1290.5 and 1292.5); mass spectrum (ESI), m/z 1268.4986 
and 1270.4956 (M + H)+ (C53H79N19O9S2Br requires 1268.4933 and 1270.4913). 
 
H
N NH2
NH2
N N
H2N
HN
O
N
H
H
O
H
N
NH
HO
CH3
O
HO CH3
H
H
O
N
S
S
N
N
H
N
O
O
NH HN
NH NH2
CH3
CH3
O NH2
H
 
Deglycobleomycin analogue 2.32.  HPLC retention time: 15.5 min; colorless 
solid; yield 1.5 mg (47%); 1H NMR (D2O) δ 0.98 (d, 3H, J = 6.4 Hz), 1.08 (d, 
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3H, J = 7.2 Hz), 1.63-1.64 (m, 4H), 1.85-1.95 (m, 7H), 2.00 (s, 3H), 2.33 (t, 1H, J 
= 12.0 Hz), 2.58-2.66 (m, 4H), 2.74 (dd, 1H, J = 9.6 and 5.6 Hz), 2.80 (dd, 1H, J 
= 11.2 and 3.2 Hz), 2.94-2.97 (m, 12H), 3.00 (t, 2H, J = 8.0 Hz), 3.31-3.37 (m, 
2H), 3.51-3.59 (m, 2H), 3.67 (t, 1H, J = 7.2 Hz), 3.99 (t, 1H, J = 5.6 Hz), 4.04-
4.07 (m, 2H), 4.08-4.11 (m, 1H), 4.20 (d, 1H, J = 4.8 Hz), 4.55 (t, 1H, J = 7.2 
Hz), 6.72 (s, 1H), 6.84-6.87 (m, 2H), 6.90 (d, 2H, J = 7.2 Hz), 7.90 (s, 1H), 8.03 
(s, 1H) and 8.39 (s, 1H); mass spectrum (MALDI-TOF), m/z 1226.6 (M+Na)+ 
(theoretical 1226.6); mass spectrum (ESI), m/z 1204.5968 (M + H)+ 
(C54H82N19O9S2 requires 1204.5984). 
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Deglycobleomycin analogue 2.33.  HPLC retention time: 16.7 min; colorless 
solid; yield 1.8 mg (56%); 1H NMR (D2O) δ 0.61 (t, 3H, J = 7.2 Hz), 0.89 (d, 3H, 
J = 7.2 Hz), 0.96 (d, 3H, J = 5.6 Hz), 1.03-1.06 (m, 2H), 1.38-1.40 (m, 2H), 1.53-
1.54 (m, 2H), 1.64 (m, 2H), 1.86-1.95 (m, 8H), 2.35-2.36 (m, 1H), 2.60-2.64 (m, 
3H), 2.94-3.01 (m, 14H), 3.09-3.18 (m, 4H), 3.37-3.41 (m, 3H), 3.52-3.56 (m, 
4H), 4.02 (t, 1H, J = 5.6 Hz), 4.11 (d, 1H, J = 4.0 Hz), 7.21 (s, 1H), 7.92 (s, 1H), 
8.08 (s, 1H) and 8.53 (s, 1H); mass spectrum (MALDI-TOF), m/z 1178.0 
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(M+Na)+ (theoretical 1178.6); mass spectrum (ESI), m/z 1156. 5979 (M + H)+ 
(C50H82N19O9S2 requires 1156.5984). 
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Deglycobleomycin analogue 2.34.  HPLC retention time: 17.6 min; colorless 
solid; yield 1.4 mg (43%); 1H NMR (D2O) δ 0.65 (d, 3H, J = 6.4 Hz), 0.69 (d, 
3H, J = 6.4 Hz), 0.90 (d, 3H, J = 7.2 Hz), 0.95 (d, 3H, J = 6.4 Hz), 1.21-1.29 (m, 
3H), 1.42-1.48 (m, 2H), 1.64 (m, 4H), 1.87-1.95 (m, 7H), 2.41-2.44 (m, 1H), 
2.57-2.67 (m, 2H), 2.91-3.03 (m, 12H), 3.06-3.18 (m, 4H), 3.38-3.49 (m, 2H), 
3.41-3.56 (m, 3H), 3.67-3.69 (m, 2H), 3.93 (t, 1H, J = 5.6 Hz), 4.11 (d, 1H, J = 
4.8 Hz), 7.21 (s, 1H), 7.93 (s, 1H), 8.08 (s, 1H) and 8.53 (s, 1H); mass spectrum 
(MALDI-TOF), m/z 1178.4 (M+Na)+ (theoretical 1178.6); mass spectrum (ESI), 
m/z 1156. 5995 (M + H)+ (C50H82N19O9S2 requires 1156.5984). 
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Deglycobleomycin analogue 2.35.  HPLC retention time: 17.2 min; colorless 
solid; yield 1.0 mg (30%); 1H NMR (D2O) δ 0.53 (d, 3H, J = 6.4 Hz), 0.93 (d, 
3H, J = 6.4 Hz), 1.63-1.64 (m, 4H), 1.86-1.94 (m, 7H), 2.52-2.59 (m, 2H), 2.61 (t, 
1H, J = 4.8 Hz), 2.69-2.72 (m, 1H), 2.82-2.86 (m, 1H), 2.93-3.01 (m, 14H), 3.09-
3.14 (m, 3H), 3.17-3.20 (m, 2H), 3.27-3.49 (m, 4H), 3.66-3.68 (m, 2H), 3.78 (t, 
1H, J = 6.4 Hz), 3.89 (d, 1H, J = 4.8 Hz), 6.95 (d, 2H, J = 7.2 Hz), 6.99-7.00 (m, 
3H), 7.23 (s, 1H), 7.92 (s, 1H), 8.07 (s, 1H) and 8.54 (s, 1H); mass spectrum 
(MALDI-TOF), m/z 1212.4 (M+Na)+ (theoretical 1212.6); mass spectrum (ESI), 
m/z 1190.5823 (M + H)+ (C53H80N19O9S2 requires 1190.5828). 
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Deglycobleomycin analogue 2.36.  HPLC retention time: 16.4 min; colorless 
solid; yield 1.2 mg (36%); 1H NMR (D2O) δ 0.53 (d, 3H, J = 7.2 Hz), 0.59 (d, 
3H, J = 6.4 Hz), 0.65-0.66 (m, 9H), 0.91-0.92 (m, 5H), 1.15-1.25 (m, 4H), 1.40-
1.42 (m, 1H), 1.63-1.64 (m, 2H), 1.88-1.95 (m, 7H), 2.57-2.61 (m, 3H), 2.93-3.01 
(m, 12H), 3.07-3.11 (m, 1H), 3.17-3.20 (m, 2H), 3.38-3.40 (m, 2H), 3.44-3.50 (m, 
2H), 3.57-3.60 (m, 1H), 3.65-3.67 (m, 1H), 3.89 (t, 1H, J = 6.4 Hz), 3.92-3.93 (m, 
1H), 3.99-4.02 (m, 1H), 4.15 (d, 1H, J = 4.8 Hz), 7.23 (s, 1H), 7.97 (s, 1H), 8.09 
(s, 1H) and 8.57 (s, 1H); mass spectrum (MALDI-TOF), m/z 1220.5 (M+Na)+ 
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(theoretical 1220.6); mass spectrum (ESI), m/z 1198.6442 (M + H)+ 
(C53H88N19O9S2 requires 1198.6454).
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                                                                      CHAPTER 3 
SYNTHESIS OF BICYCLIC PYRIDINOL ANTIOXIDANT 
3.1 Introduction 
        One of the research projects ongoing in our laboratory is focused on the 
discovery of drugs for the treatment of inherited mitochondrial diseases. 
Mitochondria are membrane-enclosed organelles found in eukaryotic cells [175]. 
Mitochondria generate most of the ATP produced by the cell, which is used as the 
source of chemical energy in the human body. In addition to supplying cellular 
energy, mitochondria are involved in a range of other processes, such as signaling, 
apoptosis and the control of the cell cycle and cell growth [176]. Mitochondrial 
dysfunction is implicated in the pathogenesis of a number of human diseases, 
including respiratory disorders and cardiac dysfunction as well as the aging 
process [177,178]. Mitochondrial electron transport chain has been recognized as 
a major intracellular source of reactive oxygen species (ROS) [179]. The leakage of 
ROS from the respiratory chain complexes may lead to lipid peroxidation, DNA 
oxidation and damage of other macromolecules [180]. Mitochondria are one of the 
key targets for the oxidative action of ROS. The natural lipophilic antioxidants, 
ubiquinone and vitamin E, have attracted enormous attention recently as potential 
agents to prevent radical damage of mitochondria. In particular, α-tocopherol (α-
TOH), a form of vitamin E, is perhaps the best known natural antioxidant 
[125(a)]. By transferring its phenolic H atom to propagating lipid radicals, it 
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quenches lipid peroxidation [132]. The development of synthetic radical 
scavenging antioxidants with activity superior to α-TOH is an ongoing aim of 
many studies.  
N N
HO
N
HO
N
3.1 3.2
O
HO
a-tocopherol 
(a-TOH)
N N
HO
3.3  
Figure 3.1. Structures of α-tocopherol and tocopherol-like antioxidants 3.1, 3.2 
and 3.3. 
        6-Amino-3-pyridinols have been synthesized and demonstrated to be very 
efficient antioxidants. In particular, the bicyclic pyridinols 3.1 and 3.2 (Figure 3.1) 
displayed 88- and 28-fold greater inhibition rate constants, respectively, than α-
TOH in quenching the oxidation of methyl linoleate in benzene solution [139]. To 
improve the effectiveness of compound 3.1, we reasoned that conjugation of the 
pyridinol antioxidant core to a lipophilic side chain might facilitate delivery of the 
antioxidant to membranes, including mitochondrial membranes, and thereby confer 
cytoprotective properties at the level of mitochondrial function. Recently our 
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laboratory has reported a lipophilic pyridinol analogue of tocopherol 3.3, in which 
the phytyl side chain of α-tocopherol was conjugated to the 5-position of the 
pyridinol core [140(c)]. This analogue was shown to suppress the level of reactive 
oxygen species in cultured cells, and to quench peroxidation of mitochondrial 
membranes. However, reported syntheses of analogue 3.3 required 16 steps and 
proceeded in moderate yields. 
        In a recent study, we have reported a short and scalable route to synthesize 
the bicyclic pyridinol antioxidants (compounds 1 and 2) [181]. The novel feature 
of this synthesis is the installation of the bicyclic structures by a 
cyclocondensation reaction of lactam acetal with an enaminone. Based on this 
methodology, a lipophilic side chain can readily be coupled to the pyridinol core 
via regioselective metalation of the 2-methyl group. Moreover, the structural 
function of the phytyl group is thought to be related to its lipophilicity 
[141(a),182]; however, generation of this side chain requires multiple steps due to 
its three chiral centers. To avoid its tedious synthesis, we chose to replace the 
phytyl group with varying alkyl chains, which could potentially mimic the phytyl 
chain. Clearly, the question was whether biological function of the analogues 
would be retained with a simpler alkyl “tail” attached to a more accessible 
position at the antioxidant core. If so, valuable aminopyridinol analogues of α-
TOH might become more accessible. A new series of antioxidants have been 
designed and prepared to diminish the effects of oxidative stress within the 
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mitochondrial electron transport chain as well as develop a facile synthesis to 
provide this novel group of antioxidants. The analogues of interest involve 
modifications that introduce a simpler lipophilic side chain to the 6-position of the 
pyridinol core (Figure 3.2). Analogues 3.4–3.9 were evaluated for their ability to 
suppress reactive oxygen species in cells under oxidative stress, and to protect 
cultured Friedreich’s ataxia fibroblasts from oxidative stress.  
  
N N
RO
N N
RO
N N
RO
3.4, R = H
3.5, R = Ac
3.6, R = H
3.7, R = Ac
3.8, R = H
3.9, R = Ac  
Figure 3.2. Structures of bicyclic pyridinol antioxidants 3.4–3.9. 
 
3.2 Results and discussion 
3.2.1 Synthesis of bicyclic pyridinols  
        A retrosynthetic analysis of pyridinols 3.1 and 3.2 is shown in Figure 3.3. 
The desired compounds could be prepared from 4,6-dimethylpyrrolo[2,3-
b]pyridine (3.12) or piperidinyl[2,3-b]pyridine (3.19) by appropriate functional 
group transformations. The formation of 3.12 and 3.19 was envisioned by a 
cyclocondensation reaction of enaminone 3.10 with lactam acetals 3.11 and 3.18, 
respectively. 
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Figure 3.3. Retrosynthetic analysis of pyridinol antioxidants 3.1 and 3.2. 
 
        As outlined in Scheme 3.1, the formation of the dihydropyrrolopyridine 
(azaindoline) intermediate is the key step of the synthesis of 3.1. Accordingly, 
1,4,6-trimethyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridine (3.12) was prepared in 
62% yield by treatment of enaminone 3.10 with lactam acetal 3.11 in t-BuOH–t-
BuONa at 90 oC [183]. The bromination of 3.12 was first attempted using NBS as 
the bromination reagent in concentrated H2SO4–TFA [184]. However, the 
bromination conditions provided di-brominated by-product as well as the desired 
monobrominated product. Since these two products were difficult to separate, we 
chose a milder bromination agent 1,3-dibromo-5,5-dimethylhydantoin [185] for 
the selective bromination of 3.12. The reaction was carried out at 0 oC in 
chloroform and gave 3.13 in 82% yield; no dibrominated by-product was 
observed. In the final step, the hydroxylation of 3.13 was attempted by using 
KOH in the presence of a Pd catalyst [186]. Due to the instability of the final 
product 3.1 toward air oxidation, we also attempted to convert this compound to 
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its acetate ester 3.17 following the in situ formation of 3.1. This strategy would 
also permit easy scale-up and storage of the intermediates prior to conversion to 
the unstable pyridinol. At first, 3.13 was treated with KOH in 1:1 H2O–1,4-
dioxane in the presence of Pd2dba3 and ligand 3.14 at 100 oC, followed by the 
addition of Ac2O. Unexpectedly, we obtained 7-azaindole 3.15 in 45% yield, 
rather than 7-azaindoline 3.17. Presumably, the generated 3.17 could be oxidized 
quickly to 3.15 under the reaction conditions in spite of efforts to maintain an 
inert atmosphere. Although 3.15 was obtained unexpectedly, we reasoned that its 
corresponding pyridinol 3.16 might also prove to be an interesting antioxidant. 
Accordingly, pyridinol 3.16 was prepared from 3.15 by hydrolysis with  
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Scheme 3.1. Synthesis of pyridinol 3.1. 
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K2CO3 in methanol in 97% yield. The desired 7-azaindole was prepared readily 
from azaindole 3.15 by reduction. The reduction of azaindole was achieved by 
using NaCNBH3 in acetic acid media, affording compound 3.17 in 92% yield 
[187]. The acetyl group was removed reductively using LiAH4 in THF to provide 
3.1 in 86% yield. The synthesis of 3.1 was thus achieved in 5 steps and 18.1% 
overall yield, as compared to the previous reported route which required 11 total 
steps and provided 3.1 in 5.8% yield [193b]. Further, this new route proceeds 
through a stable O-acetate derivative that can be stored conveniently. 
        As shown in Scheme 3.2, pyridinol 3.2, having a fused six-membered ring, 
was synthesized using a similar strategy. The cyclocondensation of 3.10 with 3.18 
afforded 3.19 in 59% yield. Bromination of 3.19 gave compound 3.20 in 86% 
yield. Hydroxylation of 3.20, followed by acetylation of the nascent OH group, 
afforded 3.21 in 55% yield. Finally, pyridinol 3.2 was obtained by treatment with 
LiAH4 in 95% yield. This method provided 3.2 in 26.5% overall yield (4 total 
steps), while 3.2 was obtained previously in 3.3% overall yield over 6 steps 
[139(b)]. 
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Scheme 3.2. Synthesis of pyridinol 3.2. 
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3.2.2 Synthesis of bicyclic pyridinols with lipophilic side chains  
        Our goal was to develop simplified and easily accessible analogues of α-
tocopherol bearing a lipophilic side chain on an appropriate antioxidant core. All 
the analogues were designed to possess a pyridinol structure with a fused five-
membered ring due to its superior radical-scavenging ability over the phenol ring. 
The phenolic group of α-TOH is responsible for the antioxidant activity, whereas 
the phytyl side chain favors the insertion of α-TOH into liposomes and 
suppresses the migration of α-TOH between liposomal membranes. This suggests 
that the “delivery” of the antioxidants into the lipid bilayer region is dependent on 
the lipophilicity of the side chain. This hypothesis led us to design analogues with 
a simpler lipophilic side chain attached to a more accessible position on the 
pyridine ring. Since the 2-methyl group can be selectively metalated, an alkyl 
bromide can be directly coupled to this ionized carbon. This coupling strategy is 
much more straightforward compared to previous methods, which involved the 
functionalization of the pyridine ring either with an aldehyde group followed by a 
Witting reaction [140(a)(b)(d)], or with a triflate group followed by a metal-
catalyzed cross coupling reaction [140(c)].  
        A retrosynthetic analysis, shown in Figure 3.4, suggested that the targeted 
compounds could be prepared from pyridines 3.22, 3.24 and 3.26 by functional 
group transformations. Conjugation of alkyl side chains to compound 3.12 was 
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envisioned by initial metalation of the 2-methyl group, followed by a subsequent 
nucleophilic substitution reaction on alkyl bromides.  
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Figure 3.4. Retrosynthetic analysis of pyridinol antioxidants 3.4, 3.6 and 3.8. 
 
        Based on the synthetic studies we described in preparing the bicyclic 
pyridinols, compound 3.12 could be constructed by a cyclocondensation reaction 
of amide acetal 3.10 with enaminone 3.11. The synthesis of the desired 
antioxidants 3.4, 3.6 and 3.8 and the corresponding acetate 3.5, 3.7 and 3.9 is 
illustrated in Scheme 3.3. Accordingly, 1,4,6-trimethyl-2,3-dihydro-1H-
pyrrolo[2,3-b]pyridine 3.12 was prepared in 45% yield by the cylocondensation 
of amide acetal 3.10 and enaminone 3.11. Aliphatic side chains were introduced by 
regioselective metalation of the 2-methyl group of azaindoline 3.12 in the presence 
of n-BuLi, followed by treatment of 1-bromobutane to generate 3.22 in 68% yield, 
1-bromonane to generate 3.24 in 64% yield and 1-bromopentadecane to generate 
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3.26 in 52% yield. Azaindoline 3.22, 3.24 and 3.26 were brominated using 1,3-
dibromo-5,5-dimethylhydantoin in chloroform at 0 oC to afford the brominated 
azaindoline 3.23, 3.25 and 3.27 in 92%, 94% and 98% yields, respectively. The 
bromides 3.23, 3.25 and 3.27 were hydroxylated using n-BuLi and 
tetramethylethylenediamine followed by treatment of trimethoxy boron and 
finally with peracetic acid. Due to the instability of pyridinol toward air oxidation, 
we protected the generated hydroxyl groups as their acetate esters. The reaction 
was carried out in the presence of NEt3, DMAP followed by the addition of Ac2O 
at 0 oC and afforded 3.5, 3.7 and 3.9 in 80%, 76% and 82% yields. This strategy 
permits the easy scale-up and storage of the acetate ester intermediates prior to 
conversion to the unstable pyridinol products. Additionally, the acetate esters 
could potentially act as prodrugs for the corresponding pyridinols. The removal of 
the acetyl group was achieved by treatment with DIBAL-H in CH2Cl2 at –78 oC. 
Due to their tendency to be oxidized, the final products 3.4, 3.6 and 3.8 were 
converted to their trifluoroacetate salts. Compounds 3.4, 3.6 and 3.8 were further 
purified by reversed-phase HPLC prior to bioassay, and were tested as their 
trifluoroacetate salts.  
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Scheme 3.3. Synthesis of pyridinol analogues of α-TOH 3.4–3.9. 
 
3.2.3 Biochemical and biological evaluation of the tocopherol analogues 
3.2.3.1 Assessment of lipid peroxidation in a membrane model system 
        All the analogues were tested for their ability to quench lipid peroxidation 
using a C11-BODIPY581/591 liposome system as illustrated in Figure 3.5. The 
oxidation of the probe results in a change of its emitted fluorescence from red to 
green [188]. The experiment emplyed small unilamellar phospholipid vesicles
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incorporating the fluorescent peroxidation probe C11-BODIPY581/591, and the 
peroxidation was initiated by addition of the radical generator 2,2’-azo-bis-(2-
amidinopropane) (AAPH). When treated with AAPH, the fluorescence of the 
fluorophore diminished with time, reflecting peroxidation of the (lipid) 
fluorophore. As shown, pyridinol analogues 3.4, 3.6 and 3.8 (left panel) were 
much more effective than α-TOH in quenching lipid peroxidation, and acetate 
analogues 3.5, 3.7 and 3.9 (right panel) were also found to be slightly more 
effective than α-TOH acetate. The lipophilic side chain appeared to be very 
important to enable the quenching of lipid peroxidation in this system. Pyridinol 
analogue 3.6 with a ten-carbon side chain displayed much higher efficiency 
compared with the other two pyridinol analogues 3.4 and 3.8.  
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Figure 3.5. Effect of pyridinol analogues of α-TOH 3.4, 3.6 and 3.8 (left panel), 
and 3.5, 3.7 and 3.9 (right panel) on lipid peroxidation induced by peroxyl radicals 
generated from thermal decomposition of AAPH in phospholipids liposomes 
containing C11-BODIPY581/591 in Tris-HCl buffer at 40 oC. Relative fluorescence 
units are normalized to 100% intensity. Identical results were obtained in replicate 
exmperiments. Mouse liver mitochondria (2 mg of protein/mL) were suspended in 
10 mM Tris-HCl, pH 7.6, containing 100 mM KCl at 37 oC. Aliquots (0.8 mL) 
were preincubated with the test compounds at 37 oC for 5 min in presence of 5 
mM succinate and 10 µM rotenone (energized mitochondria) or 20 mM malonate 
(nonenergized mitochondria). Ascorbic acid (300 µM) and 100 µM ferric 
ammonium sulfate were then added to induce lipid peroxidation. Data are 
expressed as % of control samples lacking any test compound and expressed as 
means ± SE (n = 3). This experiment was performed by Dr. Omar Khdour. 
 
3.2.3.2 Assessment of lipid peroxidation in cultured cells 
        Lipid peroxidation was determined in CEM leukemia cells by monitoring the 
fluorescence of the peroxidation-sensitive dye C11-BODIPY581/591. Diethyl maleate 
(DEM) depletes cellular glutathione (GSH), which is a physiological oxidant 
scavenger, reacting as either a one-electron donor to radicals or a two-electron 
donor to electrophiles [189]. Lowering GSH levels in CEM cells can cause a 
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significant increase in both cellular and mitochondrial ROS levels [190]. Increased 
C11-BODIPY581/591-green (oxidized) fluorescence, a measure of peroxyl radical 
production, was determined by a shift in green fluorescence to the right on the x-
axis of the FACS histogram. Figure 3.6 shows representative C11-BODIPY581/591-
green FACS histograms overlay and analyzed using the FL1-H channel. 
Glutathione depletion by DEM treatment caused the C11-BODIPY581/591-green 
fluorescence to shift right on the x-axis of the FACS histogram, indicting increased 
peroxidation as a result of GSH depletion. Pretreatment of the CEM cells with 
compound 3.6, 3.7, 3.8 and 3.9 blocked lipid peroxidation in a concentration 
manner. The acetate forms of the pyridinol analogues act as prodrugs, presumably 
due to susceptibility to enzymatic hydrolysis, exhibited an antioxidant effect. 
Analogues with ten-carbon side chain (compound 3.6 and its acetate form 3.7) 
were shown to be more effective than analogues with sixteen-carbon side chain 
(compound 3.8 and its acetate form 3.9).  
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Figure 3.6. Lipid peroxidation in CEM leukemia cells depleted of glutathione. 
Representative flow cytometric histograms overlay showing lipid peroxidation in 
glutathione depleted CEM cells. Following pretreatment with the indicated 
compounds at 2.5 µM concentration (left panel) or 5 µM concentration (right 
panel) for 16 hours, the cells were treated with 5 mM diethyl maleate (DEM) for 
90 minutes in phenol red free media. Then cells were treated with 500 nM C11-
BODIPY581/591 in the dark at 37 °C for 30 minutes. The cells were washed twice 
in phosphate buffered saline, and resuspended in Hanks’ Balanced Salt Solution 
buffer before they were subjected to flow cytometry analysis using the FL1-H 
channel for C11-BODIPY581/591 – green (oxidized form). The figure shows a 
representative example of three independent experiments. In each analysis, 10,000 
events were recorded. Bottom panel shows a bar graph of mean C11-
BODIPY581/591 – green (oxidized form) fluorescence (a.u.) recorded by FACS and 
represents the percentage of the fluorescence means of the above flow cytogram 
profiles calculated using CellQuest software. Data are expressed as means ± SE (n 
= 3). This experiment was performed by Dr. Omar Khdour. 
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3.2.3.3 Protection against mitochondrial membrane depolarization induced 
by GSH depletion 
        To demonstrate that reduction in mitochondrial oxidative stress can protect 
against mitochondrial dysfunction, we examined the effect of pyridinol analogues 
of α-TOH on mitochondrial membrane depolarization caused by treatment of 
CEM leukemia cells with DEM. Mitochondrial membrane depolarization is a 
critical antecedent event to cell death. Tetramethylrhodamine methyl ester 
(TMRM), a fluorescent cationic indicator, is taken up into mitochondria in a 
potential-dependent manner, and the opening of the mitochondrial permeability 
transition pore and depolarization leads to diminished labeling of the mitochondria 
by the fluoroprobe. Figure 3.7 demonstrates representative two-dimensional 
density dot plots of TMRM-stained cells showing the percentage of cells with 
intact ∆ψm (TMRM fluorescence in top right quadrant) vs the percentage of cells 
with reduced ∆ψm (TMRM fluorescence in bottom left and right quadrants). 
Figure 3.7 (bottom panel) shows a bar graph of the percentage (mean ± SE) of 
CEM cells with intact ∆ψm. The results show that DEM treatment reduced the 
percentage of cells with TMRM fluorescence in the top right quadrant, indicating 
that DEM treatment caused depolarization of ∆ψm. Preincubation of the CEM 
cells for 16 hr with 1 µM test compounds prior to stressing the cells with DEM 
resulted in nearly full protection by compounds 3.6 and 3.7. Increasing the 
concentration of test compounds to 2.5 µM resulted in increasing protection. 
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Analogues with ten-carbon side chain were again shown to be more effective 
compared with anaogues with five-carbon and sixteen-carbon side chains.  
 
untreated 
control 
treated control  FCCP No dye 
    
3.6 (1 µM) 3.6 (2.5 µM) 3.6 (5 µM)  
   
 
   3.7 (1 µM)   3.7 (2.5 µM) 3.7 (5 µM)  
      
 
3.8 (1 µM) 3.8 (2.5 µM) 3.8 (5 µM)  
      
 
3.9 (1 µM) 3.9 (2.5 µM) 3.9 (5 µM)  
      
 
3.4 (1 µM) 3.4 (2.5 µM) 3.4 (5 µM)  
   
 
3.5 (1 µM) 3.5 (2.5 µM) 3.5 (5 µM)  
   
 
 
 
  144 
 
 
 
Figure 3.7.  Protection against mitochondrial membrane depolarization induced 
by glutathione depletion. Representative flow cytometric two dimensional color 
dot plot analyses of mitochondrial membrane potential Δψm in CEM cells stained 
with 250 nM TMRM and analyzed using the FL2-H channel. Following 
pretreatment with the indicated compounds (1, 2.5 or 5 µM concentrations) for 16 
hours, the cells were treated with 5 mM DEM for 120 min. The cells were washed 
twice in phosphate buffered saline, and suspended in Hanks’ Balanced Salt 
Solution buffer. Cells were loaded with 250 nM TMRM for 15 min, and the red 
fluorescence was measured by flow cytometry using the FL2-H channel. The 
percentage of cells with intact Δψm is indicated in the top right quadrant of 
captions. Representative example from at least three independent experiments. In 
each analysis, 10,000 events were recorded. Bottom panel shows a bar graph of 
means the percentage of cells with intact Δψm recorded by FACS. Data are 
expressed as means ± SE (n = 3). This experiment was performed by Dr. Omar 
Khdour. 
 
3.2.4 Proposed catalytic mode of action of α-TOH analogues 
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        In the experiments described in Figue 3.6 and 3.7, diethyl maleate was used 
to deplete celluar glutathione, a physiological oxidant scavenger typically present 
at ~1–10 mM concentration in cells [191]. Both experiments demonstrated that 
much lower concentrations of 3.6 (at low micromolar levels) were capable to 
replace cellular glutathione to inhibit lipid peroxidation and maintain mitochondrial 
membrane potential. Presumably, 3.6 may function catalytically to suppress ROS 
and protect lipid membranes. Figure 3.8 depicts a proposed mechanism of action 
of 3.6. This cycle illustrates the simultaneous quenching of lipid radicals and 
superoxide, in a fashion that should be catalytic [192]. Compound 3.6 can donate 
a phenolic H to quench lipid peroxidation, leading to the formation of an 
antioxidant-derived radical. By virtue of the prooxidant character, this generated 
species should be capable of reacting with superoxide; in this way antioxidant 3.6 
could be recycled.  
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Figure 3.8. Proposed catalytic mode of action of 3.6 as a quencher of lipid 
peroxyl radicals and superoxide.  
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3.3 Experimental 
General methods: Chemicals and solvents were of reagent grade and were used 
without further purification. Anhydrous tetrahydrofuran (THF) was distilled 
from sodium/benzophenone under argon. Dichloromethane (CH2Cl2) was distilled 
from calcium hydride under argon. All reactions involving air or moisture sensitive 
reagents or intermediates were performed under an argon atmosphere. Flash 
chromatography was carried out using Silicycle 200-400 mesh silica gel. Analytical 
TLC was carried out using 0.25 mm EM silica gel 60 F250 plates that were 
visualized by UV irradiation (254 nm) or by staining with p-anisaldehyde stain. 
1H and 13C NMR spectra were obtained using 400 or 500 MHz Varian NMR 
instruments. Chemical shifts were reported in parts per million (ppm, δ) 
referenced to the residual 1H resonance of the solvent (CDCl3, 7.26 ppm). 13C 
spectra were referenced to the residual 13C resonance of the solvent (CDCl3, 77.0 
ppm). Splitting patterns were designated as follows: s, singlet; br, broad; d, 
doublet; dd, doublet of doublets; t, triplet; q, quartet; m, multiplet. High resolution 
mass spectra were obtained at the Ohio State University Mass Spectrometry 
Facility or at the ASU CLAS High Resolution Mass Spectrometry Laboratory.  
 
O NH2
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4-Amino-3-penten-1-one (3.10) [193]. To 102.7 mL (1.00 mol) of 2,4-
pentanedione was added 1.00 g of silica gel and 81.1 mL (1.20 mg) of 14.8 M aq 
NH4OH solutions (14.8 M) at room temperature. After the reaction mixture was 
stirred at room temperature for 16 h, the silica gel was filtered. The crude products 
were obtained after extraction with CH2Cl2 and the solvent was concentrated 
under diminished pressure. The crude product was obtained as a yellow solid and 
used directly for the next step: yield 95.2 g (96%); silica gel TLC Rf 0.15 (7:3 
hexanes–ethyl acetate); 1H NMR (CDCl3) δ 1.87 (s, 3H), 1.99 (s, 3H), 4.99 (s, 
1H), 5.18 (br s, 1H) and 9.66 (br s, 1H); 13C NMR (CDCl3) δ 22.2, 29.2, 95.7, 
161.1 and 196.6; mass spectrum (APCI), m/z 100.0766 (M + H)+ (C5H10NO 
requires 100.0762). 
 
N OMe
OMe
 
N-Methyl-2,2-dimethoxypyrrolidine (3.11) [194]. A solution of 52 mL (0.54 
mol) of N-methylpyrrolidone and 52 mL (0.55 mol) of dimethyl sulfate was 
heated at 90 oC for 1 h. The resulting mixture was added dropwise over 1 h to 500 
mL of 1.5 M NaOMe solution at –78 °C.  The reaction solution was stirred at 
room temperature for another 2 h, and then 200 mL of ethyl ether was added. The 
resulting mixture was filtered and the solvent was concentrated under diminished 
pressure. The product was collected by fractional distillation (15 mmHg, 58–60 
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oC) as a light yellow oil: yield 23.4g (30%); 1H NMR (CDCl3) δ 1.71-1.76 (m, 
2H), 1.88 (t, 2H, J = 7.2 Hz), 2.32 (s, 3H), 2.83 (t, 2H, J = 6.0 Hz) and 3.20 (s, 
6H); mass spectrum (MALDI-TOF), m/z 146.1 (M+H)+ (theoretical 146.1). 
 
N N
 
1,4,6-Trimethyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridine (3.12) [183]. To a 
solution of 2.36 g (23.8 mmol) of enaminone 3.10 in 8 mL of toluene was added 
5.88 g (40.5 mmol) of lactam acetal 3.11. The reaction mixture was heated at reflux 
and stirred for 2 h, cooled to 90 oC, and then treated with 4.65 g (48.4 mmol) of t-
BuONa and 4 mL of t-BuOH. The reaction mixture was stirred at 90 oC for 
another 16 h. The cooled reaction mixture was quenched by the addition of 20 mL 
of sat aq NH4Cl. The mixture was extracted with EtOAc. The combined organic 
layer was washed with brine, dried (MgSO4) and concentrated under diminished 
pressure. The residue was purified by flash chromatography on a silica gel column 
(25.4 × 2.6 cm). Elution with 10:1 hexanes/ethyl acetate gave the product 3.12 as a 
yellow oil: yield 1.6 g (42%); silica gel TLC Rf 0.15 (4:1 hexanes/ethyl acetate); 1H 
NMR (CDCl3) δ 2.05 (s, 3H), 2.32 (s, 3H), 2.76 (t, 2H, J = 8.4 Hz), 2.86 (s, 3H), 
3.34 (t, 2H, J = 8.4 Hz) and 6.10 (s, 1H); 13C NMR (CDCl3) δ 17.8, 24.0, 24.3, 
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33.1, 52.4, 113.1, 118.1, 141.2, 154.5 and 163.7; mass spectrum (MALDI-TOF), 
m/z 162.1 (M+) (theoretical 162.1). 
 
N
Br
N
 
5-Bromo-1,4,6-trimethyl-2,3-dihydro-1H-pyrrolo[2,3-b]-pyridine (3.13) 
[139(b)]. To a solution of 490 mg (3.02 mmol) of 3.12 in 5 mL of chloroform was 
added 432 mg (1.51 mmol) of 1,3-dibromo-5,5-dimethylhydantoin in portions at 0 
oC. The reaction mixture was stirred at 0 oC for 30 min at which point silica gel 
TLC analysis indicated that all starting material had been consumed. The reaction 
was quenched by the addition of 5 mL of sat aq NaHCO3. The mixture was 
extracted with portions of chloroform and the combined organic layer was washed 
with brine and dried over MgSO4. The concentrated residue was purified by flash 
chromatography on a silica gel column (20 × 1.7 cm). Elution with 100:1 hexanes–
ethyl acetate gave 3.13 as a yellow solid: yield 598 mg (82%); silica gel TLC Rf 
0.65 (4:1 hexanes–ethyl acetate); 1H NMR (CDCl3) δ 2.19 (s, 3H), 2.51 (s, 3H), 
2.88 (t, 2H, J = 8.4 Hz), 2.89 (s, 3H) and 3.44 (t, 2H, J = 8.8 Hz); 13C NMR 
(CDCl3) δ 19.4, 25.2, 25.5, 33.0, 52.5, 111.2, 120.5, 141.2, 152.8 and 161.6; mass 
spectrum, m/z 240.1 and 242.0 (M+) (theoretical 240.0 and 242.0). 
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1,4,6-Trimethyl-1H-pyrrolo[2,3-b]pyridin-5-yl Acetate (3.15). A reaction 
mixture containing 73 mg (0.30 mmol) of 3.13, 11 mg (12 µmol) of Pd2dba3, 10 mg 
(24 µmol) of ligand 3.14 and 68 mg (1.2 mmol) of potassium hydroxide in 0.5 mL 
of dioxane and 0.5 mL of degassed water was heated to 100 oC overnight under an 
argon atmosphere. After the starting material was consumed, 60 µL (0.54 mmol) 
of acetic anhydride was added to the reaction mixture. The resulting mixture was 
stirred for another 40 min, then permitted to cool to room temperature. Two mL 
of sat aq NH4Cl was added, and the mixture was extracted with EtOAc. The 
organic layer was washed successively with sat aq NaHCO3 and brine, then dried 
(MgSO4) and concentrated under diminished pressure. The residue was purified 
by flash chromatography on a silica gel column (20 × 1.7 cm). Elution with 10:1 
hexanes–ethyl acetate gave 3.15 as colorless solid: yield 29.6 mg (45%); silica gel 
TLC Rf 0.59 (1:1 EtOAc–hexanes); 1H NMR (CDCl3) δ 2.34 (s, 3H), 2.38 (s, 
3H), 2.47 (s, 3H), 3.84 (s, 3H), 6.39 (d, 1H, J = 3.6 Hz) and 7.08 (d, 1H, J = 3.6 
Hz); 13C NMR (CDCl3) δ 12.8, 20.0, 20.7, 31.5, 98.0, 119.7, 128.5, 131.2, 139.1, 
144.6, 144.9 and 169.5; mass spectrum (ESI), m/z 219.1136 (M + H)+ 
(C12H15N2O2 requires 219.1128). 
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1,4,6-Trimethyl-1H-pyrrolo[2,3-b]pyridin-5-ol (3.16). To a solution of 6.0 mg 
(28 µmol) of 3.15 in 0.5 mL of methanol was added 10 mg (94 µmol) of K2CO3. 
The reaction mixture was stirred at room temperature for 1 h then concentrated 
under diminished pressure. The residue was diluted with 2 mL of water and 
adjusted to pH ~ 6 by the addition of aqueous acetic acid (10% in water). The 
mixture was extracted with ethyl ether. The organic layer was washed with brine, 
dried (Na2SO4) and concentrated under diminished pressure to give 3.16 as a pink 
solid: yield 4.7 mg (97%); silica gel TLC Rf 0.45 (1:1 hexanes-ethyl acetate); 1H 
NMR (CDCl3) δ 2.42 (s, 3H), 2.57 (s, 3H), 3.81 (s, 3H), 5.16 (br s, 1H), 6.31 (d, 
1H, J = 3.6 Hz) and 7.02 (d, 1H, J = 3.6 Hz); 13C NMR (CDCl3) δ 12.3, 19.9, 
31.6, 97.2, 120.1, 124.5, 128.0, 140.8, 142.4 and 143.; mass spectrum, m/z 176.1 
(M+) (theoretical 176.1); mass spectrum (ESI), m/z 177.1026 (M + H)+ 
(C10H13N2O requires 177.1022). 
 
N
AcO
N
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1,4,6-Trimethyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-5-yl Acetate (3.17). To 
a solution of 28 mg (0.13 mmol) of 3.15 in 1 mL of acetic acid was added 41 mg 
(0.65 mmol) of NaCNBH3.The reaction mixture was stirred at room temperature 
for 24 h then poured into 10 mL of sat aq Na2CO3. The mixture was extracted 
with ethyl acetate. The organic layer was washed with brine, dried (MgSO4) and 
concentrated under diminished pressure. The residue was purified by flash 
chromatography on a silica gel column (20 × 1.7 cm). Elution with 10:1 hexanes–
ethyl acetate gave 3.17 as a yellowish solid: yield 26.0 mg, (92%); silica gel TLC 
Rf 0.52 (1:1 hexanes–ethyl acetate); 1H NMR (CDCl3) δ 1.88 (s, 3H), 2.13 (s, 
3H), 2.23 (s, 3H), 2.73-2.81 (m, 2H), 2.81 (s, 3H) and 3.36 (t, 2H, J = 8.7 Hz); 
13C NMR (CDCl3) δ 12.9, 19.0, 20.6, 24.7, 33.3 52.9, 120.3, 134.8, 136.8, 145.5, 
160.9 and 169.5; mass spectrum (ESI), m/z 221.1286 (M + H)+ (C12H17N2O2 
requires 221.1290). 
 
N
HO
N
 
1,4,6-Trimethyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-5-ol (3.1) [139(b)]. To 
a solution of 17.0 mg (770 µmol) of 3.17 in 0.5 mL of THF was added 154 µL 
(1M in THF, 154 µmol) of LiAlH4 at –78 oC. The reaction mixture was stirred at 
–78 oC for 1.5 h, then the reaction was quenched cautiously with 3 mL of sat aq 
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NH4Cl. The resulting mixture was allowed to warm to room temperature slowly 
and then extracted with ether. The organic layer was washed with brine, dried 
(Na2SO4) and concentrated under diminished pressure to afford 3.1 as an orange 
solid: yield 11 mg (86%); silica gel TLC Rf 0.37 (1:1 hexanes–ethyl acetate); 1H 
NMR (CDCl3) δ 2.09 (br s, 3H), 2.34 (br s, 3H), 2.82 (br s, 2H), 2.85 (br s, 3H) 
and 3.36 (br s, 2H); mass spectrum, m/z 178.1 (M+) (theoretical 178.1). 
 
 
 
N N
 
1,4-Dimethyl-6-pentyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridine (3.22). To a 
solution of 225.0 mg (1.39 mmol) of 3.12 in 4 mL of THF was added 1.39 mL 
(2.22 mmol, 1.6 M in hexanes) of n-BuLi followed by 157.0 µL (1.46 mmol) of 1-
bromobutane at –78 oC. The reaction mixture was slowly warmed to room 
temperature and stirred for another 16 h. The reaction mixture was quenched by 
the addition of 10 mL of sat aq NH4Cl at 0 oC. The mixture was extracted with 
EtOAc. The combined organic layer was washed with brine, dried (MgSO4) and 
concentrated under diminished pressure. The residue was purified by flash 
chromatography on a silica gel column (25 × 3.2 cm). Elution with 10:1 hexanes–
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ethyl acetate gave the product 3.22 as a yellow oil: yield 0.20 g (66%); silica gel 
TLC Rf 0.15 (8:1:1 hexanes–ethyl acetate–MeOH); 1H NMR (CDCl3) δ 0.88 (t, 
3H, J = 7.2 Hz), 1.30-1.36 (m, 4H), 1.66 (quint, 2H, J = 7.6 Hz), 2.08 (s, 3H), 
2.55 (t, 2H, J = 8.0 Hz), 2.81 (t, 2H, J = 8.0 Hz), 2.88 (s, 3H), 3.38 (t, 2H, J = 8.0 
Hz) and 6.13 (s, 1H); 13C NMR (CDCl3) δ 14.1, 18.0, 22.6, 24.4, 29.6, 31.8, 33.3, 
38.0, 52.5, 112.4, 118.2, 141.1, 159.1 and 163.7; mass spectrum (MALDI-TOF), 
m/z 218.2 (M+) (theoretical 218.3); mass spectrum (APCI), m/z 219.1864 (M + 
H)+ (C14H23N2 requires 219.1861). 
 
N N
Br
 
5-Bromo-1,4-dimethyl-6-pentyl-2,3-dihydro-1H-pyrrolo[2,3-b]-pyridine 
(3.23). To a solution of 108.2 mg (0.50 mmol) of 3.22 in 3 mL of chloroform was 
added 70.7 mg (0.25 mmol) of 1,3-dibromo-5,5-dimethylhydantoin in portions at 
0 oC. The reaction mixture was stirred at 0 oC for 30 min. The reaction was 
quenched by the addition of 5 mL of sat aq NaHCO3. The mixture was extracted 
with chloroform and the combined organic layer was washed with brine and dried 
over MgSO4. The concentrated residue was purified by flash chromatography on a 
silica gel column (20 × 1.7 cm). Elution with 100:1 hexanes–ethyl acetate gave 
3.23 as a yellow oil: yield 135.5 mg (92%); silica gel TLC Rf 0.65 (8:1:1 hexanes–
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ethyl acetate–methanol); 1H NMR (CDCl3) δ 0.89 (t, 3H, J = 7.2 Hz), 1.33-1.38 
(m, 4H), 1.66 (quint, 2H, J = 7.6 Hz), 2.16 (s, 3H), 2.77 (t, 2H, J = 8.0 Hz), 2.82-
2.87 (m, 5H) and 3.40 (t, 2H, J = 8.0 Hz); 13C NMR (CDCl3) δ 14.1, 19.5, 22.6, 
25.2, 28.4, 31.8, 33.0, 38.1, 52.4, 110.9, 120.4, 141.1, 156.8 and 161.8; mass 
spectrum (MALDI-TOF), m/z 297.1 and 299.1 (M + H)+ (theoretical 297.1 and 
299.1); mass spectrum (APCI), m/z 297.0968 and 199.0937 (M + H)+ 
(C14H22N2Br requires 297.0966 and 299.0946). 
 
N N
AcO
 
1,4-Dimethyl-6-pentyl-1H-pyrrolo[2,3-b]pyridin-5-yl Acetate (3.5). To a 
solution of 33.0 mg (0.11 mmol) of 3.23 in 1 mL of THF was added 16.5 µL (0.11 
mmol) of tetramethylethylenediamine (TMEDA) at –78 oC followed by 139.0 µL 
(0.22 mmol, 1.6 M in hexanes) of n-BuLi. After 30 min, 27.2 µL (0.24 mmol) of 
trimethoxy boron was added and the resulting mixture was stirred for another 1 hr. 
To the reaction mixture was slowly added 51.4 µL (0.24 mmol, 32 wt%) of 
peracetic acid and the solution was then warmed to 0 oC over 30 min. The mixture 
was diluted by 5 mL of H2O and extracted with three 5-mL portions of EtOAc. 
The combined organic layer was washed with brine, dried (MgSO4) and the 
solvent was concentrated under diminished pressure. The resulting oil was 
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dissolved in 2 mL of CH2Cl2 at 0 oC, followed by the addition of 92.8 µL (0.66 
mmol) of triethylamine, 1.4 mg (0.01 mmol) of DMAP and 31.4 µL (0.33 mmol) 
of acetic anhydride. The reaction was stirred at room temperature for 1 hr and 
quenched by the addition of 2 mL of sat aq NH4Cl. The solution was then 
extracted with three 5-mL portions of EtOAc. The combined organic layer was 
washed with brine, dried (MgSO4) and the solvent was concentrated under 
diminished pressure. The residue was purified by flash chromatography on a silica 
gel column (20 × 1.7 cm). Elution with 100:1 hexanes–ethyl acetate gave 3.5 as a 
yellow oil: yield 26.7 mg (88%); silica gel TLC Rf 0.1 (3:7 EtOAt–hexanes); 1H 
NMR (CDCl3) δ 0.90 (t, 3H, J = 7.0 Hz), 1.32-1.37 (m, 4H), 1.64 (quint, 2H, J = 
7.5 Hz), 1.95 (s, 3H), 2.31 (s, 3H), 2.47 (t, 2H, J = 8.0 Hz), 2.85 (t, 2H, J = 8.0 
Hz), 2.89 (s, 3H) and 3.44 (t, 2H, J = 8.0 Hz); 13C NMR (CDCl3) δ 14.0, 20.6, 
22.5, 24.7, 28.4, 29.6, 31.8, 32.5, 33.3, 52.4, 120.1, 134.7, 136.5, 149.7, 161.2 and 
169.9; mass spectrum (MALDI-TOF), m/z 276.2 (M+) (theoretical 276.2); mass 
spectrum (APCI), m/z 277.1910 (M + H)+ (C16H25N2O2 requires 277.1916). 
 
N N
HO
CF3COOH
 
1,4-Dimethyl-6-pentyl-1H-pyrrolo[2,3-b]pyridin-5-ol and its trifluoroacetic 
acid salt (3.4). To a solution of 20.0 mg (72.4 µmol) of 3.5 in 1 mL of CH2Cl2 
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was added 217.1 µL (84.0 µmol, 1.0 M in hexanes) of DIBAL-H at –78 °C. The 
reaction mixture was stirred at the same temperature for 1 h before 2 mL of sat aq 
sodium potassium tartrate was added slowly. The reaction mixture was slowly 
warmed to room temperature over 30 min. The solution was extracted with three 
5-mL portions of ethyl acetate. The combined organic layer was washed with 
brine, dried (MgSO4) and concentrated under diminished pressure to give the crude 
product as a yellow oil: silica gel TLC Rf 0.12 (1:9 MeOH–CH2Cl2). The residue 
was then dissolved in 1 mL of CH3CN and 1% aq TFA, frozen and lyophilized. 
The crude product was purified by Prepex C8 reversed phase semi-preparative 
(250 mm x 10 mm) HPLC column using a gradient of methanol and water. Linear 
gradients were employed using 1:4 methanol/water → 4:1 methanol/water over a 
period of 20 min, and then 4:1 methanol/water → methanol over a period of 40 
min, at a flow rate of 3.5 mL/min (monitoring at 260 nm); Fractions containing the 
desired product eluted at 21.6 min, and were collected, frozen, and lyophilized to 
give 3.4 as a light yellow solid: yield 13.5 mg (80%); 1H NMR (CD3CN) δ 0.88 (t, 
3H, J = 6.8 Hz), 1.27-1.32 (m, 4H), 1.54 (quint, 2H, J = 7.6 Hz), 2.13 (s, 3H), 
2.69 (t, 2H, J = 8.0 Hz), 2.99 (t, 2H, J = 8.4 Hz), 3.06 (s, 3H) and 3.72 (t, 2H, J = 
8.4 Hz); 13C NMR (CDCl3) δ 13.0, 13.3, 22.1, 24.4, 27.2, 28.3, 31.1, 32.4, 53.1, 
117.3, 126.1, 132.1, 140.4, 141.6 and 152.0; mass spectrum (MALDI-TOF), m/z 
234.2 (M+) (theoretical 234.2); mass spectrum (APCI), m/z 235.1806 (M + H)+ 
(C14H23N2O requires 235.1810). 
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N N
 
1,4-Dimethyl-6-decyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridine (3.24). To a 
solution of 181 mg (1.12 mmol) of 3.12 in 3 mL of THF was added 1.19 mL (1.90 
mmol, 1.6 M in hexanes) of n-BuLi followed by 255 µL (1.34 mmol) of 1-
bromononane at –78 oC. The reaction mixture was slowly warmed to room 
temperature and stirred for another 16 h. The reaction mixture was quenched by 
the addition of 10 mL of sat aq NH4Cl at 0 oC. The mixture was extracted with 
EtOAc. The combined organic layer was washed with brine, dried (MgSO4) and 
concentrated under diminished pressure. The residue was purified by flash 
chromatography on a silica gel column (25.4 × 3.2 cm). Elution with 10:1 hexanes–
ethyl acetate gave the product 3.24 as a yellow oil: yield 210 mg (66%); silica gel 
TLC Rf 0.18 (8:1:1 hexanes–ethyl acetate–MeOH); 1H NMR (CDCl3) δ 0.86 (t, 
3H, J = 6.8 Hz), 1.24-1.30 (m, 16H), 1.65 (quint, 2H, J = 7.6 Hz), 2.08 (s, 3H), 
2.54 (t, 2H, J = 8.0 Hz), 2.81 (t, 2H, J = 8.0 Hz), 2.90 (s, 3H), 3.38 (t, 2H, J = 8.0 
Hz) and 6.13 (s, 1H); 13C NMR (CDCl3) δ 14.24, 18.11, 22.82, 24.52, 29.48, 
29.68, 29.73, 29.75, 29.77, 30.10, 32.05, 33.40, 38.19, 52.60, 112.60, 118.38, 
141.25, 159.26 and 163.86; mass spectrum, m/z 288.3 (M+) (theoretical 288.3); 
mass spectrum (APCI), m/z 289.2653  (M + H)+ (C19H33N2 requires 289.2644). 
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N N
Br
 
5-Bromo-1,4-dimethyl-6-decyl-2,3-dihydro-1H-pyrrolo[2,3-b]-pyridine (3.25). 
To a solution of 286 mg (0.99 mmol) of 3.24 in 4 mL of chloroform was added 
143 mg (0.50 mmol) of 1,3-dibromo-5,5-dimethylhydantoin in portions at 0 oC. 
The reaction mixture was stirred at 0 oC for 30 min. The reaction was quenched by 
the addition of 5 mL of sat aq NaHCO3. The mixture was extracted with 
chloroform and the combined organic layer was washed with brine and dried over 
MgSO4. The concentrated residue was purified by flash chromatography on a 
silica gel column (20 × 1.7 cm). Elution with 100:1 hexanes–ethyl acetate gave 
3.25 as a yellow oil: yield 342 mg (94%); silica gel TLC Rf 0.7 (8:1:1 hexanes–
ethyl acetate–methanol); 1H NMR (CDCl3) δ 0.87 (t, 3H, J = 6.8 Hz), 1.25-1.39 
(m, 16H), 1.66 (quint, 2H, J = 7.2 Hz), 2.17 (s, 3H), 2.77 (t, 2H, J = 8.0 Hz), 
2.83-2.87 (m, 5H) and 3.40 (t, 2H, J = 8.0 Hz); 13C NMR (CDCl3) δ 14.11, 19.50, 
22.68, 25.22, 28.69, 29.36, 29.54, 29.59, 29.64, 29.64, 31.92, 33.00, 38.13, 52.44, 
110.92, 120.37, 141.10, 156.79 and 161.78; mass spectrum, m/z 366.2 and 268.2 
(M)+ (theoretical 366.2 and 368.2); mass spectrum (APCI), m/z 367.1747 and 
369.1723 (M + H)+ (C19H32N2Br requires 367.1749 and 369.1728). 
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1,4-Dimethyl-6-decyl-1H-pyrrolo[2,3-b]pyridin-5-yl Acetate (3.7). To a 
solution of 43.0 mg (0.12 mmol) of 3.25 in 1 mL of THF was added 17.4 µL (0.12 
mmol) of tetramethylethylenediamine (TMEDA) at –78 oC followed by 146.3 µL 
(0.23 mmol, 1.6 M in hexanes) of n-BuLi. After 30 min, 28.7 µL (0.26 mmol) of 
trimethoxy boron was added and the resulting mixture was stirred for another 1 hr. 
To the reaction mixture was slowly added 54.2 µL (0.26 mmol, 32 wt%) of 
peracetic acid and the solution was then warmed to 0 oC over 30 min. The mixture 
was diluted by 5 mL of H2O and extracted with three 5-mL of EtOAc. The 
combined organic layer was washed with brine, dried (MgSO4) and the solvent 
was concentrated under diminished pressure. The resulting oil was dissolved in 2 
mL of CH2Cl2 at 0 oC, followed by the addition of 97.9 µL (0.70 mmol) of 
triethylamine, 1.4 mg (0.01 mmol) of DMAP and 33.1 µL (0.35 mmol) of acetic 
anhydride. The reaction was stirred at room temperature for 1 hr and quenched by 
the addition of 2 mL of sat aq NH4Cl. The solution was then extracted with three 
5-mL of EtOAc. The combined organic layer was washed with brine, dried 
(MgSO4) and the solvent was concentrated under diminished pressure. The 
residue was purified by flash chromatography on a silica gel column (20 × 1.7 cm). 
Elution with 100:1 hexanes–ethyl acetate gave 3.7 as a yellow oil: yield 28 mg 
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(68%); silica gel TLC Rf 0.15 (3:7 EtOAt–hexanes); 1H NMR (CDCl3) δ 0.86 (t, 
3H, J = 6.8 Hz), 1.24-1.28 (m, 16 H), 1.60 (quint, 2H, J = 7.6 Hz), 1.92 (s, 3H), 
2.28 (s, 3H), 2.44 (t, 2H, J = 8.0 Hz), 2.82 (t, 2H, J = 8.4 Hz), 2.87 (s, 3H) and 
3.41 (t, 2H, J = 8.4 Hz); 13C NMR (CDCl3) δ 12.88, 14.10, 20.54, 22.66, 24.62, 
28.68, 29.33, 29.50, 29.58, 28.63, 31.89, 32.49, 33.31, 52.82, 120.08, 134.68, 
136.50, 149.65, 161.17 and 169.91; mass spectrum, m/z 346.3 (M)+ (theoretical 
246.3); mass spectrum (APCI), m/z 347.2696 (M + H)+ (C21H35N2O2 requires 
347.2699). 
 
N N
HO
CF3COOH
 
1,4-Dimethyl-6-decyl-1H-pyrrolo[2,3-b]pyridin-5-ol and its trifluoroacetic 
acid salt (3.6). To a solution of 19.0 mg (54.8 µmol) of 3.7 in 1 mL of CH2Cl2 
was added 165 µL (165 µmol, 1.0 M in hexanes) of DIBAL-H at –78 °C. The 
reaction mixture was stirred at the same temperature for 1 h before 2 mL of sat aq 
sodium potassium tartrate was added slowly. The reaction mixture was slowly 
warmed to room temperature over 30 min. The solution was extracted with three 
5-mL ethyl acetate. The combined organic layer was washed with brine, dried 
(MgSO4) and concentrated under diminished pressure to give the crude product as 
a yellow oil: silica gel TLC Rf 0.16 (1:9 MeOH–CH2Cl2). The residue was then 
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dissolved in 1 mL of CH3CN and 1% aq TFA, frozen and lyophilized. The crude 
product was purified by Prepex C8 reversed phase semi-preparative (250 mm x 10 
mm) HPLC column using a gradient of methanol and water. Linear gradients were 
employed using 1:4 methanol/water → 4:1 methanol/water over a period of 20 
min, and then 4:1 methanol/water → methanol over a period of 40 min, at a flow 
rate of 3.5 mL/min (monitoring at 260 nm); Fractions containing the desired 
product eluted at 28.2 min, and were collected, frozen, and lyophilized to give 3.6 
as a light yellow solid: yield 13.0 mg (76%); 1H NMR (CD3CN) δ 0.89 (t, 3H, J = 
6.8 Hz), 1.27-1.31 (m, 16H), 1.54 (quint, 2H, J = 7.6 Hz), 2.13 (s, 3H), 2.70 (t, 
2H, J = 8.0 Hz), 2.99 (t, 2H, J = 8.4 Hz), 3.06 (s, 3H) and 3.72 (t, 2H, J = 8.4 
Hz); 13C NMR (CDCl3) δ 13.0, 13.4, 22.4, 24.4, 27.3, 28.6, 28.9, 29.00, 29.04, 
29.3, 29.3, 31.6, 32.4, 53.1, 117.3, 126.1, 132.1, 140.4, 141.5 and 152.1; mass 
spectrum, m/z 304.3 (M)+ (theoretical 304.3); mass spectrum (APCI), m/z 
305.2590 (M + H)+ (C19H33N2O requires 305.2593). 
 
N N
 
1,4-Dimethyl-6-hexadecyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridine (3.26). To a 
solution of 277 mg (1.71 mmol) of 3.12 in 5 mL of THF was added 1.71 mL (2.73 
mmol, 1.6 M in hexanes) of n-BuLi followed by 518 µL (1.79 mmol) of 1-
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bromononane at –78 oC. The reaction mixture was slowly warmed to room 
temperature and stirred for another 16 h. The reaction mixture was quenched by 
the addition of 10 mL of sat aq NH4Cl at 0 oC. The mixture was extracted with 
EtOAc. The combined organic layer was washed with brine, dried (MgSO4) and 
concentrated under diminished pressure. The residue was purified by flash 
chromatography on a silica gel column (25.4 × 3.2 cm). Elution with 10:1 hexanes–
ethyl acetate gave the product 3.26 as a white solid: yield 330 mg (52%); mp 43–
45 oC; silica gel TLC Rf 0.25 (8:1:1 hexanes–ethyl acetate–MeOH); 1H NMR 
(CDCl3) δ 0.88 (t, 3H, J = 7.2 Hz), 1.25-1.31 (m, 28H), 1.66 (quint, 2H, J = 7.6 
Hz), 2.08 (s, 3H), 2.55 (t, 2H, J = 8.0 Hz), 2.80 (t, 2H, J = 8.4 Hz), 2.90 (s, 3H), 
3.38 (t, 2H, J = 8.4 Hz) and 6.13 (s, 1H); 13C NMR (CDCl3) δ 14.1, 18.0, 22.7, 
24.4, 29.38, 29.38, 29.57, 29.62, 29.65, 29.68, 29.72, 29.72, 29.72, 29.72, 29.72, 
29.72, 28.0, 32.0, 33.2, 38.1, 52.4, 112.4, 118.2, 141.0, 159.1 and 163.7; mass 
spectrum, m/z 372.3 (M+) (theoretical 372.4); mass spectrum (APCI), m/z 
373.3574 (M + H)+ (C25H45N2 requires 373.3583). 
 
N N
Br
 
5-Bromo-1,4-dimethyl-6-hexadecyl-2,3-dihydro-1H-pyrrolo[2,3-b]-pyridine 
(3.27). To a solution of 278 mg (0.75 mmol) of 3.26 in 4 mL of chloroform was 
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added 108 mg (0.38 mmol) of 1,3-dibromo-5,5-dimethylhydantoin in portions at 0 
oC. The reaction mixture was stirred at 0 oC for 30 min. The reaction was 
quenched by the addition of 5 mL of sat aq NaHCO3. The mixture was extracted 
with chloroform and the combined organic layer was washed with brine and dried 
over MgSO4. The concentrated residue was purified by flash chromatography on a 
silica gel column (20 × 1.7 cm). Elution with 100:1 hexanes–ethyl acetate gave 
3.27 as a white solid: yield 331 mg (98%); mp 49–50 oC; silica gel TLC Rf 0.78 
(8:1:1 hexanes–ethyl acetate–methanol); 1H NMR (CDCl3) δ 0.88 (t, 3H, J = 7.2 
Hz), 1.25-1.31 (m, 28H), 1.66 (quint, 2H, J = 7.6 Hz), 2.08 (s, 3H), 2.55 (t, 2H, J 
= 8.0 Hz), 2.80 (t, 2H, J = 8.4 Hz), 2.90 (s, 3H), 3.38 (t, 2H, J = 8.0 Hz) and 6.13 
(s, 1H); 13C NMR (CDCl3) δ 14.13, 19.49, 22.69, 25.22, 28.68, 29.38, 29.57, 
29.61, 29.65, 29.68, 29.71, 29.71, 29.71, 29.71, 29.71, 29.71, 31.9, 33.0, 38.1, 
52.4, 110.92, 120.33, 141.07, 156.79 and 161.78; mass spectrum, m/z 451.3 and 
453.2 (M + H)+ (theoretical 451.3 and 453.3); mass spectrum (APCI), m/z 
451.2680 and 453.2697 (M + H)+ (C25H44N2Br requires 451.2688 and 453.2667). 
 
N N
AcO
 
1,4-Dimethyl-6-hexadecyl-1H-pyrrolo[2,3-b]pyridin-5-yl Acetate (3.9). To a 
solution of 43.5 mg (0.10 mmol) of 3.27 in 1 mL of THF was added 14.2 µL (0.10 
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mmol) of tetramethylethylenediamine (TMEDA) at –20 oC followed by 119 µL 
(0.19 mmol, 1.6 M in hexanes) of n-BuLi. After 30 min, 23.4 µL (0.21 mmol) of 
trimethoxy boron was added and the resulting mixture was stirred for another 1 hr. 
To the reaction mixture was slowly added 44.1 µL (0.21 mmol, 32 wt%) of 
peracetic acid and the solution was then warmed to 0 oC over 30 min. The mixture 
was diluted by 5 mL of H2O and extracted with three 5-mL portions of EtOAc. 
The combined organic layer was washed with brine, dried (MgSO4) and the 
solvent was concentrated under diminished pressure. The resulting oil was 
dissolved in 2 mL of CH2Cl2 at 0 oC, followed by the addition of 79.6 µL (0.57 
mmol) of triethylamine, 1.2 mg (0.01 mmol) of DMAP and 27.0 µL (0.29 mmol) 
of acetic anhydride. The reaction was stirred at room temperature for 1 hr and 
quenched by the addition of 2 mL of sat aq NH4Cl. The solution was then 
extracted with three 5-mL of EtOAc. The combined organic layer was washed 
with brine, dried (MgSO4) and the solvent was concentrated under diminished 
pressure. The residue was purified by flash chromatography on a silica gel column 
(20 × 1.7 cm). Elution with 100:1 hexanes–ethyl acetate gave 3.9 as a yellow oil: 
yield 15.0 mg (37%); silica gel TLC Rf 0.20 (3:7 EtOAt–hexanes); 1H NMR 
(CDCl3) δ 0.86 (t, 3H, J = 6.8 Hz), 1.23-1.28 (m, 28H), 1.60 (quint, 2H, J = 7.6 
Hz), 1.93 (s, 3H), 2.28 (s, 3H), 2.44 (t, 2H, J = 8.0 Hz), 2.82 (t, 2H, J = 8.0 Hz), 
2.87 (s, 3H) and 3.41 (t, 2H, J = 8.0 Hz); 13C NMR (CDCl3) δ 12.88, 14.10, 
20.54, 22.67, 24.62, 28.69, 29.35, 29.51, 29.59 29.64, 29.68, 29.68, 29.68, 29.68, 
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29.68, 29.68, 29.68, 31.91, 32.50, 33.32, 52.82, 120.08, 134.68, 136.50, 149.66, 
161.18 and 169.91; mass spectrum, m/z 430.3 (M)+ (theoretical 430.4); mass 
spectrum (APCI), m/z 431.3637 (M + H)+ (C27H47N2O2 requires 431.3638). 
 
N N
HO
CF3COOH
 
1,4-Dimethyl-6-hexadecyl-1H-pyrrolo[2,3-b]pyridin-5-ol and its 
trifluoroacetic acid salt (3.8). To a solution of 15.0 mg (34.8 µmol) of 3.9 in 1 
mL of CH2Cl2 was added 105 µL (105 µmol, 1.0 M in hexanes) of DIBAL-H at –
78 °C. The reaction mixture was stirred at the same temperature for 1 h before 2 
mL of sat aq sodium potassium tartrate was added slowly. The reaction mixture 
was slowly warmed to room temperature over 30 min. The solution was extracted 
with three 5-mL portions of ethyl acetate. The combined organic layer was 
washed with brine, dried (MgSO4) and concentrated under diminished pressure to 
give the crude product as a yellow oil: silica gel TLC Rf 0.22 (1:9 MeOH–
CH2Cl2). The residue was then dissolved in 1 mL of CH3CN and 1% aq TFA, 
frozen and lyophilized. The crude product was purified on a Prepex C8 reversed 
phase semi-preparative (250 mm x 10 mm) HPLC column using a gradient of 
methanol and water. Linear gradients were employed using 1:4 methanol/water → 
4:1 methanol/water over a period of 20 min, and then 4:1 methanol/water → 
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methanol over a period of 40 min, at a flow rate of 3.5 mL/min (monitoring at 260 
nm); Fractions containing the desired product eluted at 37.5 min, and were 
collected, frozen, and lyophilized to give 3.8 as a light yellow solid: yield 11.0 mg 
(82%); 1H NMR (CD3CN) δ 0.89 (t, 3H, J = 6.4 Hz), 1.27-1.36 (m, 28H), 1.55 
(quint, 2H, J = 7.2 Hz), 2.13 (s, 3H), 2.70 (t, 2H, J = 8.0 Hz), 3.00 (t, 2H, J = 8.4 
Hz), 3.06 (s, 3H) and 3.73 (t, 2H, J = 8.4 Hz); 13C NMR (CDCl3) δ 13.00, 13.39, 
22.40, 24.41, 27.23, 28.61, 28.71, 28.99, 29.06, 29.07, 29.21, 29.30, 29.33, 29.36, 
29.39, 29.39, 29.39, 31.64, 32.39, 53.11, 117.30, 126.16, 131.92, 140.24, 141.44 
and 152.06; mass spectrum, m/z 388.3 (M)+ (theoretical 388.3); mass spectrum 
(APCI), m/z 389.3526 (M + H)+ (C25H45N2O requires 389.3532). 
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